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ATOME at a glance 
§ The World Health Organization (WHO) defines opioids as essential medicines for the treat-
ment of severe pain and other symptoms, as well as for the treatment of opioid dependence. 
Access to opioid medicines is considered a human right. 
§ In the twelve European countries addressed by this project, strict regulations and inappropri-
ate policies were found to have negative impact on adequate access to opioid medicines. Ma-
jor barriers were found to exist in these countries in the field of legislation; national policies; 
knowledge and societal attitudes; and economic aspects, including affordability. 
§ Recommendations were developed for each country to address barriers to adequate opioid 
availability on different levels.  
§ In all participating countries, to some degree, action has already been taken to change poli-
cies and the legislation in order to improve access to opioid medicines. Factors enhancing 
change were committed opinion leaders and openness among relevant stakeholder groups 
towards a critical analysis of the national situation. 
§ It is recommended that governments implement the WHO policy guidelines Ensuring Balance 
in National Policies on Controlled Substances, Guidance for Availability and Accessibility for 
Controlled Medicines including the self-assessment checklist in order to analyse the situation 




The ATOME project 
This report presents the outcomes of the Access To Opioid Medication in Europe (ATOME) 
project funded under the European Union’s 7th Framework Programme. The project investi-
gated why opioid medicines for moderate to severe pain and for the treatment of opioid de-
pendence are not used adequately in twelve European countries, and developed tailor-made 
solutions for improved access to opioid medicines in these countries. The intended reader-
ship of this report is regulatory and law enforcement authorities, policy makers, opinion lead-
ers, and healthcare professionals.  
Background and problem statement 
Opioid medicines are the mainstay of medical treatment of severe pain and breathlessness, 
and the treatment of opioid dependence. They are effective and cheap medicines to relieve 
unbearable suffering from physical symptoms in severe progressive illness, and to prevent 
unnecessary harm and deterioration of health in people suffering from opioid dependence. 
For these reasons, WHO defines opioid medications as essential medicines.  
Due to their potentially harmful effects, opioids are defined as controlled substances and are 
controlled under the Single Convention on Narcotic drugs. The purpose of this treaty is to 
prevent the misuse of controlled substances while guaranteeing their availability for scientific 
and medical use. This implies a dual obligation for governments – that is, to implement regu-
lations and policies that help to prevent potential harm resulting from opioids while ensuring 
that they are adequately available, accessible and affordable for those in need of them (the 
‘principle of balance’). However, in many countries the emphasis is on control and restriction, 
hereby unduly interfering with availability of opioid medicines. 
ATOME goals and activities 
The ATOME project was initiated by the Access to Controlled Medications Programme of 
WHO. It was a five-year project funded under the 7th Framework Programme of the European 
Community [FP7/2007-2013] under grant agreement n° 222994. The project consortium con-
sisted of partners from the field of law, governance and public health, palliative care, and 
harm reduction.  
A central feature of the ATOME work plan was close collaboration with national counterparts. 
In the beginning of the project, key stakeholders were invited to contribute to the project by 
becoming a member of the national country teams. These country teams comprised govern-
ment officers, legal experts, palliative care and harm reduction specialists, and patient repre-
sentatives. The national counterparts were key contacts for the ATOME consortium through-
out the whole project. Collaboration with the national counterparts cumulated in a series of 
ATOME conferences in the 12 target countries. 
The basic foundation of the project activities was the production of the revised WHO policy 
guidelines Ensuring Balance in National Policies on Controlled Substances, Guidance for 
Availability and Accessibility for Controlled Medicines using an expert consensus process. 
The resulting guidelines were the basis for all subsequent research and dissemination activi-
ties: both the legal and policy analysis were guided by the recommendations made in the 
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guidelines document; the self-assessment checklist was an important tool for the national 
problem analysis and development of strategic action plans towards improving access to 
opioid medication; and the barriers addressed in the guidelines built an important framework 
for the lectures and working groups during national conferences. 
Building on this milestone, the ATOME project followed two tracks in parallel – one track of 
activities focused on legal analysis, the other on the analysis of national policies. The legal 
analysis looked at optimising the relevant legislation by identifying provisions that may im-
pede access to controlled medicines and by making recommendations for improvement in 
consultation with the national counterparts. The policy analysis was related to an examina-
tion of national policies and circumstances affecting the accessibility and availability of opioid 
medicines. The goals were both to make professionals aware of problems arising from their 
professional practice, and to make recommendations to the governments. 
ATOME key findings 
Analysis of barriers  
Scientific research undertaken within the ATOME project provided information on four areas 
relevant for access to opioid medicines: challenges concerning policy and guidance on ac-
cess to opioids, legal and regulatory barriers, policy barriers, and the perception of barriers in 
different stakeholder groups. 
A consensus process with experts from law and governance, public health, human rights, 
palliative care and pain treatment, and harm reduction revealed the difficulty of defining con-
cepts such as ‘rational (medical) use’ versus. ‘misuse’ of controlled substances, and reflected 
the challenge of outweighing the risks and benefits of certain substances. The consensus 
process underlined the complexity of political guidance in balancing between control and 
availability, between protection and harm. 
An in-depth evaluation of the legislative and regulatory barriers in the participating countries 
found a wide range of potential barriers in the national legislation. The review identified po-
tential legal and regulatory barriers in the following areas: prescribing, dispensing, and usage 
of opioid medicines; trade and distribution; manufacturing; affordability; penalties; and lan-
guage. The outcomes of the legislation review resulted in detailed reports for each of the 
countries, describing the potential barriers, explaining the potential negative impact of the 
respective provisions on access to opioid medicines, and making a set of recommendations 
on how to lift these barriers and thereby improving the availability of opioids for those in need 
of them.  
The findings of the review of national policies illustrate that beside barriers in the national 
legislation there are also several challenges concerning national policy strategies with regard 
to improved access to opioids and the use of these medicines for medical treatment. A de-
tailed analysis of documents collected throughout the ATOME project and discussions with 
national stakeholders showed major challenges to opioid access in four areas; financial and 
economic aspects and governmental support, formularies, education and training, and socie-
tal attitudes. The analysis resulted in individual reports for each country, including recom-
mendations on how to address the identified barriers and improve access to opioid medi-
cines in relation to country specific backgrounds. 
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Several of the countries participating in the ATOME project are already in the process of re-
vising legislation and policies, and implementing recommendations for improvement. As a 
result, several changes in legislation and policy have already come into force, lifting potential 
barriers to access to opioids.  
Discussions with different stakeholders throughout the ATOME project revealed that percep-
tions may differ considerably with regard to what is seen as a ‘barrier’. A questionnaire sur-
vey among different stakeholder groups provided insights into the different perceptions in a 
range of relevant stakeholder groups such as government officers, legal experts, healthcare 
professionals or advocacy workers. Government representatives often saw the impact of 
certain provisions on access to opioids less problematic than, for example, healthcare pro-
fessionals. The outcomes of this survey underlined the importance of intensified dialogue 
between different stakeholder groups to facilitate a mutual understanding and establish a 
common ground for discussion on access to opioid medicines, and to develop effective solu-
tions for improvement. 
Achievements and societal impact 
Next to the findings of the scientific research activities, achievements of the project are publi-
cation and dissemination activities that were targeted at providing guidance and having a 
societal impact.  
} The publication of the WHO policy guidelines Ensuring Balance in National Policies on 
Controlled Substances, with 21 recommendations, as well as a checklist that can be used 
to survey legal and regulatory settings in each country. 
} Implementation of several workshops and events with the aim of capacity building, sensi-
tisation and awareness raising, education and training, and dissemination of knowledge 
regarding access to opioid medicines and findings from the project. In detail, these were 
two workshops directed at the legislation analysis – a lawyer’s training workshop and a 
legislation review workshop; and two six-country workshops as well as a national follow-
up conference in each of the twelve countries. 
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Key recommendations from the ATOME project 
§ Implement the WHO policy guidelines Ensuring Balance in National Policies on Controlled 
Substances, Guidance for Availability and Accessibility for Controlled Medicines; 
§ Identify potential legal and regulatory barriers to access to opioid medicines and working on 
changes with the aim to improve accessibility, availability and affordability. 
§ Ensure non-stigmatizing language in legal documents and language in official documents 
(e.g. by using the term ‘Narcotic drug’ only when referring to substances controlled under the 
Single Convention); 
§ Establish regular exchange opportunities (communication networks) between legal and gov-
ernmental authorities, healthcare professionals and patients/families in order to raise aware-
ness for practical impact and requirements of legal and policy decisions (target-performance 
comparison) regarding opioid availability and accessibility; 
§ Provide and support the implementation and development of national databases (including 
data on long-term outcomes and national fear of opioids) suitable for scientific research, eval-
uation of models of treatment with opioids and for monitoring the national demand on Essen-
tial Medicines; 
§ Ensure that treatment with opioids (knowledge, skills, attitudes) will be included in undergrad-
uate and postgraduate education for relevant healthcare professionals (primarily physicians, 
nurses, pharmacists); 
§ Raise awareness and sensitisation for treatment with opioids among practicing healthcare 
professionals (e.g. via Continuing Medical Education, publication series on the rational use of 
opioids in highly-accessed national medical journals, a survey on knowledge and attitudes re-
garding opioid medicines); 
§ Raise awareness in the general public, e.g. via media campaigns or information, brochures 
for patients and relatives. 
Conclusion 
The impact of the different activities of ATOME has resulted in major improvements in access 
to essential controlled medicines in several of the participating countries. The ATOME project 
contributed to building a critical mass of interested parties, bringing together people from 
different fields such as pain therapy, palliative care, harm reduction, and from national gov-
ernments. It is hoped that the activities initiated in ATOME will be sustained after the end of 
the project, improving accessibility, availability and affordability of essential medicines, in-
cluding opioid analgesics and long-acting opioids used for the treatment of opioid depend-
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Improving Access to Opioid Medication in Europe 
ATOME  
Final Report and recommendations to 
the Ministries of Health 
Part I: General Part 
 
1. Introduction 
The WHO European region has a population of 881 million. Each year, 1.3 million people in 
the European Union die from cancer and approximately 5.7 million from non-cancer chronic 
diseases. In the 12 ATOME countries each year 300,000 people die from cancer (1). With 
the aging population, the pattern of mortality also changes (2). As more people live to older 
ages, and as chronic diseases become more common with older age, the numbers of people 
living with and suffering from these diseases will increase as well. With ongoing medical pro-
gress, patients will survive longer with chronic disabling disease, and in consequence suffer 
from pain or breathlessness over a longer period of time. A considerable percentage of these 
patients will require treatment with morphine or other opioids to achieve symptom control. 
However, many of them will not receive adequate treatment of their pain.  
Opium has been used as an analgesic as long as 4000 years ago. Today, medicines derived 
from opium such as morphine are still the mainstay of analgesic therapies and most people 
will require their use at least once throughout their lifetime for acute or chronic pain. The 
World Health Organization has acknowledged the importance of opioid medicines in its Mod-
el List of Essential Medicines (3) and its Model List of Essential Medicines for Children (4). 
WHO considers fentanyl, hydromorphone, methadone, morphine and oxycodone essential 
medicines both for adults and children. The WHO Guidelines for the Pharmacological Treat-
ment of Persisting Pain in Children with Medical Illnesses and the WHO guidelines on cancer 
pain management (5, 6) list a number of essential opioid analgesics equally. 
The International Association for Hospice and Palliative Care lists not only codeine and mor-
phine, but also tramadol, fentanyl, methadone and oxycodone as essential medicines for 
palliative care (7); and more recently the European Association for Palliative Care published 
new guidelines on the use of opioid medicines (8), reinforcing the value of these medicines 
as the mainstay of cancer pain management. 
Opioids are also considered to be effective for the treatment of opioid dependence. Opioid 
maintenance treatment can interrupt the cycle of intoxication and withdrawal and reduces 
illicit opioid use and the risk of death through overdose and infection with hepatitis and HIV. 
In addition, it also reduces public nuisance and petty crime. The WHO Guidelines for the 
Psychosocially Assisted Pharmacological Treatment of Opioid Dependence found opioid 
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agonist maintenance treatment, combined with psychosocial assistance, to be the most ef-
fective of all treatment options examined (9). 
The United Nations Office on Drugs and Crime (UNODC) estimated that there are 15-39 mil-
lion problem drug users in world, and 12 to 14 million heroin users (10). In Europe, it is esti-
mated that between 3.1 and 3.5 million people use opioids illicitly.  
In spite of the beneficial effects of opioid medicines, the fear of misuse has resulted in drug 
control regulations that have proven to be a major barrier against state-of-the-art medical use 
of opioids and other controlled medicines. In 1961, a number of treaties and protocols were 
merged into the Single Convention on Narcotic Drugs (11). In 1971 another convention, the 
Convention on Psychotropic Substances was agreed on (12). Together they cover about 120 
substances and their medical preparations. Codeine, morphine and most other opioids are 
scheduled in the Single Convention and are subject to the measures of control detailed in 
this convention. This includes the estimation of medical needs for opioids, as well as rules 
concerning production, manufacture and distribution, and statistical reports. The Single Con-
vention governs how opioids are shipped between countries, using a system of import and 
export permits, and also defines to some extent the requirements for safe distribution within a 
country. Governments that are party to the Single Convention have agreed to bring their laws 
and regulations in line with its requirements. The few countries that are not a party to the 
Single Convention often follow its basic procedures. 
The broad purpose of the treaty is to prevent the misuse of ‘narcotics’ (a legal term referring 
to all substances regulated by this convention on ‘narcotic drugs’, but not a class of medi-
cines) including opioids, while guaranteeing their availability for scientific and medical use. 
The preamble of the Single Convention recognizes that "the medical use of narcotic drugs 
continues to be indispensable for the relief of pain and suffering". However, the implementa-
tion of the treaty rules in national legislation and national policies are often much stricter than 
the treaties require. For this reason the availability of opioids for medical purposes is low in 
many countries, if not non-existent. 
A survey on availability and accessibility of opioids for the management of cancer pain in 41 
countries in Europe found substantial limitations of the opioid formularies in many of the 21 
Eastern-European countries included in the survey  (13). Regulatory restrictions such as re-
quirements for patients for registration or physicians to hold a special licence for the prescrip-
tion of opioids were much more common in Eastern-European countries than in the West. 
There is currently a strong momentum worldwide to improve access to opioid medication with 
strong international initiatives advocating policy reform activities and supporting change to-
wards more appropriate controlled substances policies and better public health outcomes. 
One important working group is the WHO Collaborating Centre for Pain and Palliative Care / 
Pain and Policy Studies Group (PPSG) in Wisconsin. The PPSG has developed methods 
and resources to assist governments and pain and palliative care groups to examine national 
policies and make regulatory changes – Romania, India, Italy are examples (14). The PPSG 
also developed an International Pain Policy Fellowship (IPPF) to expand leadership for 
change in more countries. Recognizing the requirement to balance the need to protect the 
population from harmful effects with the need to access controlled medicines for medical use, 
the World Health Organization (WHO) in 2007 established the Access to Controlled Medica-
tions Programme (ACMP) (15) in consultation with the International Narcotics Control Board 
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(INCB) in response to resolutions of the World Health Assembly (WHA) and the Economic 
and Social Council of the United Nations (ECOSOC) (WHA58.22 and ECOSOC 2005/25) 
(15,16). The programme aims at promoting the availability, affordability, accessibility and 
rational use of controlled medicines; it addresses all aspects that act as barriers in obtaining 
controlled medicines for medical treatment and furthermore, provides normative guidance, 
development and dissemination of internationally recognized standards for treatment, policy 
analysis, as well as training and support in drafting national action plans for improving access 
to opioid medicines. The ACMP, among others, collaborates with the WHO Collaborating 
Centre for Pain and Palliative Care, with the European Association for Palliative Care 
(EAPC), the International Association for Hospice and Palliative Care (IAHPC), the Interna-
tional Observatory on End of Life Care (IOELC), Human Rights Watch and Harm Reduction 
International (HRI). 
The ACMP initiated the project Access to Opioid Medication in Europe (ATOME) with the aim 
to undertake applied research into the reasons why opioid medicines for moderate to severe 
pain and for the treatment of opioid dependence are not used adequately in 12 European 
countries. The ATOME project is embedded in these international activities; it was intended 
to address the inequality in access to opioid medicines in Europe and more specifically to 
implement activities in twelve Eastern European countries. Developed in 2006-2007 by 
WHO, it started in 2009 as a five-year project. It is funded by the European Community’s 
Seventh Framework Programme [FP7/2007-2013] under grant agreement n° 222994, which 
has a section on cancer research. The project aimed to deliver a clear set of recommenda-
tions to governments on making controlled medicines accessible for the treatment of patients 
in need of them for medical reasons such as pain, including from cancer and opioid depend-
ence, based on the principle of balance as enshrined in the preambles of the drug control 
conventions and promoted by the World Health Organization (WHO) (17) – ensuring that in 
parallel to a system of control in order to prevent misuse, controlled medicines will be suffi-
ciently available for patient care. 
Textbox 1 The principle of balance in the WHO policy guidelines (17) 
The central principle of ‘balance’ 
The central principle of ‘balance’ represents a dual obligation of governments to establish a sys-
tem of control that ensures the adequate availability of controlled substances for medical and sci-
entific purposes, while simultaneously preventing abuse, diversion and trafficking. Many controlled 
medicines are essential medicines and are absolutely necessary for the relief of pain, treatment of 
illness and the prevention of premature death. To ensure the rational use of these medicines, 
governments should both enable and empower healthcare professionals to prescribe, dispense 
and administer them according to the individual medical needs of patients, ensuring that a suffi-
cient supply is available to meet those needs. While misuse of controlled substances poses a risk 
to society, the system of control is not intended to be a barrier to their availability for medical and 
scientific purposes, nor interfere in their legitimate medical use for patient care. 
The ATOME Consortium aimed at helping to build a critical mass of interested parties, bring-
ing people together from different fields such as pain therapy and palliative care, and from 
national governments. The work includes comprehensive legislative and policy reviews, in 
close cooperation with government officials and public health and medical experts in various 
countries. Specifically, the work entails: 
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§ analysis of national policies and circumstances that affect the availability of opioid medi-
cines 
§ proposing amendments to current law to better balance the need to prevent drug abuse, 
while allowing patients access to such medicines 
§ understanding the socio-cultural context of drug use and abuse in each country, and 
evaluating the impact of the activities of the ATOME project. 
The ATOME project is also contributing to increasing awareness of the issues around opioid 
medicines. For example, the project has organised a series of workshops and conferences 
aimed at sensitising different stakeholder groups to the negative effects of too-tight re-
strictions on opioid medicines – for patients, their families, and also for healthcare profes-
sionals. 
The concrete outcome are 12 country reports, offering recommendations for legislative 
changes. These reports are being presented to the relevant governments, national organisa-
tions and health-care professionals. In some countries, changes in legislation have already 
been prepared and even implemented, supported by the recommendations resulting from the 
ATOME legislation analysis. 
 
2. Problem to be addressed  
Opioid medicines are strictly controlled under the law because of their potential for harm and 
misuse. However, in some cases the controls are so restrictive that patients are denied ac-
cess for medical use, including those who need treatment for pain or opioid dependence. 
Regulations to reduce substance misuse and to restrict the diversion of opioid medicines into 
illicit markets often unduly interfere with medical availability for the relief or pain and other 
symptoms, as well as for the treatment of opioid dependence. This has been identified as 
“the basis for the internationally recognized public health problem of overregulation” (13). 
 
2.1. Inequality in access to opioid medicines 
International health and regulatory authorities are increasingly concerned about wide dispari-
ties in access to opioid medicines (14). The problem has been highlighted by the Open Soci-
ety Foundations International Palliative Care Initiative, the International Observatory on End 
of Life Care, the International Association for Hospice and Palliative Care (IAHPC), the Inter-
national Narcotics Control Board (INCB), the WHO, the Council of Europe, Human Rights 
Watch, as well as by leading harm reduction organizations such as Harm Reduction Interna-
tional and the Eurasian Harm Reduction Network. 
It is estimated that over 80% of the world's population, at one time or another, is denied 
treatment because the opioid medicines they need have been restricted as ‘controlled sub-
stances’ (18). In the European Union, for example, about 1.3 million people die from cancer 
each year, many in severe pain, even though effective pain medications are available. In six 
EU countries, medical consumption of opioids and similar medicines is low and in six others it 
is very low (19). Meanwhile, it was estimated that there are between 3.3 and 5.8 million in-
jecting drug users in Europe (with absolute figures in Eastern Europe being three times as 
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high as in Western Europe) (20). However, only a minority has access to a methadone ther-
apy that could help them to normalize their lives and re-integrate into society, prevent them 
from using and buying illegal drugs and reduce their risk of becoming infected with blood-
borne diseases such as HIV. 
While opioid consumption has significantly increased in Western European countries, the 
situation has hardly changed in Eastern Europe during the last 20 years (21). Although the 
European region in general is ‘performing best’ in the worldwide comparison, the consump-
tion is far below average in Eastern Europe. In many European countries, particularly those 
in Eastern Europe, patient access to the opioid medicines recommended by the WHO to re-
lieve pain is profoundly restricted due to inadequate formularies, excessive regulation and 
the attitudes and misconceptions by the administration, clinicians and patients (13, 21). 
WHO’s Access to Controlled Medicines Programme (ACMP) in its Briefing Note from 2012 
stated that “The realization of the Millennium Development Goal ‘Provide access to afforda-
ble essential drugs in developing countries’ is likely to be further away for opioid analgesics 
than for any other class of medicines” (15). 
 
2.2. Reasons why opioids should be available 
There is scientific evidence for the benefits of opioid medicines for the treatment of specific 
symptoms and conditions, as well for the patients’ and families’ quality of life. The treatment 
is simple and inexpensive with at the same time good outcomes for the individual and public 
health (15). 
Benefits for the treatment of pain 
Pain management in palliative care follows the rules of cancer pain management, with anal-
gesic medications according to the principles of the World Health Organisation (22) in the 
centre of the therapeutic approach. Opioids such as oral morphine are essential for pain 
management in palliative care, in acute pain as well as in many chronic pain conditions. They 
are relatively inexpensive and effective palliative care is not possible without the availability 
of a potent opioid. Whereas opioids are well established as the mainstay of pain manage-
ment, it is less well known that opioids are also very effective for the treatment of breathless-
ness (dyspnea) in palliative care (22). 
In 2013, the WHO Expert Committee on the Selection and Use of Medicines made important 
changes in the Model List of Essential Medicines and the Model List of Essential Medicines 
in Children. The most recent versions (18th Edition for adults and 4th Edition for children) 
have a separate section Medicines for Pain and Palliative Care (3, 4). The new section in-
cludes three subsections: non-opioids and non-steroidal anti-inflammatory medicines 
(NSAIMs); Opioid Analgesics; and Medicines for other symptoms common in palliative care. 
Benefits for treatment of opioid dependence 
Strong evidence suggests that methadone can reduce health risks for people with long-term 
opioid dependence, including a reduction of craving and drug-seeking behaviour, prevention 
of infection with Hepatitis C and HIV, improved psychosocial health, stability in people’s eve-
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ryday lives, a better quality of life, as well as a reduction of criminal behaviour (19). In re-
sponse to a resolution to the United Nations Economic and Social Council (ECOSOC), the 
WHO developed Guidelines for the Psychosocially Assisted Pharmacological Treatment of 
Opioid Dependence (9). These guidelines are intended for policy makers and healthcare pro-
fessionals.  
The major benefit of methadone “is not only to reduce or stop opioid use, but also to improve 
health and social functioning” (9). Moreover, pharmacological treatment of drug dependence 
has the potential to provide psychological empowerment and give hope to a drug user by 
helping to see his or her problems from a different perspective (9). In addition, treatment can 
help to connect drug users with the main stream healthcare services, implying access to 
much wider health-care provision such as physical and psychiatric care, social assistance, 
and family support. Therefore, such long-term treatment should not be seen as treatment 
failure, but as an evidence-based way of protecting the drug users’ health. 
Opioids are essential medicines 
Due to their benefits for medical treatment, opioids – particularly orally administered mor-
phine – are regarded as the treatment gold standard for moderate and severe pain, including 
pain associated with cancer, AIDS, and other diseases or conditions requiring palliative or 
end-of-life care, as well as pharmacological treatment of opioid dependence (23). For this 
reason, the WHO Expert Committee on the Selection and Use of Essential Medicines has 
designated morphine and other opioid analgesics as essential medicines (18). Essential 
medicines “satisfy the priority healthcare needs of the population. They are selected with due 
regard to public health relevance, evidence on efficacy and safety, and comparative cost-
effectiveness. Essential medicines are intended to be available within the context of function-
ing health systems at all times in adequate amounts, in the appropriate dosage forms, with 
assured quality and adequate information, and at a price the individual and the community 
can afford.” (3), p. 2. 
Insufficient access to opioid medicines does have manifold and profound consequences for 
healthcare professionals, patients and their families. It also has severe negative impact on 
the public health that many patients in Europe do not receive adequate treatment for pain, 
dyspnea and opioid dependence because of inadequate regulations and deficiencies in pub-
lic policy (13). 
For an individual patient, it can cause serious and unnecessary suffering when opioid medi-
cines – an essential, inexpensive and safe medication – are not adequately accessible. Nu-
merous scandalous examples have illustrated the existential consequences of unnecessary 
and unspeakable suffering from pain and terminal dyspnea, as well as fatal consequences of 
illicit drug use like getting infected with HIV especially in low- and middle-income countries 
(23, 3). As a last resort, for some patients suicide appears the only way out. Family mem-
bers’ distress associated with trying to support their loved ones in receiving opioid medicines 
and witnessing their suffering everyday can burden close relatives for years (3). 
Access to opioid medicines as a human right 
For the reasons highlighted above, health authorities are increasingly advocating for ade-
quate access to opioid medicines as a human right. Because of their status as essential 
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medicines according to WHO, their availability for medical treatment is considered to be part 
of the right to the enjoyment of the highest attainable standard of health and well-being as 
defined in the International Covenant on Economic, Social and Cultural Rights (article 12, the 
Right to Health in conjunction with General Comment 14, paragraph 12) (15). WHA Resolu-
tion 67.19 Strengthening of palliative care as a component of comprehensive care through-
out the life course affirms that access to palliative care and to essential medicines for medi-
cal and scientific purposes manufactured from controlled substances, including opioid anal-
gesics such as morphine contributes to the realization of the right to the enjoyment of the 
highest attainable standard of health and well-being. The ACMP’s recommendations are also 
taken on by those of Human Rights Watch, an international nongovernmental organization 
that has included opioid inaccessibility as a human right issue (3). 
 
3. The principle of balance 
A balance in national drug control policies needs to be ensured, allowing access to controlled 
medicines for the relief of pain and suffering in all cases while preventing their diversion and 
misuse. Therefore, a balanced strategy is needed to counter the problem, which not only 
focuses on law enforcement, but also includes a public health perspective (Textbox 2; (17)). 
Textbox 2 Balanced public health outcome according to WHO 
WHO considers the public health outcome to be at its maximum (or ‘balanced’) when the optimum 
is reached between maximizing access for rational medical use and minimizing substance abuse. 
All countries have a dual obligation with regard to these medicines based on legal, political, public 
health and moral grounds. The dual obligation is to ensure that these substances are available for 
medical purposes and to protect populations against abuse and dependence. Countries should 
aim at a policy that ultimately achieves both objectives; in other words, a ‘balanced policy’ (17). 
 
Governments’ obligation 
The principle of balance implies a government’s obligation to ensure their country’s best pub-
lic health outcome. One of the objectives of the Single Convention on Narcotic Drugs (11) is 
to ensure availability of opioids that are indispensable for the relief of pain and suffering. To 
accomplish this objective, the Single Convention requires that governments adopt laws, 
regulations and administrative procedures to implement mechanisms to ensure adequate 
availability of opioid medicines. Joranson et al. (14, 18) stated that “Any attempt to address 
adequate availability and accessibility of opioid analgesics should take a public health sys-
tems approach, the elements of which parallel those of patient care: examination of national 
and sometimes state-controlled drug policy and distribution systems; diagnosis of weakness-
es and blockages; prescription of the necessary treatments; monitoring of outcomes; and re-
treatment if necessary. The distribution system is only as strong as its weakest link. Figure 1 
illustrates the basic elements of an opioid distribution system in which information about the 
requirement for opioids moves upward from the patient, and the adequate amount of medica-
tions move downward.” (14, 18). 
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Guidance on government mechanisms to ensure adequate medicines availability is detailed 
in the WHO policy guidelines Ensuring Balance in National Policies on Controlled Substanc-
es, Guidance for Availability and Accessibility of Controlled Medicines (17). Annual estimates 
of the amount of opioids required for medical and scientific need to ensure sufficient import, 
reporting of consumption data, and dialogue with healthcare professionals to ensure appro-
priate procedures and sufficient supply of opioids in medical practice (18). 
However, in many countries the focus of drug policies is on control at the cost of availability 
for medical purposes. Often governments have established control measures that are much 
stricter than required by the Single Convention, resulting in a disproportionate burden for 
healthcare professionals and patients compared to the potential public health outcome in 
terms of prevention of misuse and diversion. This includes excessive bureaucratic proce-
dures such as complex prescription forms and prescription books, restrictions that limit the 
diagnoses of eligible patients, limitations on prescription amounts or on the daily dose, as 
well as complicated requirements for storage and dispensing of opioid medications (18). 
These unduly strict national laws have negative impact on the availability of opioid medica-
tions, resulting in a discrepancy between good medical practice and treatment reality, and 
eventually impeding relief of pain and suffering - an effect that was clearly not intended by 
the International Conventions (21). 
Distribution System Ensuring Availability 
International Narcotics Control Board (INCB) 
Plan poppy cultivation 
Confirm national estimates, supplements 
National „Competent Authority“ 
Estimate requirements, report statistics 
License products, importers, and all entities  
in distribution chain, approve importation 
Importers, Manufacturers, Distributors 
Produce/import sufficient amounts 
Distribute promptly to retail level 
Hospitals, Pharmacies, Service Providers 
Obtain license, training 
Purchase adequate supplies 
Dispense according to prescription 
Anticipate needs 
Physicians/Nurses 
Assess patients‘ symptoms and needs 
Prescribe according to needs 
Medication                 Patients                 Information 
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4. Barriers to access to opioid medicines 
Barriers to opioid availability are of multi-factorial nature; therefore tackling the problem from 
one side will not resolve it entirely. In a critical reflection on access to therapeutic opioid med-
ications in Europe fifty years on from the Single Convention on Narcotic Drugs, James F. 
Cleary (Pain and Policy Studies Group) stated that “Implementation may be the hardest step 
as it would be false to state that the inadequate treatment of cancer pain is due entirely to 
regulatory restrictions. We know from experience that policy change alone does not bring 
about increased access. We need to address the low priority of pain with health care, inade-
quate education, exaggerated fear of opioids and addiction, and problems in the supply chain 
for the medications.” (21), p. 2. Next to legal and regulatory obstacles, barriers were identi-
fied in the following areas: national policies, knowledge and societal attitudes; and economic 
aspects, including affordability (17). 
Legal and regulatory barriers include restrictive laws and regulatory barriers, resulting in 
burdensome bureaucratic procedures relating to the prescribing and dispensing of opioid 
medicines and in fear of legal sanctions and criminal prosecution due to unintended viola-
tions among healthcare professionals and pharmacists. But also restrictions regarding a pa-
tient’s eligibility for treatment with opioids, as well as professional restrictions such as specific 
license requirements for the prescribing and administering of opioid medicines can pose a 
barrier to access to opioids and interfere with clinical decision making. 
Policy barriers refer to a country’s national policies related to availability of and access to 
opioids, such as the national health policy and infrastructure of service provision, reimburse-
ment systems, but also the national priority for health problems requiring treatment with opi-
oid medicines and how these factors can be barriers to the access of opioids.  
Knowledge and societal attitudes include a lack of education in healthcare professionals 
resulting in inadequate medical practice, but also fears, misconceptions and stigma regard-
ing opioids among patients, relatives, healthcare professionals, government officers, and the 
general public. For example, in the treatment of drug dependence there is a prevailing nor-
mative idea of ‘abstinence orientation’, i.e. the conviction that drug-freeness is the only pos-
sible therapeutic goal for people dependent on opioids. In pain treatment and palliative care, 
fear of dependence, side effects or even hastened death may prevent physicians from pre-
scribing opioids but also patients from taking them. Lack of knowledge in healthcare profes-
sionals may lead to discomfort in physicians due to uncertainty in the appropriate assess-
ment and treatment of pain or dyspnea, as well as insufficient knowledge in methadone 
maintenance treatment. 
Economic aspects, including affordability refer both to a limited range of available formu-
laries and to a gap in the supply of available opioids that would be required for medical 
treatment. A lack of available opioids can have different reasons such as problems in the 
storage, dispensing and distribution of opioids, gaps in the supply chain, inappropriate esti-
mates and reporting of annual consumption data, or an inappropriate market of the neces-
sary range of opioid formularies. 
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5. The ATOME project – an overview 
The European Commission’s 7th Framework programme funded the Access to Opioid Medi-
cation in Europe (ATOME) project from December 2009 for five years. Its objective is to im-
prove access to opioids in 12 European countries (Figure 2) where there is statistical evi-
dence of very low per capita morphine consumption: Estonia, Latvia, Lithuania, Poland, Slo-
vakia, Hungary, Slovenia, Serbia, Bulgaria, Turkey, Greece and Cyprus. 
Figure 2 Countries included in ATOME 
 
 
The ATOME project was initiated and developed by the World Health Organization and coor-
dinated by the University Hospital Bonn1. The consortium consisted of 10 partners including 
members from the areas of palliative care, law and health policy as well as harm reduction 
(Table 1). 
                                               
1 From December 2009 until March 2011 by the University Hospital Aachen. 
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Table 1 Partners in the ATOME consortium 
Palliative care 
Law / health policy/  
governance 
Harm reduction 
Department of Palliative Medicine, 
University Hospital Bonn, Germany 
Hospice Casa Sperantei,  
Brasov, Romania 
Help the Hospices, London, UK 
International Observatory on End of Life 
Care, Lancaster University, UK 
European Association for Palliative 
Care, Milan, Italy 
World Health Organization, Geneva, 
Switzerland 
Utrecht University, Utrecht,  
the Netherlands 
 National Anti Drug Agency, Bucharest, 
Romania 
Eurasian Harm Reduction Network, 
Vilnius, Lithuania 
Harm Reduction International, London, 
United Kingdom 
 
5.1. ATOME specific objectives and work plan 
The partners of the ATOME project worked with country teams, including government offi-
cials and healthcare experts, to carry out applied legislative and policy research, leading to 
recommendations that would facilitate access for all patients requiring treatment with medi-
cines controlled under the international drug conventions. The integration of palliative care 
and harm reduction was a key aim of the project. To accomplish its objectives, the ATOME 
project followed two tracks of activities in parallel (Figure 3). 
One track looked at optimising the relevant legislation in order to acknowledge both the pre-
vention of misuse and dependence and the medical need for these medicines. The goal was 
to optimise relevant legislation by identifying provisions that may impede access to controlled 
medicines and to make recommendations for improvement in consultation with the national 
counterparts. Activities in this track started with a legislation review training for lawyers and 
national counterparts from the 12 target countries. This training focused on how to review 
national controlled substances legislation from the perspective of balancing availability and 
prevention of misuse and how to identify relevant legislation for the national legislation analy-
sis. Based on this training, national counterparts selected legislation and provisions relevant 
for the access to opioid medicines in their country. A ‘quick scan’ of the pre-selected national 
legislation was undertaken followed by a deeper review of relevant legislation (for details on 
the methodology see Annex 2). The quality of final results, i.e. the identified legal barriers 
and appropriate recommendations for each country, was assured during a legislation review 
workshop with participants from the target countries and experts from relevant areas. 
The other track was related to the analysis of national policies and national circumstances 
that affect the accessibility and availability of the medicines involved. The goals were both to 
make recommendations to the government and to make professionals aware of problems 
arising from their professional practice, by undertaking a national situational analysis with 
regard to controlled medicines, including their availability, rational use and reasons for un-
deruse. Activities in this track were two six-country-workshops where the national delega-
tions developed a national action plan for the improvement of the access to and availability of 
opioids in their country. The situation analysis, the identification of relevant challenges and 
appropriate proposals for solutions were elaborated by the national representatives them-
selves by using the value of an international exchange framework and by learning from mod-
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els in other countries with similar problems. The national strategic action plans developed 
during these workshops were an important foundation for the subsequent activities of the 
country teams. 
As a follow-up to the six-country workshops, national conferences were held in the respective 
countries. The aim of these one-day events was the sensitisation of key stakeholders to-
wards opioid availability in their country, and dissemination of the results of the legislation 
analysis and the strategic action plan for improving access to opioids on a national level. The 
conferences also provided an opportunity for national experts to present their analysis and 
views and for national and international professionals from the fields of palliative care and 
harm reduction to network and engage in discussion about issues relating to opioid access. 
Building on the previously developed national strategic action plans, the conferences result-
ed in specific recommendations being developed in relation to improving opioid availability 











Parallel to these two tracks, research and monitoring activities were undertaken in order to 
illuminate the background situation and the socio-cultural context in each country. Data were 
collected on the characteristics of each country such as demographic information, political 
and economic background, national healthcare system, public health context, prevalence of 
conditions associated with a potential need for opioid medicines, service provision and edu-
cational situation regarding controlled substances, as well as socio-cultural issues such as 
religion and spirituality, attitudes towards suffering, and public awareness regarding opioid 
medicines. The results of these research and monitoring activities were used to inform the 
ATOME database including country profiles for each of the countries addressed by this pro-
ject. 
  













Outcome: country specific 
recommendations for legis-
lation improvement 
WP3 & 4: Six-
country workshops 
Outcome: country specific 
recommendations for con-




mentation of national rec-
ommendations 
Figure 3 Two tracks of ATOME activities: legislation review and national situation analysis 
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5.2. ATOME strategic impact 
The ATOME project was designed to have strategic impact on six levels: (1) developments of 
tools and standards; (2) national policy making processes and access to pain medication and 
substitution treatment; (3) national capacity building; (4) research collaboration and sharing 
of experiences in Europe; (5) contribution towards the implementation of European policies; 
and (6) impact on the patients and populations themselves – those in need of pain medica-
tion, people with opioid dependence, and related to the latter, populations at risk for HIV and 
HCV infections. 
 
6. Key findings 
Research conducted throughout the ATOME project provided insights and outcomes in four 
related areas relevant for access to opioid medicines: challenges in policy and guidance 
concerning access to opioids, legal barriers, policy barriers and the perception of barriers. 
 
6.1. Challenges in policy and guidance concerning access to opioids 
A substantial revision of the previous WHO Guidelines on national opioids control policy from 
2000 (3) resulted in the WHO policy guidelines Ensuring Balance in National Policies on 
Controlled Substances, Guidance for Availability and Accessibility for Controlled Medicines 
(17). An expert consensus process reflected the challenges to the principle of balance inher-
ent in the Single Convention on Narcotic Drugs (24). The expert panel consisted of experts 
from many countries and different work areas. The revision of the guidelines was developed 
through a three-stage Delphi process followed by a conference during which remaining dif-
ferences of views were resolved. This consensus process reflected the difficulty of defining 
the ‘right’ balance between ‘rational use’ and ‘misuse’ of opioids. The definition of the con-
cepts of ‘rational (medical) use’ vs. ‘misuse’ of controlled substances can be seen as pivotal 
for the principle of balance in controlled substances policies. However, it can also be ques-
tioned whether this distinction is an existing fact or a social construct in an attempt to cope 
with the challenge of outweighing the risks and benefits of certain substances. Disagreement 
emerging from the consensus process underlines the complexity of political guidance, which 
takes into account the delicate balance between control and easy availability, between nec-
essary and unnecessary barriers, and between protection and harm. The resulting WHO pol-
icy guidelines provide guidance and recommendations on how to ensure balanced drug con-
trol policies (17). 
 
6.2. Legal barriers 
An external review of national legislation was undertaken to optimise relevant legislation by 
identifying provisions that may impede access to controlled medicines and by making rec-
ommendations for improvement in consultation with the national counterparts. The new WHO 
policy guidelines Ensuring Balance in National Policies on Controlled Substances provided 
the basis for the identification of potential barriers to access to opioids. The legislation review 
focused on nine different categories of potential legal and regulatory barriers, i.e. barriers 
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related to prescribing; dispensing; usage; trade and distribution; manufacturing; affordability; 
penalties; language; and other. A short summary of the most common potential legal and 
regulatory barriers identified in eleven of twelve European countries participating in the 
ATOME project is provided in this section.  
The prescribing of opioids is subject to more or less strict administrative and non-
administrative requirements. As an example, in several countries the authorisation to pre-
scribe designated controlled medicines is restricted to a limited number of medical specialists 
(e.g. oncologists or psychiatrists). Some countries require a special permit, license or author-
isation for prescribing controlled medicines. The procedures for prescribing opioid medicines 
can be complex and bureaucratic. Physicians are often obliged to use special prescription 
forms often in multiple copies. These forms are not always available free of charge. Complex 
reporting requirements can be applicable for physicians authorised to prescribe. In addition, 
limitations have been identified regarding the validity of medical prescriptions, the treatment 
period, the total amount of opioid medicines to be prescribed and some countries have lists 
with maximum daily dosages of opioid medicines in their legislation. 
Similar to the prescribing of opioid medicines, most countries have complex administrative 
requirements regarding dispensing of opioids in their legislation. In some countries, only des-
ignated pharmacies are allowed to dispense these products or a license is required for dis-
pensing. In addition, several countries require that opioid medicines are stored under overly 
strict and costly security conditions. Strict inclusion requirements can apply to accessing de-
pendence treatment and the legislation in several countries contains administrative require-
ments and geographical restrictions to using opioid medicines. 
The overly strict administrative requirements and the overly strict and costly storage require-
ments regarding the dispensing are also seen in the area of manufacturing, trade and distri-
bution of opioid medicines. In some countries, intimidating language is used in punitive provi-
sions and severe sanctions apply for patients, healthcare professionals or for persons in-
volved in manufacturing, trade and distribution. In several countries treatment with necessary 
controlled medicines is not fully reimbursed or fees are applicable for receiving dependence 
treatment. In addition, all countries use language in their legislation that contributes to the 
stigmatisation of opioid medicines, for example by referring to opioid medicines as danger-
ous intoxicating drugs. Definitions are often absent or incorrectly used and patients with de-
pendence syndrome are frequently referred to in a disrespectful manner. 
The results of this external review of national legislation give rise to a critical internal review 
of national legislation and revision of provisions that might impede access to opioid medi-
cines. This revision is recommended to take place in consultation with healthcare profes-
sionals to provide a legal framework that focuses on optimizing healthcare outcomes and 
preventing diversion and misuse. Several of the countries participating in the ATOME project 
are already in the process of revising legislation and implementing recommendations for im-
provement. As a result, several changes in legislation have already come into force, lifting 
potential barriers to access to opioids. 
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6.3. Policy barriers 
To identify potential policy barriers to accessing opioid medication, documents developed 
during the project, such as protocols of national problem analyses, strategic action planning 
worksheets, and minutes of national ATOME conferences were systematically analysed. The 
identified policy barriers2 and the resulting recommendations were sent to the respective 
national country teams for review and verification. For the twelve Eastern European countries 
participating in this project the major challenges to opioid access were identified in four main 
categories i.e. financial/ economic aspects and governmental support, formularies, education 
and training and societal attitudes. Based on material collected during several project events 
different provisions per category that have been considered to impede access to opioid med-
ication in each country were also identified.  
In terms of financial/economic aspects and governmental support, in most countries, the ma-
jor provisions considered to impede opioid access were associated with insufficient funding 
for palliative care and harm reduction initiatives. The impact of economic recession currently 
experienced by a number of European countries as well as the lack of governmental support 
(of non-economic nature) were also identified as barriers to opioid access in almost half of 
the countries involved in this project. In some countries the governmental commit-
ment/endorsement is more focused on prevention of diversion than on development, exten-
sion or promotion of effective standards for opioid treatment. 
In terms of formularies in most countries, the major provisions considered to impede opioid 
access were associated with the high cost or the inadequate reimbursement of opioid treat-
ment and palliative care services as well as the insufficient provision of such services or the 
conflicts observed between medical specialties during service provision. The shortage of 
palliative care experts and the lack of established multi-disciplinary palliative care networks 
were also identified as major barriers to opioid access in more than half of the countries in-
volved in this project. In some countries, it was reported that there was a prevailing biomedi-
cal approach to illness and priority was given to causal treatment and cure of diseases, while 
the relief of pain and other symptoms, as well as psychosocial aspects were neglected. 
Moreover, provisions such as bureaucracy or overly restrictive regulations as well as geo-
graphical or age constraints were also identified as impeding access to opioid medication. 
In terms of education and training, provisions related to absent, limited or fragmented post-
graduate education and lack of training initiatives were identified in all countries whereas the 
absence or the inadequacy of continuing medical education was also observed in some of 
the participating countries. The impact of this type of barrier affects the implementation of 
legal changes in a country as well. Despite of formal changes such as facilitated require-
ments to use special prescription forms, physicians’ prescribing activities do not change. As 
no formal barriers exist to obtain this type of prescription forms this is rather an effect of the 
lack of knowledge and inappropriate education or attitude towards opioid treatment of those 
physicians 
                                               
2 A barrier is reported for an individual country if it was identified to have an impact on access to opioid medicines 
in the respective country based on the collected data. Not for all countries was the similar amount of data (e.g. in 
the form of policy documents) available and therefore, the level to which access to opioids is impeded is not nec-
essarily related to the number of barriers that was found. In countries where a particular barrier was not identified 
or directly reported, it can still be existent but may not have been focused or emphasised during the discussion 
with national stakeholders. 
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Related to societal attitudes, fears of opioids (fear of dependence, tolerance, diversion, and 
death), inadequate social dialogue and dissemination (of information and advice) as well as 
lack of awareness (misinformation and misconception) about the use of opioids in pain man-
agement, palliative care and harm reduction comprise barriers to opioid access identified in 
all twelve countries. In most countries stigma and discrimination was also considered to be 
one of the main barriers to impede access to opioid medication.  
The findings of the review of national policies illustrate that beside barriers in the national 
legislation there are also several challenges concerning national policy strategies with regard 
to improved access to opioids and the use of these medicines for medical treatment. This 
outcome is based on problem analyses conducted by the country teams and on discussions 
with national stakeholders throughout the ATOME project. For several challenges recom-
mendations have been made in relation to country specific backgrounds. Some of them have 
already been considered in national policies, some of them still are waiting for opportunities 
to be realized or to be completed. For that purpose the recommendations should be used in 
further exchange between authorities, stakeholders and the civil society. 
 
6.4. Perception of barriers 
Access to opioids can be hampered by barriers on different levels as described in chapters 
6.2 and 6.3. Discussions within the ATOME project indicated that healthcare professionals 
and decision makers may have a different perception of barriers to opioid use. A question-
naire was compiled to compare the perception of barriers in different stakeholder groups in 
the field of pain management, palliative care and harm reduction. 
A survey was conducted using a questionnaire partially constructed from already existing 
surveys, containing three sections: (1) knowledge and attitudes regarding medical use of 
opioids; (2) the perception of different types of barriers towards access to opioids; and (3) 
respondents’ personal and professional details. The questionnaire was reviewed for content 
validity by four experts in pain management, palliative care, harm reduction and policy, and 
was pilot-tested in Latvia. Participants of the ATOME national conferences were invited to 
complete the questionnaire.  
Data were collected from 233 stakeholders, among which 55% healthcare professionals, 
17% government officers/ healthcare decision makers, 10% harm reduction professionals 
and 3% patient representatives during ATOME national conferences in seven countries (Es-
tonia, Latvia, Lithuania, Poland, Slovakia, Hungary and Serbia). 
The aspects that were most frequently perceived as a major barrier and as having major im-
pact in practice were inadequate knowledge, skills and training in healthcare professionals; 
absence of a specific national policy on pain management/ palliative care; physicians’ reluc-
tance to prescribe opioids and lack of financial resources at an institutional level. Considera-
ble differences were identified between groups; overall, government officers perceived issues 
less often as a major barrier compared to other stakeholder groups. 
For example, a high proportion of healthcare professionals and patients reported that exces-
sive regulation had a major impact on accessing opioids in practice, while this was seen less 
often as a problem by government officials. The regulatory burden perceived by healthcare 
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professionals could be one reason for the reported physicians’ reluctance to prescribe opi-
oids. The data do not allow to explain the reasons for the difference in perception between 
different stakeholder groups. Therefore, intensified dialogue will be necessary to facilitate a 
mutual understanding and develop effective solutions to improve access to opioid medicines.  
 
6.5. General recommendations 
Based on the analyses and the outcomes of the ATOME project general recommendations 
can be derived for all countries aiming to achieve and to ensure a balanced approach in na-
tional policies on controlled substances. A selection of them is presented in Textbox 3.  
 
Textbox 3  Recommendations applicable to all countries 
§ Implement the WHO policy guidelines Ensuring Balance in National Policies on Controlled 
Substances, Guidance for Availability and Accessibility for Controlled Medicines; 
§ Identify potential legal and regulatory barriers to access to opioid medicines and working on 
changes with the aim to improve accessibility, availability and affordability; 
§ Ensure non-stigmatizing language in legal documents and language in official documents 
(e.g. by using the term ‘Narcotic drug’ only when referring to substances controlled under the 
Single Convention); 
§ Establish regular exchange opportunities (communication networks) between legal and gov-
ernmental authorities, healthcare professionals and patients/families in order to raise aware-
ness for practical impact and requirements of legal and policy decisions (target-performance 
comparison) regarding opioid availability and accessibility; 
§ Provide and support the implementation and development of national databases (including 
data on long-term outcomes and national fear of opioids) suitable for scientific research, eval-
uation of models of treatment with opioids and for monitoring the national demand on Essen-
tial Medicines; 
§ Ensure that treatment with opioids (knowledge, skills, attitudes) will be included in undergrad-
uate and postgraduate education for relevant healthcare professionals (primarily physicians, 
nurses, pharmacists); 
§ Raise awareness and sensitisation for treatment with opioids among practicing healthcare 
professionals (e.g. via Continuing Medical Education, publication series on the rational use of 
opioids in highly-accessed national medical journals, a survey on knowledge and attitudes re-
garding opioid medicines); 
§ Raise awareness in the general public, e.g. via media campaigns or information, brochures 
for patients and relatives. 
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7. An outlook beyond ATOME 
ATOME has produced some remarkable changes in the participating countries throughout 
the lifetime of the project. There are examples of the changes that may be directly attributa-
ble to the ATOME project. In Estonia validity of prescriptions for controlled medicines have 
been extended from 14 to 30 days, and digital prescription has been implemented in October 
2012. Similarly, Turkey has started to implement an e-prescription system in July 2012. In 
Greece, legislation on controlled medicines was changed in March 2013, changing the des-
ignation from ‘narcotics law’ to ‘law on substances causing addiction’, introducing the princi-
ple of balance with mentioning of patients with chronic illnesses as potential users of con-
trolled substances and an option for pharmacists to fill a prescription with a higher amount in 
emergency cases. In addition, a palliative care specialist was included in the Committee on 
Narcotics in the Ministry of Health. In Lithuania, the Department of Pharmacy in the Ministry 
of Health has prepared amendments to the regulations on opioid agonist therapy (OAT) 
which will allow to increase the amount of opioid medications to be stored in healthcare facili-
ties from 7 to 60 days of supplies.  
Some of these changes might have been triggered not only by ATOME activities, but also by 
other recent palliative care developments. The target countries of the ATOME project had 
been selected to include only countries where no major palliative care initiative had been 
reported, but parallel activities from other projects were evident in some countries. In Serbia, 
the project on ‘Development of Palliative Care Services in Serbia’ also looked at the legisla-
tion on controlled medicines and contributed to a change in legislation in December 2013 
allowing non-governmental organizations to provide palliative care and prescribe medicines 
in the same way as public health institutions. However, feedback from the country teams 
suggested that ATOME activities had contributed significantly to these developments.  
Even if not related directly to changes in legislation, ATOME activities resulted in more subtle 
changes, bringing together stakeholders from government, palliative care and pain manage-
ment as well as harm reduction. This collaboration and networking has resulted in a change 
of atmosphere, and will produce more changes in legislation in the medium and long-term 
development that will overcome regulatory and legislative barriers.  
ATOME has made an impact not only in the 12 participating countries, but also in other coun-
tries in Europe as well as in other regions of the world. The guidelines on ensuring balance in 
access to opioid medications of the World Health Organization have been used by govern-
ment and non-government stakeholders, and the methodology with country teams and coun-
try workshops has also been used in other regions. National conferences with government 
representatives and palliative care experts from non-governmental organizations for example 
have been organized in Central and South American countries by the International Associa-
tion for Hospice and Palliative Care.  
ATOME results also have to be discussed in the context of recent advances in the global 
development of palliative care. Palliative Care has received considerable support from sev-
eral international activities during the project time of ATOME. Foremost, a resolution on 
strengthening of palliative care at the World Health Assembly in May 2014 (25) has raised 
much attention on a global level. This was the first time that the highest global health authori-
ty published a statement on palliative care. The resolution urged member states to support 
access to essential medicines, and strengthen palliative care as a component of integrated 
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treatment throughout the life course, and stated that palliative care is an ethical responsibility 
of health systems.  
Similarly, the inclusion of a palliative care indicator in the Action Plan for the Global Strategy 
for the Prevention and Control of Non communicable Diseases (26) (NCD) of the World 
Health Organization (WHO) has acknowledged pain relief and palliative care as among the 
top 12 issues on the global health agenda. The proposed indicator is: access to palliative 
care assessed by morphine-equivalent consumption of strong opioid analgesics (excluding 
methadone) per death from cancer. This indicator has some limitations and weaknesses, and 
morphine-equivalent consumption of strong opioid analgesics (excluding methadone) per 
capita has been suggested as an alternative (27). 
Another important window of opportunity to put palliative care on the global health agenda: 
opens with the Sustainable Development Goals (SDGs) of the United Nations that will define 
global health priorities from 2015 to 2030 (28). The SDGs replace the eight millennium de-
velopment goals (MDGs) that have been in place from 2000 until 2015. Palliative care is rel-
evant to two of the targets related to the third goals in the SDGs. The target of achieving uni-
versal health coverage (UHC, target 3.8) includes access to essential health care services, 
and access to safe, effective, quality, and affordable essential medicines and vaccines for all. 
In addition target 3.9b aims to support research and development of vaccines and medicines 
for the communicable and non-communicable diseases that primarily affect developing coun-
tries, and provide access to affordable essential medicines and vaccines. 
Results from the ATOME project such as the guidelines on ensuring balance (17) will be use-
ful in the implementation of these global activities. The ultimate goal is to ensure access to 
adequate pain management, palliative care and harm reduction for every patient who needs 
it, no matter where he lives. Access to controlled medicines is needed for this goal. 
 
8. Reference to the other chapters in this book 
Part II of the ATOME final report provides twelve country reports including detailed findings 
and country specific recommendations to the Ministries of Health for each of the twelve Eu-
ropean countries participating in the ATOME project. The country reports are presented ac-
cording to the geographical order from North to South: Estonia, Latvia, Lithuania, Poland, 
Slovakia, Hungary, Slovenia, Serbia, Bulgaria, Turkey, Greece and Cyprus. Each country 
specific report starts with an introduction presenting the statistical evidence of very low per 
capita morphine consumption followed by a summary of identified legal and regulatory barri-
ers and a selection of respective recommendations specific to each country. This section is 
followed by identified policy barriers and a selection of policy recommendations for the re-
spective state. The forth section of each country report presents citations of ATOME partici-
pants highlighting changes regarding access to opioid medicines in the country since the 
beginning of the project. Each report ends with a conclusion followed by a timescale present-
ing the ATOME activities and events in respective country during the five project years. 
A further relevant element of the ATOME final report is the Annex collection. This collection 
includes four attachments:  
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§ Annex 1 Additional country information contains selected parts of the respective 
country profile, a report of the national conference and an overview of national coun-
terparts, i.e. the members of the ATOME national country team; 
§ Annex 2 Legislation Review Reports presents the original contents of eleven legisla-
tion review reports including a detailed description of methodology used for the law-
yers’ legislation review training, the ‘quick scan’ and the deep scan of legislation. 
These reports were prepared by the Utrecht Institute for Pharmaceutical Sciences, 
Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht University 
(Utrecht, the Netherlands) as this project partner was the responsible work package 
leader for the above mentioned activities; 
§ Annex 3 ATOME publications provides an overview on the ATOME articles in scien-
tific journals and abstracts of international congresses as part of the dissemination ac-
tivities; 
§ Annex 4 Description of Consortium Members presents organizations and staff mem-
bers participating in the Consortium of the ATOME project. 
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Access to Opioid Medication in Europe (ATOME) 
Report and recommendations to the Ministry of Social  
Affairs 
1. Country Report - Estonia 
1.1. Introduction 
Estonia is one of the countries with statistical evidence of inadequate morphine consumption 
per capita. In 2006, the adequacy of opioid analgesic consumption was only 11% - based on 
a per capita consumption of 24.63 morphine equivalents (mEq) while 216 mEq would have 
been adequate for treatment of all pain conditions3. Estonia was selected as one of the coun-
tries to participate in the ATOME project due to its low per capita morphine consumption. 
Four years later, in 2010, the adequacy of opioid analgesic consumption had even slightly 
decreased (both in absolute and in relative terms) – it was only 6%4 (based on a per capita 
consumption of opioid analgesics of 18.39 morphine equivalents (mEq) while 310.09 mEq in 
mg per capita would have been adequate). This report presents a summary of the results of 
the situational analysis that has been undertaken with regard to opioid availability and acces-
sibility in Estonia. The results of the situational analysis are divided in two parts: the first part 
addresses legal and regulatory issues and the second part focuses on issues relating to poli-
cy. Both parts present the main barriers and recommendations for improving access to opioid 
medication in Estonia.  
1.2. Identified legal and regulatory barriers 
The results of the ATOME legislation review have been divided into nine different categories 
of potential legal and regulatory barriers, i.e. barriers related to prescribing; dispensing; us-
age; trade and distribution; manufacturing; affordability; penalties; language; and other. In 
Estonia, potential legal and regulatory barriers have been identified in eight of these nine 
categories: all except affordability (see Annex 2). A selection of these potential barriers is 
highlighted below according to category, followed by recommendations to remove these bar-
riers. For a more detailed description of the methods and results, see Annex 2. Notably, in 
the course of the project – not least related to the continuing engagement of the legal experts 
in the ATOME Estonia country team – several changes to the legislation came into force. As 
a consequence, a number of major barriers were lifted before the end of the project and are 
not applicable anymore. For reasons of transparency, the original results of the external re-
view of national legislation concerning controlled substances which was collected in the peri-
od March 2011 – February 2013 (legislative changes that were implemented after February 
2013 have not been taken into account) are presented here; parts that were changed are 
                                               
3 Seya MJ, Gelders SFAM, Achara UA, Milani B, Scholten WK. A First Comparison between the Consumption of 
and the Need for Opioid Analgesics at Country, Regional and Global Level. Journal of Pain and Palliative Care 
Pharmacotherapy, 2011; 25: 6-18. Accessible at: 
http://apps.who.int/medicinedocs/documents/s17976en/s17976en.pdf 
4 Duthey, B., Scholten, W. Adequacy of Opioid Analgesic Consumption at Country, Global, and Regional Levels in 
2010, Its Relationship With Development Level, and Changes Compared With 2006. Journal of Pain & Symptom 
Management 47(2); 2014: 283-97 doi:10.1016/j.jpainsymman.2013.03.015; 
http://www.sciencedirect.com/science/article/pii/S0885392413002728  
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highlighted with an asterisk and the changes including the current situation are described in 
an amendment below the respective paragraph. 
PRESCRIBING: The prescribing of opioids in Estonia is subject to many administrative and 
non-administrative requirements. For example, the total amount of controlled substance to be 
prescribed is limited to the quantity necessary for one month. In addition, the validity of a 
special medical prescription used for prescribing controlled substances is limited to 30 days 
from the date of issuance of the prescription5. These restrictions are potential barriers to ac-
cess; patients who require medical treatment with controlled medicines for a longer period 
will need to visit the physician and pharmacy frequently. 
Administrative requirements that apply to the prescribing of opioid medicines may deter 
healthcare professionals from prescribing these medicines. For example, special prescription 
forms - in three copies printed in green on red self-copying paper - must be used when pre-
scribing controlled medicines classified as ‘narcotic drugs’. A copy of the prescription form 
has to be stored for 5 years according to prescription date at the place of employment of the 
healthcare professional who prescribed the controlled medicine6. 
In addition, medical practitioners are required to collect the remaining controlled medicines 
for destruction upon the death of a patient7. All these requirements may increase the admin-
istrative burden and potentially cause medical practitioners in Estonia to be reluctant to treat 
patients with controlled medicines. 
DISPENSING: Additional requirements for the dispensing of controlled medicines may in-
crease the administrative burden and may cause pharmacists to be reluctant to dispense 
controlled medicines. According to the Estonian legislation, a license is required to be author-
ised to dispense controlled medicines containing substances listed in Schedule II. In addition, 
only pharmacies that have obtained this license are authorised to receive unusable medicinal 
products classified as ‘narcotic drugs’ or ‘psychotropic substances’ from consumers. The 
requirement for a license to dispense controlled medicines in pharmacies is a potential barri-
er to access as it may deter pharmacist for applying for such a license8. The prohibition to 
receive unusable controlled substances without a license contributes to the stigma of con-
trolled substances use. 
TRADE AND DISTRIBUTION: Requirements regarding the trade and distribution (and also 
the manufacturing) of controlled medicines may increase the administrative burden and may 
delay or impede the availability of medicinal products on the market. According to the Estoni-
an legislation, substances subject to special recording must be received in the presence of at 
least three members of the committee9. In addition, controlled substances have to be stored 
in a room without windows, separated from the surrounding rooms by partitions extending up 
                                               
5 In October 2012 the prescription validity has been prolonged from 14 to 30 days and digital prescription has 
been implemented. 
6 However, the digital prescription system, introduced in Estonia on 1st January 2010, ensures fast and paperless 
communication between the doctor, the pharmacist and the patient. Since 2010 more than 90% of all prescrip-
tions were electronic (digital prescription). Drugs can also be bought from pharmacy for someone else (by family 
member, social worker etc.). 
7 This specific requirement for collecting remaining controlled medicines was entirely repealed, entered into force 
on 23.09.2013 (Regulation No. 73 of the Minister of Social Affairs of 18 May 2005 § 10. Gathering for destruction 
and destruction of narcotic drugs and psychotropic substances. 
8 In July 2013, the requirement that an authorisation is needed to be allowed to dispense controlled medicines has 
been removed. Since 01.07.2013 all pharmacies can order and dispense controlled medicines. 
9This requirement/provision was repealed, entered into force on 23.09.2013, the whole paragraph was revised 
and paraphrased. 
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to the ceiling. The room must have a metal door and must be equipped with a separate alarm 
system connected to the security centre10. The costs of these security measures may be dis-
proportional compared to the risk of misuse and diversion, and may therefore deter legal en-
tities from trading in controlled medicines. 
LANGUAGE: In the Estonian legislation, the distinction between medical use and abuse or 
illicit use is not always clear. In addition, the terms ‘addict(s)’, ‘addiction’ and ‘persons addict-
ed’ are considered to be stigmatising, and are used in the reviewed Estonian legislation.  
Textbox 4 Selection of recommendations specific to Estonia: legal and regulatory 
§ Reconsider the restrictions that apply to the amount to be prescribed and the validity of a 
medical prescription, in particular if these restrictions do not apply to other non-controlled me-
dicinal products; 
§ Decrease the administrative burden for prescribing and dispensing opioid medicines; 
§ Remove the obligation for medical practitioners to collect the remaining controlled medicines 
for destruction upon the death of a patient11; 
§ Remove the requirement for pharmacies to obtain a special license to be authorised to dis-
pense (and receive unusable) controlled medicines11; 
§ Ensure that the costs of security measures for the storage of controlled medicines are not 
disproportional compared to the risk of abuse and diversion; 
§ Provide clear language in legislation and avoid language that stigmatises the medical use of 
opioids or refers to patients with dependence in a disrespectful way.  
1.3. Identified policy barriers 
For Estonia, the main challenges concerning access to opioids were identified in finan-
cial/economic aspects, issues relating to formularies, education and training and social atti-
tudes.  
FINANCIAL/ ECONOMIC ASPECTS: Economic welfare appears to be the foremost priority in 
Estonia with more emphasis being placed on living rather than on how you are going to die. 
There is an evident lack of interest in pain management and palliative care with education 
and training on these fields being rarely available due to lack of sufficient funding. Hospitals 
do not have enough money to send their staff to attend refresher training although at least 60 
hours per year of this kind of training is required for every healthcare worker. Given that re-
fresher courses have to be paid for, most healthcare professionals abstain from attending 
since this is something they cannot afford. More money should be invested on palliative care 
opportunities and harm reduction initiatives. However, the financial crisis that Estonia suffers 
the last few years has resulted in the financial situation in healthcare being seriously affect-
ed. 
FORMULARIES: Palliative care is not a medical specialty in Estonia and there is an overall 
lack of recognition leading to a shortage of experts. This lack of palliative care experts results 
                                               
10 Storage conditions were revised and simplified, entered into force on 23.09.2013. 
11 These two recommendations have already been implemented. Entered into force 23rd of September 2012 and 
1st of July 2013. 
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in physicians or nurses often ‘working alone’. The idea of the ‘multidisciplinary team’ is not 
common in Estonia as there is lack of awareness of certain professional roles (for example, 
the role of social workers is particularly ‘clouded’). This is mainly because biomedical ap-
proaches are given more priority than psychosocial or spiritual issues. In addition, the cost of 
receiving palliative care in a hospital or nursing home is reported as being ‘very expensive’ 
(partly-paid for by the patient/family).  
For some patients living in areas with low prevalence the travel costs of getting Opioid Ago-
nist Therapy (OAT) are extremely high. Some medications available in other EU countries 
or/and Estonia are either not listed as subsidized by healthcare funds or they are only subsi-
dized by 50%. But Estonian Health Insurance reimburses all essential medicines listed in 
WHO Model Lists of Essential Medicines. Moreover, there is lack of experience in prescribing 
amongst family practitioners.  
AVAILABILITY AND QUALITY OF OAT SERVICE PROVISION: Few healthcare profession-
als wish to become involved in OAT due to a lack of motivation and the fact that ‘additional 
competencies’ required by healthcare professionals working in this area (debt counselling, 
teaching skills, etc.) have not been identified. If a patient already starts working to get better 
and making progress but the attending healthcare professional does not have the qualifica-
tions or the competencies to offer as much as the person to be treated is actually able to take 
on, this will hamper the progress and the outcomes of the treatment. In many countries there 
are patient organisations that stand for the rights of this target group. The idea is to approach 
consultants in other countries where this experience already exists and to build up a group 
that could advise healthcare professionals in Estonia. 
EDUCATION AND TRAINING: Education and training in pain management is rarely available 
in Estonia, mainly due to lack of priorities in this area. Undergraduate medical education 
does include pain management but this is quite fragmented. In addition, lecturers are not well 
informed about the contents of other programmes and, as a result, the curriculum on pain 
management is not well coordinated and not all important topics are sufficiently addressed. 
At universities or colleges, coordination within the faculty is necessary in order to agree on 
what exactly needs to be taught to the students. Training programmes are also weakly de-
veloped with few routes for accreditation/professional recognition. Training appears to focus 
heavily on oncology which makes it practically impossible for other medical specialties to be 
considered. Furthermore, there are no Continuing Medical Education (CME) opportunities in 
pain management. Continuing education or refresher courses should be made more obliga-
tory or there should be more incentives for physicians to participate in refresher training 
courses. These could not only provide specific skills to physicians, nurses, social workers, 
and others healthcare professionals which were not acquired through their basic education 
but also address the outdated views of older colleagues by raising their awareness of the 
progress made in the field of pain treatment.  
SOCIAL ATTITUDES: There is serious lack of awareness with respect to palliative care at all 
societal levels - politicians, healthcare professionals, and the general public. If people do not 
understand what palliative care is, the purpose, the potential benefits, and the long-term 
goals of this type of care provision. There is also ‘much negative’ media coverage relating to 
the use of opioids in pain management and palliative care. As a result, fear of opioids per-
sists, mainly rooted in ‘not knowing’. Awareness and education is, therefore, important in 
order to break through the misunderstandings that opioids are dangerous, that someone will 
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become dependent on them straight away, or that an opioid prescription means that ‘you are 
ready for your grave’. It is extremely difficult to change the existing ‘mindset’ of people com-
pounded by the societal perception that suffering/pain is normal, heroic and necessary. 
There is also a lot of scepticism surrounding OAT in Estonia. Therefore, a differentiated and 
professionally substantiated view of patients’ individual motivation and capability to change 
their situation in order to offer the adequate treatment approach. More resources will be 
needed to explore this appropriately and help patients and their families to achieve their 
goals more effectively. Moreover, it is important to work with families in order to support the 
patient’s treatment since their attitude towards OAT will have an impact on the patient’s 
compliance.  
Textbox 5 Selection of recommendations specific to Estonia: policy 
§ Provide additional finance for palliative care opportunities and harm reduction initiatives;  
§ Invest more money on continuing education/refresher training; 
§ Reform education and training curricula on pain management and palliative care;  
§ Make continuing education/refresher training compulsory and offer more incentives to physi-
cians in order to participate in such courses; 
§ Address traditional views (concerning attitudes towards opioids) in older colleagues and raise 
their awareness of the progress made in the field; 
§ Compile a list of essential medicines (based on WHO) to maintain supply chains; 
§ Improve the exchange of information between wholesalers, pharmacists, doctors and patients 
(enabled by the National Medicines Board); 
§ Liaise with public health institutions to contribute to the provision of OAT services; 
§ Identify ‘additional competencies’ required by healthcare professionals involved in OAT; 
§ Promote the concept of multi-disciplinary team work both in OAT and in pain management / 
palliative care; 
§ Involve patients and families in the process of developing OAT; 
§ Raise awareness of the general population with respect to opioid use for pain management 
and palliative care; 
§ Challenge the misunderstandings surrounding opioid use. 
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1.4. Voices from Estonia ATOME participants 
In the summer of 2012 and of 2014, national key contacts and representatives of the national 
ATOME country teams were asked what had changed regarding access to opioid medicines 
in their country since the beginning of the project. Additionally, the national country team pro-
vided information concerning some changes in legislation in February 2014. These are ex-
amples of answers by representatives of the Estonia country team. 
Textbox 6 Voices from Estonia ATOME participants  
“Although there has been only one month since previously mentioned changes of legislation came 
into force [prescription for narcotic drugs valid for 30 days; new reimbursement possibilities for 
opioids etc.; entered into force 01.10.2012], feedback from doctors has been very positive. […] 
Hopefully new less restrictive provisions in legislation will increase accessibility of opioids to pa-
tients who need them for pain treatment” (Ms Eda Lopato, 05.11.2012). 
“By the time of and shortly after the ATOME Estonia National Symposium on Access to Opioid 
Medication in Tallinn (19.09.2013) we introduced some changes in legislative acts, e.g. ‘Act on 
Narcotic Drugs and Psychotropic Substances and Precursors thereof’ - sections 4 (6), 4 (7), 4 (8) 
and 4 (12) were repealed, entry into force 27.04.2013, in part 01.07.2013. Since then all pharma-
cies have been able to dispense controlled substances to patients. 
We also introduced changes to the Regulation No. 73 of the Minister of Social Affairs of 18 May 
2005, i.e. ‘Conditions and Procedure for Handling of Narcotic Drugs and Psychotropic Substances 
for Medical and Scientific Purposes, and Conditions and Procedure for Maintaining Records and 
Reporting in that Area and Schedules of Narcotic Drugs and Psychotropic Substances’ (entered 
into force on 23.09.2013). 
Estonian legislation is in a continuous improvement process. There will be more changes (for ex-
ample simplifying the requirements for travellers etc.) in the near future. 
Furthermore, I am happy to let you know that according to the Estonian Health Insurance Fund 
97% of all prescriptions were electronic (digital prescription) in 2013 in Estonia” (Ms Eda Lopato, 
07.03.2014). 
“The statistics on the consumption of opioids in Estonia (2008-2013) shows that the consumption 
of opioids increases. But we think that it takes more time to see the obvious impact of the ATOME 
project” (Ms Marta Mäe, 01.07.2014). 
  




Potential barriers to accessing opioids in Estonia have been identified in the areas of legisla-
tion and policy. The ATOME project recommends that the Estonian legislation should be re-
vised to provide a legal framework that focuses on optimizing healthcare outcomes while 
preventing diversion and misuse. The project also recommends that prescribing and dispens-
ing should be facilitated (maximum amount of controlled medicines to be prescribed and the 
validity of a prescription should be reconsidered as well as special licenses for pharmacies). 
The costs of security measures for the storage of controlled medicines should not be dispro-
portional compared to the risk of misuse and diversion. Clear language and non-stigmatizing 
terms in the Estonian legislation should be guaranteed. Considering the identified policy bar-
riers in Estonia the ATOME project advises the provision of additional finance for palliative 
care and harm reduction initiatives; the reform of education and training curricula on pain 
management and palliative care; and identification of additional competencies required by 
healthcare professionals involved in OAT. Refresher training should become compulsory and 
at the same time accessible and affordable for healthcare professionals; a particular focus 
should be laid on awareness of the progress made in the field of opioid treatment as well as 
of the concept of multi-disciplinary team work. The reimbursement of essential medicines and 
of OAT treatment should be improved. Furthermore, the awareness of the general population 
with respect to opioid use should be raised – e.g. by improving the exchange of information 
between wholesalers, pharmacists, doctors and patients and by involving patients and fami-
lies in the process of developing OAT. 
Throughout the ATOME project, encouraging developments have been observed in terms of 
improved access to opioids in Estonia, supported by an extraordinary commitment of the 
Estonia country team. Some of the recommendations made in this report have already been 
implemented, but others remain as a barrier to access to opioids, and a balance between 
preventing misuse and ensuring availability still needs to be achieved. 
The continuing efforts of the country team to implement the specific goals elaborated in the 
early stages of the ATOME project are expected to have facilitated improvements at different 
strategic levels. 
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Access to Opioid Medication in Europe (ATOME) 
Report and recommendations to the Ministry of Health 
2. Country Report – Latvia 
 
2.1. Introduction 
Latvia is one of the countries with statistical evidence of inadequate morphine consumption 
per capita. In 2006, the adequacy of opioid analgesic consumption was only 9% - based on a 
per capita consumption of 21.31 morphine equivalents (mEq) while 233 mEq would have 
been adequate for treatment of all pain conditions12. Latvia was selected as one of the coun-
tries to participate in the ATOME project due to this reason. Four years later, in 2010, the 
adequacy of opioid analgesic consumption had even slightly decreased (both in absolute and 
in relative terms) – it was only 6%13 (based on a per capita consumption of opioid analgesics 
of 19.64 morphine equivalents (mEq) while 332.56 mEq in mg per capita would have been 
adequate). This report presents a summary of the results of the situational analysis that has 
been undertaken with regard to opioid availability and accessibility in Latvia. The results of 
the situational analysis are divided in two parts: the first part addresses legal and regulatory 
issues and the second part focuses on issues relating to policy. Both parts present the main 
barriers and recommendations for improving access to opioid medication in Latvia.  
2.2. Identified legal and regulatory barriers 
The results of the ATOME legislation review have been divided into nine different categories 
of potential legal and regulatory barriers, i.e. barriers related to prescribing; dispensing; us-
age; trade and distribution; manufacturing; affordability; penalties; language; and other. In 
Latvia, potential legal and regulatory barriers have been identified in all nine categories (see 
Annex 2). A selection of these potential barriers is highlighted below according to category, 
followed by recommendations to remove these barriers. For a more detailed description of 
the methods and results, see Annex 2.  
PRESCRIBING: The prescribing of opioids in Latvia is subject to many administrative and 
non-administrative requirements. For example, the authorisation to prescribe controlled med-
icines is restricted to physicians working in medical treatment institutions. In addition, only 
‘narcologists’ are allowed to prescribe the controlled medicines methadone and buprenor-
phine. These restrictions can be a potential barrier to access, in particular if these physicians 
are not readily available to prescribe these medicines. Restrictions also apply to the amount 
of controlled medicines to be prescribed on a single prescription: physicians are not allowed 
                                               
12 Seya MJ, Gelders SFAM, Achara UA, Milani B, Scholten WK. A First Comparison between the Consumption of 
and the Need for Opioid Analgesics at Country, Regional and Global Level. Journal of Pain and Palliative Care 
Pharmacotherapy, 2011; 25: 6-18. Accessible at: 
http://apps.who.int/medicinedocs/documents/s17976en/s17976en.pdf 
13 Duthey, B., Scholten, W. Adequacy of Opioid Analgesic Consumption at Country, Global, and Regional Levels 
in 2010, Its Relationship With Development Level, and Changes Compared With 2006. Journal of Pain & Symp-
tom Management 47(2); 2014: 283-97 doi:10.1016/j.jpainsymman.2013.03.015; 
http://www.sciencedirect.com/science/article/pii/S0885392413002728 
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to exceed the maximum amounts specified in regulations and for outpatient treatment ‘nar-
cologists’ are not allowed to prescribe treatment with the controlled medicine buprenorphine 
more than once every two weeks. These restrictions can be potential barriers to access; pa-
tients who require medical treatment with controlled medicines for a longer period will need 
to visit the physician and pharmacy frequently.  
Administrative requirements that apply to the prescribing of opioid medicines may deter 
healthcare professionals from prescribing these medicines. For example, special prescrip-
tions with margins coloured in light red must be used when prescribing controlled medicines. 
The issuance of these prescription forms shall be ensured by a responsible official upon a 
request approved by the manager of a medical treatment institution. The requisites of the 
medical treatment institution, date of request, request number, number and type of prescrip-
tion forms shall be indicated in the request, which will be valid for only seven days. In addi-
tion, the medical practitioner must - when prescribing controlled medicines - notify the patient 
that unused special prescriptions shall be turned in to the medical treatment institution in 
which they have been written out. All these requirements may increase the administrative 
burden and potentially cause medical practitioners in Latvia to be reluctant to treat patients 
with controlled medicines. 
DISPENSING: Additional requirements for the dispensing of controlled medicines may in-
crease the administrative burden and may cause pharmacists to be reluctant to dispense 
controlled medicines. According to the Latvian legislation, controlled substances have to be 
stored in a separate room or a safe, or in a metal cabinet, which is attached to a wall or to 
the floor and equipped with an alarm system. The costs of these security measures may be 
disproportional compared to the risk of misuse and diversion, and may therefore deter phar-
macists from dispensing controlled medicines. In addition, pharmacies are obliged to provid-
ed many details to the State Agency of Medicines regarding medicinal products that have 
been ordered using the special prescription forms, including the prescription series and num-
ber; personal identity number of the patient; the name of the medical treatment institution; 
code of diagnosis; name of insurance company (if an insurance company compensates the 
patient for the purchase of medicinal products); code and quantity (number of packages) of 
the medicinal products dispensed. The recording of these details (in particular the code of 
diagnosis and personal identity number) may also unnecessary violate the privacy of patients 
and may deter patients from entering or continuing treatment. 
USAGE: Treatment with controlled medicines for patients with dependence should be availa-
ble within a reasonable distance to ensure that all patients in need of treatment of depend-
ence can have access to treatment. According to the Programme for Limiting the Spread of 
Human Immunodeficiency Virus for 2009–2013 pharmacological maintenance treatment for 
opioid dependence has only been available in Riga. Geographical restrictions to the availabil-
ity of controlled substances can impede access, depending on the geographical spread of 
the places where the rehabilitation programs are running. According to the Latvian legisla-
tion, replacement treatment for opioid dependence will be terminated if patients use other 
controlled medicines without an order of the physician who prescribes treatment for opioid 
dependence. This provision can be a potential barrier to access to pain treatment for patients 
with dependence if this prohibition deters physicians from prescribing medicines for the 
treatment of pain when pain treatment is medically necessary.  
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AFFORDABILITY: High costs for controlled medicines can impede access to medicines. In 
Latvia, the controlled medicine buprenorphine used for the treatment of dependence is not 
reimbursed, which is considered to impede access to this specific controlled medicine. 
LANGUAGE: In the Latvian legislation, the distinction between medical use and misuse or 
illicit use is not always clear. In addition, the terms ‘addict(s)’, ‘addiction’ and ‘persons addict-
ed’ are considered to be stigmatising, and are frequently used in the reviewed Latvian legis-
lation. This also applies to referring to controlled medicines as dangerous or addictive drugs.  
Textbox 7 Selection of recommendations specific to Latvia: legal and regulatory 
§ Remove the restriction that only ‘narcologists’ are allowed to prescribe methadone and bu-
prenorphine for the treatment of dependence, especially if the number of ‘narcologists’ availa-
ble to treat dependence is too low or not well spread throughout the country, causing a delay 
in onset of treatment; 
§ Reconsider the restrictions that apply to the amount of controlled medicines to be prescribed 
on a single prescription; 
§ Decrease the administrative burden for prescribing and dispensing opioid medicines; 
§ Ensure that the costs of security measures for the storage of controlled medicines are not 
disproportional compared to the risk of misuse and diversion; 
§ Ensure that patients are able to receive treatment with controlled medicines within a reasona-
ble time and distance, also in the situation that patients need controlled medicines for the 
treatment of dependence; 
§ Ensure that necessary controlled medicines are affordable for people in need of these medi-
cines and medical institutions treating patients with these medicines, including buprenorphine 
for the treatment of patients with dependence; 
§ Provide clear language in legislation and avoid language that stigmatises the medical use of 
opioids or refers to patients with dependence in a disrespectful way.  
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2.3. Identified policy barriers 
For Latvia, the main challenges concerning access to opioids were identified in governmental 
supports including financial/economic aspects, issues relating to formularies, education and 
training and social attitudes. 
GOVERNMENTAL SUPPORT and FINANCIAL/ ECONOMIC ASPECTS: The importance of 
State/Governmental support needs to be emphasised since without their endorsement rais-
ing awareness about opioids in the general population is considered to be ‘impossible’. Addi-
tional finance is also required. More money should be invested on harm reduction initiatives. 
However, politicians seem to be reluctant to support methadone treatment programmes in 
spite of strong evidence for the effectiveness of methadone maintenance programmes, which 
have various positive long-term effects both for the individual and for national public health 
(14). In addition, there is insufficient funding for palliative care services and the people who 
work in palliative care settings are underpaid. During the last few years, Latvia has been 
heavily hit by the financial crisis and, as a result, the financial situation in healthcare is cur-
rently worse than ever before. 
FORMULARIES: Better access to opioids needs to be provided. Access needs to be im-
proved for older people and for people living in rural areas of the country. This should also 
include reimbursement of the patients’ travel costs. Moreover, opioids are reimbursed for 
HIV/AIDS patients but not for patients with other non-oncological diseases. This is an issue 
that needs to be addressed. In relation to harm reduction, Latvia ranks the lowest in Europe 
with respect to the coverage of long-term pharmacological treatment for opioid dependence 
compared to the estimated number of illicit opioid users. Further, it is estimated to have the 
lowest number of clients in methadone treatment programmes. Methadone treatment is very 
expensive (there are high fees for entering a treatment programme). Currently people have 
to spend half of their monthly salary to pay for treatment. General practitioners need to be-
come more involved in order to improve access to harm reduction initiatives outside the cen-
tral treatment centres. Finally, there is a lack of collaboration between the different parties 
involved to ensure the effectiveness of treatment. Social workers need to be also included in 
the multidisciplinary teams involved in the treatment of pain. 
EDUCATION AND TRAINING: Human resources need to be considered as a top priority. 
The quality of education and training remains an important issue in Latvia. The amount of 
palliative care education opportunities currently available in the country is limited. There is a 
lack of certified teaching programmes on palliative care at both an undergraduate and post-
graduate level. Sometimes general practitioners and specialists end up using different lan-
guage which can be confusing and frustrating for patients and their families. Therefore, im-
provement of education is imperative. Definitions and language to be used needs to be 
agreed on for a better understanding between physicians themselves and between physi-
cians and patients. Training in palliative care should be provided for physicians and nurses. 
Their knowledge about correct usage of opioids according to indications, prevention of side 
effects and substitution therapy with methadone seems to be quite restricted. Life-long learn-
ing and specialist courses should also be provided. Problems appear in the area of prescrip-
tion with physicians not having the time for proper assessment of patients. Another important 
problem is measuring pain effectively as scales or other tools to measure pain are not used 
                                               
14 World Health Organization. Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid 
Dependence. Geneva 2009. ISBN 978 92 4 154754 3. Accessible at: 
http://www.who.int/substance_abuse/publications/opioid_dependence_guidelines.pdf 
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on a regular basis. Every clinician should be familiar with pain management. It is therefore 
crucial to introduce pain assessment and pain management in general practice. There is also 
a lack of education/trained clinical pharmacists, especially in rural areas.  
SOCIAL ATTITUDES: There are persistent misunderstandings surrounding opioid use 
amongst society and healthcare professionals (e.g. fear of dependence, diversion and 
death). Stigmatisation comprises a major problem (e.g. pain is seen a natural component of 
some diseases such as cancer and therefore needs to be accepted, suspicion of drug seek-
ing behaviour) leading to resistance to the use of opioids for the treatment of pain. Commu-
nication and information exchange between physicians and patients needs to be facilitated. 
This way patients and families (which are often ignored) can get correct knowledge and ac-
curate information (they have the right to get) concerning the use of opioids in pain manage-
ment and palliative care.  
Textbox 8 Selection of recommendations specific to Latvia: policy 
§ Encourage cooperation and collaboration between key stakeholders (Ministry of Health, Lat-
vian Pharmacist Society, National Health Service, and Local Municipalities); 
§ Increase funding for palliative care and organise effective structures (including daycare cen-
tres and primary care services); 
§ Promote palliative care for non-oncological patients; 
§ Develop graded opioid education and training programs in collaboration with the Ministry of      
Health - especially the Pharmacy Division - and family doctor associations; 
§ Further develop palliative care education and training curricula; 
§ Provide additional finance for harm reduction initiatives (including reimbursement of bupren-
orphine); 
§ Improve cross-sectoral collaboration between different healthcare disciplines in relation to 
harm reduction initiatives; 
§ Amend unclear/stigmatizing terminology relating to opioids; 
§ Raise awareness of the general population with respect to opioid use; 
§ Challenge the stereotypes surrounding opioid use. 
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2.4. Voices from Latvia ATOME participants 
In the summer of 2013, national key contacts and representatives of the national ATOME 
country teams were asked what had changed regarding access to opioid medicines in their 
country since the beginning of the project. This is an exemplary answer by one representa-
tive of the Latvia country team. 
Textbox 9 Voices from Latvia ATOME participants 
“This year, new formulations of Fentanyl tabs were included in the reimbursed system to treat the 
breakthrough pain in cancer. I see this as a direct impact of our work in the ATOME programme“ 
(Vilnis Sosars, 15.01.2014). 
2.5. Conclusion 
Potential barriers to accessing opioids in Latvia have been identified in the areas of legisla-
tion and policy. The ATOME project recommends that the Latvian legislation should be re-
vised to provide a legal framework that focuses on optimizing healthcare outcomes while 
preventing diversion and misuse. The project also recommends that prescribing and dispens-
ing should be facilitated (maximum amount of controlled medicines on a single prescription 
should be reconsidered as well as the restrictions on the authorisation to prescribe metha-
done and buprenorphine, the costs of security measures for the storage of controlled medi-
cines should not be disproportional compared to the risk of misuse and diversion). Geo-
graphical availability of treatment for patients with dependence and the affordability of the 
controlled medicine buprenorphine should be improved. Clear language and non-stigmatizing 
terms in the Latvian legislation should be guaranteed. Considering the identified policy barri-
ers in Latvia the ATOME project advises to encourage cooperations and collaborations be-
tween key stakeholders and between healthcare disciplines and to increase funding for palli-
ative care and for harm reduction initiatives. Access to opioid treatment and reimbursement 
should be improved for specific population groups (older people, people living in rural areas, 
patients with other non-oncological diseases than HIV/AIDS, clients in methadone treatment 
programmes). Additional education opportunities and trainings, terminological work and in-
troduction of pain measuring are necessary. Furthermore, the awareness of the general pop-
ulation should be raised – e.g. by providing correct knowledge and accurate information to 
patients and families. 
Throughout the ATOME project, encouraging developments have been observed in terms of 
improved access to opioids in Latvia. Some of the recommendations made in this report may 
have already been implemented, but others remain to be a barrier to access to opioids and a 
balance of preventing misuse and ensuring availability still needs to be achieved. 
The continuing efforts of the country team to implement the specific goals elaborated in the 
early stages of the ATOME project are expected to have facilitated improvements at different 
strategic levels. 
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Access to Opioid Medication in Europe (ATOME) 
Report and recommendations to the Ministry of Health 
3. Country Report - Lithuania 
3.1. Introduction 
Lithuania is one of the countries with statistical evidence of inadequate morphine consump-
tion per capita. In 2006, the adequacy of opioid analgesic consumption was only 12% - 
based on a per capita consumption of 24.62 morphine equivalents (mEq) while 208 mEq 
would have been adequate15. Lithuania was selected as one of the countries to participate in 
the ATOME project due to its low per capita morphine consumption. Four years later, in 
2010, the adequacy of opioid analgesic consumption had even slightly decreased (in relative 
terms) – it was only 10%16 (based on a per capita consumption of opioid analgesics of 28.31 
morphine equivalents (mEq) while 279 mEq in mg per capita would have been adequate). 
This report presents a summary of the results of the situational analysis that has been under-
taken with regard to opioid availability and accessibility in Lithuania. The results of the situa-
tional analysis are divided in two parts: the first part addresses legal and regulatory issues 
and the second part focuses on issues relating to policy. Both parts present the main barriers 
and recommendations for improving access to opioid medication in Lithuania. 
3.2. Identified legal and regulatory barriers 
The results of the ATOME legislation review have been divided into nine different categories 
of potential legal and regulatory barriers, i.e. barriers related to prescribing; dispensing; us-
age; trade and distribution; manufacturing; affordability; penalties; language; and other. In 
Lithuania, potential legal and regulatory barriers have been identified in eight of these nine 
categories: all except penalties (see Annex 2). A selection of these potential barriers is high-
lighted below according to category, followed by recommendations to remove these barriers. 
For a more detailed description of the methods and results, see Annex 2.  
PRESCRIBING: The prescribing of opioids in Lithuania is subject to many administrative and 
non-administrative requirements. For example, according to the Lithuanian legislation the 
total amount of controlled substance to be prescribed is limited to the quantity necessary for 
a 7 day treatment course. This requirement is applicable until the individual and effective 
maintenance dose per day for pain relief has been determined. Than all oral unmodified-
release forms, all injection forms allowed for outpatients, sublingual tablets and suppositories 
of opioid medicines may be prescribed for a maximum treatment course of 15 days. Oral 
modified-release medicine and transdermal therapy systems of opioid medicines may be 
prescribed for a maximum treatment course of 30 days. Methadone can be prescribed for 
                                               
15 Seya MJ, Gelders SFAM, Achara UA, Milani B, Scholten WK. A First Comparison between the Consumption of 
and the Need for Opioid Analgesics at Country, Regional and Global Level. Journal of Pain and Palliative Care 
Pharmacotherapy, 2011; 25: 6-18. Accessible at: 
http://apps.who.int/medicinedocs/documents/s17976en/s17976en.pdf 
16 Duthey, B., Scholten, W. Adequacy of Opioid Analgesic Consumption at Country, Global, and Regional Levels 
in 2010, Its Relationship With Development Level, and Changes Compared With 2006. Journal of Pain & Symp-
tom Management 47(2); 2014: 283-97 doi:10.1016/j.jpainsymman.2013.03.015; 
http://www.sciencedirect.com/science/article/pii/S0885392413002728 
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pain relief for a maximum of 45 days. In addition, the validity of a special medical prescription 
used for prescribing controlled substances is limited to 5 days including the day of issuing of 
the prescription. These restrictions are potential barriers to access; patients who require 
medical treatment with controlled medicines for a longer period will need to visit the physician 
and pharmacy frequently. 
In Lithuania, the authorisation to prescribe opioid agonist maintenance therapy for the treat-
ment of dependence is restricted to a consulting panel of physicians. If there is ‘a serious 
somatic condition’, substitution maintenance therapy can also be delivered by a practicing 
psychiatrist, provided that this decision is approved within two weeks by the consulting panel 
of physicians. These restrictions regarding the authorisation to prescribe medicines for the 
treatment of dependence can be a potential barrier to access. This is especially the case if 
the ‘consulting panel of physicians’ is not readily available to deliver substitution maintenance 
therapy. 
Administrative requirements for medical practitioners in the Lithuanian legislation regarding 
the treatment of patients with controlled medicines can be considered disproportional. Spe-
cial prescription blanks used for prescribing opioid medicines have to be stored in a desig-
nated safe and may not exceed a six-month demand. Physicians are not allowed to receive 
more than 10 special prescription blanks17. These requirements may increase the administra-
tive burden and may cause medical practitioners to be unable (no prescription forms availa-
ble) or reluctant to treat patients with controlled medicines.  
The storage of controlled medicines in pharmacies is subject to many strict requirements. For 
example, the amount of controlled medicines to be stored shall not exceed a 7-day supply in 
healthcare institutions without a pharmacy, a 5-day supply in separate healthcare institution 
departments and a 30 day supply in the hospital pharmacy18. Premises in hospital pharma-
cies where controlled medicines are kept must have a steel door or a solid wood door, cov-
ered with steel plate, fastened with nails no shorter than 35cm. Many other storage require-
ments are applicable. The costs of these storage measures may be disproportional com-
pared to the risk of misuse and diversion, and may therefore deter healthcare institutions 
from storing controlled medicines. 
TRADE AND DISTRIBUTION: Requirements regarding the trade and distribution of con-
trolled medicines may increase the administrative burden and may delay or impede the 
availability of medicinal products on the market. According to the Lithuanian legislation, con-
trolled substances have to be stored in premises with external walls made from reinforced 
concrete 250 mm brick walls or made from other material with the same strength. The exter-
nal walls that do not meet these requirements shall be reinforced with protective grilles. Addi-
tional requirements apply, the costs of which may be disproportional compared to the risk of 
                                               
17 These requirements have been changed. Since 12. 05. 2014 physicians are allowed to have 20 blank prescrip-
tions for narcotic medications (instead of 10). 
18 These requirements have been changed first in 2011 by new annex in the law which set out the requirements 
for storage and accounting of narcotic medicinal products in the Healthcare institutions. Since that the amount of 
controlled medicines to be stored shall not exceed a 30 day supply in healthcare institutions without a pharmacy, 
a 30 day supply in the hospital pharmacy, a 5-day supply in separate healthcare institution departments and a 15 
day supply in emergency medical service departments. In 2014 the legal requirements related to the quantity of 
opioids that is allowed to be stored in Healthcare Institutions providing service of Opioid Agonist Therapy (OAT) 
have been changed from 7 days of demand to 60 days in healthcare Institutions which do not have their own 
hospital pharmacies; in hospital pharmacies it has been changed from 14 days of demand to 60 days and in de-
partments of Health Care Institution from 5 days to 7 days. 
ATOME REPORT AND RECOMMENDATIONS - COUNTRY REPORT LITHUANIA 
 
53 
misuse and diversion, and may therefore deter legal entities from trading in controlled medi-
cines.  
LANGUAGE: The distinction between medical use and misuse or illicit use is not always 
clear. In the reviewed Lithuanian legislation, death, intoxication and dependence are referred 
to as a result of the use of ‘narcotic drugs’ and ‘psychotropic substances’. This may cause 
fear and confusion and may deter healthcare professionals from prescribing or dispensing 
opioid medicines or may deter patients from using controlled medicines for legitimate pur-
poses. This is particularly the case if severe sanctions are involved for unintended violations. 
In addition, the terms ‘addict(s)’, ‘addiction’ and ‘persons addicted’ are considered to be 
stigmatising, and are used in the reviewed Lithuanian legislation. 
Textbox 10 Selection of recommendations specific to Lithuania: legal and regulatory 
§ Remove limitation of the validity of 7 days for prescriptions for medicines containing controlled 
substances; 
§ Remove restrictions that apply to the amount to be prescribed, in particular if these re-
strictions do not apply to other non-controlled medicinal products;  
§ Remove the restriction that opioid agonist therapy for the treatment of dependence can only 
be assigned by a panel of physicians;  
§ Remove the limitations regarding the total amount of controlled medicine to be stored; 
§ Remove the storage requirements for special prescription blanks, and remove the limitation 
that physicians are not allowed to receive more than 10 special prescription blanks; 
§ Decrease the administrative burden for prescribing and dispensing opioid medicines; 
§ Remove the obligation for public pharmacies to collect unused controlled medicines for de-
struction; 
§ Ensure that the costs of security measures for the storage of controlled medicines are not 
disproportional compared to the risk of misuse and diversion; 
§ Provide clear language in legislation and avoid language that stigmatises the medical use of 
opioids or refers to patients with dependence in a disrespectful way.  
 
3.3. Identified policy barriers 
For Lithuania, the main challenges concerning access to opioids were identified in finan-
cial/economic aspects, issues relating to formularies, education and training and social atti-
tudes.  
FINANCIAL/ ECONOMIC ASPECTS: The Lithuanian association for the support of cancer 
patients, established in 2011, together with the Lithuanian Palliative Medicine Association put 
pressure on the government and policy-makers to ensure the development, appropriate fund-
ing and recognition of palliative care. A national Hospice Support Fund, whose council in-
cludes a member of the Lithuanian parliament, was created in 2013 to try to alleviate funding 
issues. However, the current model of funding does not promote more service provision - 
incentives are lacking since pharmacotherapy with opioids requires a heavy workload (e.g. 
managing prescription blanks, urine tests, involvement of other social services etc.). 
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Healthcare institutions need to invest when they plan to offer such treatment (storage, 
equipment, safe doors, etc.). The Ministry of Health only finances two to four palliative care 
beds in smaller regions and this insufficient funding precludes team-work. In addition, there is 
no funding basis and no system of incentives for healthcare organizations to offer opioid ag-
onist therapy. Centres for dependency disorders have to supply medicines to prisons; they 
also have the responsibility for storage, recording, and control. This means that a series of 
additional activities need to be undertaken with no additional funding provided to cover the 
cost of such activities or even support any efforts made towards this direction. 
FORMULARIES: The treatment of breakthrough pain becomes more difficult since medicines 
are not reimbursed. As a result, this treatment is not applied even when appropriate. The 
prescription of analgesics for non-cancer patients is also a problem that needs to be ad-
dressed, as well as treatment for neuropathic pain and the possibility to reimburse this treat-
ment. Another problem regarding service provision is that guidelines or recommendations 
are often not implemented. No equal service provision is ensured in different healthcare insti-
tutions. In addition, the services available are not always provided in a good professional 
manner. Although a standardised methodology and evaluation procedure have been devel-
oped, it cannot be guaranteed that all institutions implement these recommendations proper-
ly. Finally, the special requirements regarding the prescription of narcotics make physicians 
reluctant to use opioid medicines for the treatment of pain. Also, the assessment of pain is 
not always adequately performed. When monitoring the patient and correcting or adapting 
treatment options, it is important to explore the reasons which generate the pain and to 
measure the level of pain. The aetiology and the nature of the pain need to be assessed 
properly and various other factors that may increase the level of pain need to be addressed 
in order to be able to provide the necessary treatment which is not always the case in Lithu-
ania.  
EDUCATION AND TRAINING: Education and training are a very important and essential 
requirement for palliative care provision. Palliative care in Lithuania is taught in some univer-
sities. Since 2009 there have been programmes on palliative care but they are mostly linked 
to geriatric medicine. Several scientific articles on palliative care are published every year 
and it is not uncommon for students to write their bachelor’s or master’s theses on topics 
related to palliative care. However, the concept of palliative care seems to be not clear con-
sidering that palliative care is often perceived merely as end-of-life care. Training for special-
ists is essential in order to change attitudes in healthcare professionals and improve the ap-
proach in medical staff. The approach of pain by many older physicians sometimes does not 
meet modern standards. They often support the opinion that opioids should only be pre-
scribed in patients with stage 4 cancer. In addition, the teams offering palliative care at home 
are not well educated and equipped for this type of care provision. Finally, there is a lack of 
inter-institutional collaboration not only to promote research on palliative care and the use of 
opioids for pain management (in cancer patients and others), but also to ensure best practice 
and optimal quality of the services provided.  
SOCIAL ATTITUDES: In Lithuania, the use of opioids is affected by a range of attitudinal 
barriers. A couple of years ago even talking about opioid medicines was a taboo. Stigma still 
persists not only in patients and their families but also among medical staff, stakeholders and 
the general public. Some politicians think they can resolve issues that professionals should 
resolve instead, which gives rise to stereotype notions in the society. Fear of depend-
ence/tolerance comprises a major issue regarding pain treatment in Lithuania. Dependence 
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is not understood as a disease but as a moral deviation from the norm. Many physicians are 
reluctant to prescribe opioid medicines in young people for fear of unsafe situations in peo-
ple’s everyday life (work, driving, etc.). Another issue that deserves attention is what a physi-
cian should do if a patient is in his dying phase but his family/relatives do not want them to 
use opioids. Another problem is ‘demonisation’ of patients who are treated with certain medi-
cation (e.g. tramadol). To this end, peer-to-peer education (e.g. in nursing staff) should be 
implemented in order to eliminate misunderstandings considering that the message received 
from peers is always different. In addition, drug users are frequently ‘demonised’. For exam-
ple a patient suffering from withdrawal syndrome, and therefore being in unbearable pain 
might be treated like a ‘drug addict’ in a pharmacy and may have to confront barriers before 
getting any help. The majority of healthcare centres have negative attitudes towards people 
who are addicted to drugs. Even traffickers spread misunderstandings since it is in their in-
terest that people continue using illicit drugs. Articles in the press often show a biased pic-
ture. Case stories and real life stories should help to promote understanding and respect 
towards people who are addicted to drugs. Decreasing the stigma in society and also the 
stigma among patients to reduce fear about treatment is imperative. An analysis of the socie-
tal mechanisms underlying the various misunderstandings around opioids and the reasons 
that generate fear of opioids should be conducted. The social media and other interactive 
ways should be used to promote education and raise awareness of the general public, pa-
tients, families, physicians and other stakeholders concerning the benefits of opioid use for 
pain management and palliative care in Lithuania. 
Textbox 11 Selection of recommendations specific to Lithuania: policy 
§ Minimize the bureaucratic burden surrounding the prescription of opioids;  
§ Address the issue of opioid prescription for non-cancer patients and those with neuropathic 
pain;  
§ Reimburse costs and minimise bureaucracy regarding OAT; 
§ Provide healthcare institutions with incentives to offer OAT; 
§ Revise the prescription procedures of opioids in hospitals to make sure that patients will have 
sufficient medication available after discharge home;  
§ Provide outpatient treatment for withdrawal symptoms;  
§ Promote inter-institutional collaboration;  
§ Implement training courses for healthcare professionals to improve the quality of the services 
provided; 
§ Monitor the process of pain treatment to ensure quality;  
§ Enhance doctor-patient communication;  
§ Inform (educate) the general public and other stakeholders about the usefulness of opioids in 
pain treatment and palliative care;  
§ Use the social media and other interactive ways to raise awareness of opioid use; 
§ Implement peer education to eliminate misunderstandings over opioid use. 
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3.4. Voices from Lithuanian ATOME participants 
In the summer of 2013, national key contacts and representatives of the national ATOME 
country teams were asked what had changed regarding access to opioid medicines in their 
country since the beginning of the ATOME project. These are examples of answers by one 
representative of the Lithuania country team. These quotations show that some of the legal 
and policy barriers identified during the ATOME legal and policy analysis have already been 
lifted towards the end of the project. 
Textbox 12 Voices from Lithuanian ATOME participants 
§ “After the discussion at the ATOME national follow-up conference a representative of the De-
partment of Pharmacy in the Ministry of Health has prepared amendments on the Order Nr V-
653 from August 6, 2007 (about Opioid Agonist Therapy (OAT)) and suggested to significantly 
increase the amounts of opioid medications that will be allowed to be stored in healthcare fa-
cilities (from 7 to 60 days of supplies). This was requested by healthcare facilities, mainly be-
cause of significant interruptions of funding for OAT and to reduce frequent travel for supplies.  
§ Also the proposal was made to change order Nr. V-1051 from May 13, 2006 (about the gen-
eral requirements on the control of narcotic medications). A new specification allows for a 
physician to have 20 blank prescriptions for narcotic medications (instead of 10). 
§ Proposed changes to the orders V-653 and V-1051 have been introduced accordingly with the 
orders V-557 and V-556 of the Minister of Health on 12 May 2014. 
§ In addition one more barrier to access OAT programmes has been lifted – the order V-819 of 
the Minister of Health of 16 July 2014 allows for one psychiatrist to initiate OAT (before that 
the decision to initiate OAT for a patient had to be made by the Consultative Commission of 
Doctors.” (Marija Subataite, Program Manager of the Eurasian Harm Reduction Network 
(EHRN), 06.04.2014). 
  




Potential barriers to accessing opioids in Lithuania have been identified in the areas of legis-
lation and policy. The ATOME project recommends that the Lithuanian legislation should be 
revised to provide a legal framework that focuses on optimizing healthcare outcomes while 
preventing diversion and misuse. The project also recommends that prescribing should be 
facilitated (maximum amount of controlled medicines to be prescribed and the limited pre-
scription validity should be removed as well as the administrative requirements regarding the 
used prescription blanks; the restrictions on the authorisation to prescribe opioid agonist 
maintenance therapy should be reconsidered). The administrative burden for dispensing opi-
oid medicines should be decreased (total amount of controlled medicines to be stored). The 
costs of security measures for the storage of controlled medicines should not be dispropor-
tional compared to the risk of misuse and diversion. Clear language and non-stigmatizing 
terms in the Lithuanian legislation should be guaranteed. Considering the identified policy 
barriers in Lithuania the ATOME project advises to enhance the financial support for pallia-
tive care and to ensure funding and incentives to offer Opioid Agonist Therapy. The reim-
bursement of particular medicines (e.g. for breakthrough pain as well as for neuropathic pain; 
analgesics for non-cancer patients) should be guaranteed. Training courses for healthcare 
professionals should be implemented to improve the quality of services provided, and in or-
der to enhance the communication between physicians and patients. Furthermore, the 
awareness concerning the usefulness of opioids in pain treatment and palliative care 
amongst the general public and stakeholders should be raised; misunderstandings about 
opioid use should be challenged – e.g. by implementing peer education, by using social me-
dia and other interactive ways. 
Throughout the ATOME project, encouraging developments have been observed in terms of 
improved access to opioids in Lithuania. Some of the recommendations made in this report 
may have already been implemented, but others remain as barriers to access to opioids and 
a balance of preventing misuse and ensuring availability still needs to be achieved. 
The continuing efforts of the country team to implement the specific goals elaborated in the 
early stages of the ATOME project are expected to have facilitated improvements at different 
strategic levels. 
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Access to Opioid Medication in Europe (ATOME) 
Report and recommendations to the Ministry of Health 
4. Country Report – Poland 
 
4.1. Introduction 
Poland is one of the countries with statistical evidence of inadequate morphine consumption 
per capita. In 2006, the adequacy of opioid analgesic consumption was 19% - based on a 
per capita consumption of 42.8 morphine equivalents (mEq) while 230 mg would have been 
adequate for treatment of all pain conditions19. Poland was selected as one of the countries 
to participate in the ATOME project due its low per capita consumption. Four years later, in 
2010, the adequacy of opioid analgesic consumption had even decreased (both in absolute 
and in relative terms) – it was only 12%20 (based on a per capita consumption of opioid anal-
gesics of 35.76 morphine equivalents (mEq) while 232 mEq in mg per capita would have 
been adequate)21. This report presents a summary of the results of the situational analysis 
that has been undertaken with regard to opioid availability and accessibility in Poland. The 
results of the situational analysis are divided in two parts: the first part addresses legal and 
regulatory issues and the second part focuses on issues relating to policy. Both parts present 
the main barriers and recommendations for improving access to opioid medication in Poland.  
4.2. Identified legal and regulatory barriers 
For Poland no legislational analysis has been applied because no legal documents were 
provided. 
4.3. Identified policy barriers 
For Poland, the main challenges concerning access to opioids that were identified are finan-
cial/economic issues and issues relating to formularies, education, training and social atti-
tudes.  
FINANCIAL/ ECONOMIC ASPECTS: There is not an equal geographical distribution of pain 
clinics due to financial reasons in Poland. Moreover, financing of procedures provided by 
pain clinics is not sufficient for some new procedures to be introduced in order to encourage 
pain clinic staff to engage more actively in the assessment and treatment of pain. In addition, 
                                               
19 Seya MJ, Gelders SFAM, Achara UA, Milani B, Scholten WK. A First Comparison between the Consumption of 
and the Need for Opioid Analgesics at Country, Regional and Global Level. Journal of Pain and Palliative Care 
Pharmacotherapy, 2011; 25: 6-18. Accessible at: 
http://apps.who.int/medicinedocs/documents/s17976en/s17976en.pdf 
20 Duthey, B., Scholten, W. Adequacy of Opioid Analgesic Consumption at Country, Global, and Regional Levels 
in 2010, Its Relationship With Develoment Level, and Changes Compared With 2006. Journal of Pain & Symptom 
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inadequate financing appears to be allocated to palliative care and harm reduction initiatives. 
The results of the economic recession that the country has recently experienced have con-
siderably affected such initiatives. More specifically, general budget constraints seem to pose 
a serious challenge to the wider availability of palliative care and the implementation of opioid 
agonist therapy (OAT) in Poland. As a result, changes in the allocation of financial resources 
by the National Health Fund (NHF) are deemed necessary.  
FORMULARIES: One of the most important barriers to opioid access in Poland relates to the 
reimbursement of opioid treatment and palliative care services22. On the one hand, although 
opioid medication is available free of charge or at a low basic price for cancer patients, pa-
tients with other diseases can only get a 30% reimbursement23. Moreover, in the case of real-
ly expensive formulations even cancer patients are forced to pay partial costs. Also, if physi-
cians want to prescribe fentanyl for nasal application, it is necessary to prove that other for-
mulations of short term application did not work, as the health system does not want to be 
burdened with the cost of fentanyl nasal applications. This is probably why fentanyl con-
sumption appears to have strongly decreased in the country. Regarding other strong opioids 
an equally significant decrease is observed in morphine consumption whereas methadone 
consumption has also slightly decreased. However, methadone appears to be available on 
the black market which means that the legal supply of methadone for patients in Poland is 
not satisfactory24. On the other hand, palliative and end of life care consultations appear to 
be used rather informally; as a result, they cannot be properly reimbursed. Such consulta-
tions are also restricted to cancer patients whereas palliative care should be broader and 
cover a bigger spectrum of patients with chronic and advanced diseases. 
Reimbursed medicines have defined levels of payment and reimbursement limit. In Poland, 
four levels of payment have been established: free of charge, lump sum, 30% and 50%. If 
the retail price of the medicine is higher than the reimbursement limit, a patient has to pay 
the difference between the retail price and the reimbursement limit. About 73% of reimbursed 
opioids (in different indications) are available at max. 2€. 
EDUCATION AND TRAINING: Daily experience shows that inadequate education comprises 
one of the main barriers to opioid access in Poland. There is lack of knowledge about opioids 
as medicines and their role in pain management and palliative care. Training on pain treat-
ment to provide at least basic knowledge and familiarize physicians with the use of opioids is 
also insufficient at postgraduate level. Therefore, changes in the postgraduate curricula for 
physicians should be implemented and the course on psychiatry and dependence treatment 
should be revised. This is a responsibility of the Ministry of Health and the Medical Centre for 
Postgraduate Education. Because physicians need to be able to effectively cope with the 
fears and concerns expressed patients and families, their knowledge needs to be up-to-date, 
focusing particularly on communication skills. Although a platform for best practices has been 
established in Poland in an attempt to relieve physicians’ concerns, inconsistent pain treat-
ment situations are still observed in the country and should comprise the reason for further 
                                               
22 This has been changed. Since the 1st of May 2014 tramadol in combination with paracetamol is being reim-
bursed. Oxycodone in combination with naloxone will be reimbursed from the 1st of November 2014. Moreover, 
the reimbursement procedure of medicines containing tapentadol is in progress. 
23 The situation concerning this matter has changed. Cancer patients have to pay 0-6 € (there are different levels 
of payment). Patients with other indications (all registered indications) have to pay 0,2-7€ (different levels of pay-
ment). For most medicines there are less expensive generics available. Medicines that are being reimbursed in 
Poland are: buprenorphine (5 products with unique EAN code), dihydrocodeine (2), fentanyl (32), methadone (3), 
morphine (17), oxycodone (10), tramadol (51), tramadol in combination with paracetamol (22). 
24 Methadone is being reimbursed for cancer patients at max.1,5€. 
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education and training initiatives to be developed and implemented. Such initiatives should 
not only include physicians (providing educational credits for professional development), but 
also regional/local decision-makers and specialists in psychiatry (raising awareness of the 
regional needs) and employees of the NHF (analysing the regional situation and revising 
policy for appropriate allocation of funds). This is to ensure further support from regional and 
local authorities which is currently lacking. Finally, education and training in relation to pallia-
tive care needs to be improved including promoting active team work and multi-disciplinary 
collaborations.  
SOCIAL ATTITUDES: Fear of opioids comprises another major barrier to opioid access in 
Poland. This fear can be observed not only amongst patients and their families but also 
amongst healthcare professionals and the general public. More specifically, the main fears of 
patients and families relate to dependency, tolerance and death. Such fears are much more 
common in patients taking strong opioids. Moreover, there are cases where patients and 
families feel hopeless because many physicians seem to believe that pain does not need to 
be assessed and treated. Also, although physicians should know that at the early stages of 
palliative care treatment they need to sit down and talk to patients and families about opioid 
use and the benefits of opioid treatment, they do not provide adequate information about 
risks and side-effects so that fear of opioids can be averted. In addition, reluctance to pre-
scribe opioids in many GPs results in patients being frequently referred to a pain clinic. Final-
ly, there is still prejudice against opioids in the Polish society. Harm reduction is seen as a 
controversial area which is currently highly stigmatized. For example, employment for pa-
tients involved in an OAT programme is a serious problem; they have to hide their therapy or 
stay away from work to get methadone treatment. Although there have been several initia-
tives to raise public awareness, prejudice against opioids remains a major issue that needs 
to be addressed and resolved. 
Textbox 13 Selection of recommendations specific to Poland: policy 
§ Ensure better reimbursement of opioid treatment; 
§ Expand palliative care to include a wider spectrum of patients (e.g. non cancer patients); 
§ Formally arrange and properly reimburse palliative care consultations; 
§ Change the knowledge and attitudes of medical staff with respect to the treatment of pain; 
§ Encourage the collaboration amongst healthcare professionals and palliative care specialists; 
§ Implement more practical pain management education (training initiatives, workshops); 
§ Monitor the process of pain treatment to ensure quality and patient safety; 
§ Lower the threshold (entry barriers, restrictive rules) for people to join harm reduction pro-
grams; 
§ Improve OAT availability and reduce the stigma on people receiving OAT but also integrate it 
into the range of treatment approaches of opioid dependence; 
§ Provide more information on OAT, e.g. via the media; 
§ Educate patients and families about the usefulness of opioids in pain relief and palliative care; 
§ Educate patients, families and the public about the impact of fear of opioids. 
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4.4. Voices from Poland ATOME participants 
In the summer of 2013 and of 2014, national key contacts and representatives of the national 
ATOME country teams were asked what had changed regarding access to opioid medicines 
in their country since the beginning of the project. These are exemplary answers by two rep-
resentatives of the Poland country team. 
Textbox 14 Voices from Poland ATOME participants 
“According to amendments from the 21st of December 2012 regulation of Minister of Health on 
prescriptions there is no need to issue a copy of prescription for drugs containing substances like 
morphine, methadone, oxycodone or fentanyl. It’s possible to prescribe those medicines for a 
longer period of time (up to 90 days instead of 30 days). Those prescriptions are valid longer (30 
instead of 14 days). 
As for the drugs containing tramadol, tramadol with paracetamol, buprenorphine or dihydroxyco-
deine – they can be prescribed now on common prescriptions. In addition to that, in 2014 there 
was a change of law which allowed to prescribe those medicines for a longer period, up to 360 
days” (Agata Krupa, 21.10.2014). 
“There were several changes regarding opioid availability. Despite of formal changes however 
some physicians still do not have prescription forms for opioids. As no formal barriers exist to ob-
tain this type of prescription forms this is rather an effect of the lack of education and inappropri-
ate knowledge or attitude towards pain management of those physicians. 
Recently, a National Medical Council (Naczelna Rada Lekarska) has published an appeal on ap-
propriate treatment of pain in Poland to physicians. The Vice Minister of Health Igor Winnicki 
promised to implement the obligatory program on pain management for all medical students at all 
medical universities.” 
An active role apart from physicians’ associations (the Polish Association for Palliative Medicine – 
Polskie Towarzystwo Medycyny Paliatywnej and the Polish Association for the Study of Pain – 
Polskie Towarzystwo Badania Bólu) a patient organization take part in campaigning for appropri-
ate pain management in Poland. For example the foundation ‘Let’s Win with Pain’ (Wygrajmy z 
Bólem) is an active in campaigning through the voice of patients. A recent press conference took 
place on 9th October 2014 to inform journalists from public TV and main newspapers about de-
velopments and still existing barriers in appropriate pain management” (Wojciech Leppert, 
24.10.2014). 
  




Potential policy barriers to accessing opioids in Poland have been identified. The ATOME 
project recommends the revision of the allocation of financial resources by the National 
Health Fund in order to improve the geographical availability of pain clinics, the availability of 
palliative care services and to widen the availability of Opioid Agonist Therapy (OAT). The 
reimbursement of opioid treatment for non-cancer patients as well as of palliative care con-
sultations should be enhanced. Specific opioids (e.g. fentanyl nasal applications) should be 
refunded and sufficient legal supply of methadone should be ensured25. The postgraduate 
curricula for healthcare professionals should be revised in order to provide sufficient 
knowledge about the use of opioid analgesics in pain treatment and palliative care. Training 
opportunities should be developed and implemented to ensure consistent quality in pain 
treatment; to promote multi-disciplinary collaborations; and to improve the communication 
and information exchange between physicians and patients. Furthermore, the fear of opioids 
within the general public should be challenged as well as the stigmatization on people receiv-
ing OAT – e.g. by providing education initiatives for patients and their families; or by provid-
ing more information on OAT via media. 
Some of the recommendations made in this report may have already been implemented, but 
others remain to be as barriers to access to opioids and a balance of preventing misuse and 
ensuring availability still needs to be achieved. 
The continuing efforts of the country team to implement the specific goals elaborated in the 




                                               
25 Fentanyl nasal applications are refunded for the following indications: Breakthrough pain in adult patients with 
cancer who are in the treatment of chronic cancer pain with opioid maintenance therapy, with documented contra-
indications while using other short-term working opioids or ineffectiveness of these drugs. Patients have to pay 
less than 1€. 
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Access to Opioid Medication in Europe (ATOME) 
Report and recommendations to the Ministry of Health 
5. Country Report - Slovakia 
 
5.1. Introduction 
Slovakia is one of the countries with statistical evidence of inadequate morphine consump-
tion per capita. In 2006, the adequacy of opioid analgesic consumption was 58% - based on 
a per capita consumption of 120.98 morphine equivalents (mEq) while 210 mg would have 
been adequate for treatment of all pain conditions26. Slovakia was selected as one of the 
countries to participate in the ATOME project due to this reason. Four years later, in 2010, 
the adequacy of opioid analgesic consumption had even decreased (both in absolute and in 
relative terms) – it was only 27%27 (based on a per capita consumption of opioid analgesics 
of 74.28 morphine equivalents (mEq) while 275.76 mEq in mg per capita would have been 
adequate). This report presents a summary of the results of the situational analysis that has 
been undertaken with regard to opioid availability and accessibility in Slovakia. The results of 
the situational analysis are divided in two parts: the first part addresses legal and regulatory 
issues and the second part focuses on issues relating to policy. Both parts present the main 
barriers and recommendations for improving access to opioid medication in Slovakia.  
5.2. Identified legal and regulatory barriers 
The results of the ATOME legislation review have been divided into nine different categories 
of potential legal and regulatory barriers, i.e. barriers related to prescribing; dispensing; us-
age; trade and distribution; manufacturing; affordability; penalties; language; and other. In 
Slovakia, potential legal and regulatory barriers have been identified in seven of these nine 
categories: all except affordability and penalties (see Annex 2). A selection of these potential 
barriers is highlighted below according to category, followed by recommendations to remove 
these barriers. For a more detailed description of the methods and results, see Annex 2.  
PRESCRIBING: The prescribing of opioids in Slovakia is subject to many overly strict admin-
istrative and non-administrative requirements. For example, according to the Slovak legisla-
tion the total amount of controlled medicines to be prescribed is limited to the quantity neces-
sary for a 30 day treatment course. In addition, the validity of a special medical prescription 
used for prescribing controlled medicines is limited to 5 days. These restrictions are potential 
barriers to access; patients who require medical treatment with controlled medicines for a 
longer period will need to visit the physician and pharmacy frequently. 
                                               
26 Seya MJ, Gelders SFAM, Achara UA, Milani B, Scholten WK. A First Comparison between the Consumption of 
and the Need for Opioid Analgesics at Country, Regional and Global Level. Journal of Pain and Palliative Care 
Pharmacotherapy, 2011; 25: 6-18. Accessible at: 
http://apps.who.int/medicinedocs/documents/s17976en/s17976en.pdf 
27 Duthey, B., Scholten, W. Adequacy of Opioid Analgesic Consumption at Country, Global, and Regional Levels 
in 2010, Its Relationship With Development Level, and Changes Compared With 2006. Journal of Pain & Symp-
tom Management 47(2); 2014: 283-97 doi:10.1016/j.jpainsymman.2013.03.015; 
http://www.sciencedirect.com/science/article/pii/S0885392413002728  
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Administrative requirements for medical practitioners in the Slovak legislation regarding the 
treatment of patients with controlled medicines can be considered disproportional. Special 
prescription forms marked with a diagonal blue stripe have to be used and persons author-
ised to prescribe controlled medicines are obliged to keep records of these special prescrip-
tion forms. The special prescription forms may be sold to medical practitioners authorised to 
prescribe controlled medicines after verification of his/her identity and production of the letter 
of assignment of his/her code from the Health Care Surveillance Authority. These require-
ments may increase the administrative burden and may have the effect that medical practi-
tioners are unable (no prescription forms available) or reluctant to treat patients with con-
trolled medicines.  
DISPENSING: Additional requirements for the dispensing of controlled medicines may in-
crease the administrative burden and may cause pharmacists to be reluctant to dispense 
controlled medicines. In Slovakia, the procedures for dispensing controlled medicines are 
complex and bureaucratic. For example, a special record book has to be kept to record the 
dispensing of controlled medicines without any delay. Upon dispensing, a special document 
which contains information regarding the dispensing has to be filed to demonstrate the dis-
pensing. This document has to be signed by the person who personally dispensed the con-
trolled medicine. Additional requirements apply, all increasing the administrative burden and 
potentially deterring pharmacists from dispensing controlled medicines.  
OTHER: Other requirements in legislation may limit access to opioid medicines to patients in 
need of medical treatment with these medicines. For example, according to the Slovak legis-
lation methadone maintenance treatment can only be provided by a psychiatrist in special-
ised outpatient programmes or in drug dependence outpatient facilities. In addition, patients 
who live too far from the dispensary and clinic and patients with a pending unconditional im-
prisonment without the possibility of providing methadone in prison are excluded from receiv-
ing methadone maintenance treatment. During transportation, like by airline companies, it is 
allowed to have a first aid kit on board containing small amounts of controlled medicines pro-
vided that the Ministry grants permission based on an application submitted by the interna-
tional transporter. This application should contain data about the person responsible for ma-
nipulation with medicines including a declaration of his/her good health condition and profes-
sional capacity. These complex application requirements may deter the international trans-
porter from applying for permission. 
LANGUAGE: The distinction between medical use and misuse or illicit use is not always 
clear. In the reviewed Slovak legislation, narcotic and psychotropic substances are referred 
to as a ‘problem’. This may cause fear and confusion and may deter healthcare professionals 
from prescribing or dispensing opioid medicines or may deter patients from using controlled 
medicines for legitimate purposes. This is particular the case if severe sanctions are involved 
for unintended violations. In addition, the terms ‘addict(s)’, ‘addiction’ and ‘persons addicted’ 
are considered to be stigmatising, and are used in the reviewed Slovak legislation. 
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Textbox 15 Selection of recommendations specific to Slovakia: legal and regulatory 
§ Reconsider the prescription validity of 5 days that applies to prescriptions for medicines con-
taining controlled substances; 
§ Remove restrictions that apply to the amount to be prescribed, in particular if these re-
strictions do not apply to other non-controlled medicinal products, 
§ Remove the administrative requirements for receiving special prescription forms, 
§ Decrease the administrative burden for dispensing opioid medicines; 
§ Ensure that patients in prison or patients living in a remote area are able to access controlled 
medicines if medically needed; 
§ Allow for controlled medicines to be on board in small amounts in first aid kits during interna-
tional transportation without complex application requirements; 
§ Provide clear language in legislation and avoid language that stigmatises the medical use of 
opioids or refers to patients with dependence in a disrespectful way. 
 
5.3. dentified policy barriers 
For Slovakia, the main challenges concerning access to opioids were identified in finan-
cial/economic aspects, issues relating to formularies, education and training and social atti-
tudes.  
GOVERNMENTAL SUPPORT and FINANCIAL/ ECONOMIC ASPECTS: There is lack of 
financial resources available for palliative care in Slovakia whereas funding of centres offer-
ing palliative care services in specific regions of the country needs to be further facilitated. 
Political/ Governmental support is needed as well as improved communication between 
healthcare professionals and stakeholders. For example, the Ministry of Health should work 
closely with the Ministry of Finance and the National Health Insurance Funds to provide the 
necessary economic support. Moreover, the Ministry of Health should be actively involved in 
promoting education and training on pain management, pain medicine and palliative care in 
Slovakia. For this purpose, collaboration is recommended with other regional authorities, as 
well as national and international specialist associations such as the Association of Hospice 
and Palliative Care in Slovakia (AHPS), the Slovak Society for the Study and Treatment of 
Pain (SSSLB), or the European Association for Palliative Care (EAPC).  
FORMULARIES: Palliative care is currently not recognized as a specialty in Slovakia. The 
major barrier identified relates to reimbursement of palliative care services and opioid treat-
ment. There is lack of a basic palliative care network which means that insurance companies 
can provide no contracts and there are no government-reimbursed palliative care services 
offered at outpatient clinics. Similarly, patients in home-based palliative care services need to 
pay out of their pocket for any prescriptions signed by hospice or palliative care physicians, 
the cost of which is as a high as a monthly pension. Only pain physicians are allowed to pro-
vide strong opioids that are reimbursed by insurance companies. Moreover, there is no reim-
bursement of mobility costs which can exacerbate the problem of access to opioids in Slo-
vakia. In addition, the process of pain treatment needs to be further monitored and pain 
guidelines need to be developed and implemented. Finally, the meaning of strong opioids 
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needs to be reassessed and pre- and post- treatments need to be extended, emphasizing 
the importance of specialist input to ensure optimal quality of the services provided.  
EDUCATION AND TRAINING: There is lack of basic education and training opportunities 
regarding palliative medicine and the use of opioid analgesics in undergraduate and post-
graduate curricula for physicians and other healthcare professionals. A good illustration of 
the gap in existing knowledge is the fact that the two-week detoxification procedure neces-
sary before a patient can enter an opioid dependence treatment program is not something 
that all physicians seem to be aware of. In addition, most physicians are reluctant to pre-
scribe due to the lack of adequate education leading to insufficient knowledge. To improve 
this situation, education and training of healthcare professionals need to be facilitated. More 
regional / community courses and workshops on pain management, opioid treatment and 
palliative care should be designed and implemented. To achieve this, the Ministry of Health, 
the Ministry of Education, regional authorities and specialist associations such as the 
AHAPS, the SSSLB or the EAPC should be involved. Finally, more networks need to be de-
veloped in order to effective handle the barrier of insufficient knowledge about how to work 
with palliative care patients or how to establish palliative care centres.  
SOCIAL ATTITUDES: Although treatment principles and attitudes towards opioids have 
changed in Slovakia the stigma of morphine has not retreated. Still, this stigma seems to be 
diminishing considering that there is no word for ‘addiction’ in Slovak language and the word 
frequently used in such situations is ‘abuse’. However, there are still negative cultural stereo-
types about opioids (fear of opioids) mainly related to fear of dependence, fear of tolerance 
and fear of side effects. There is a misunderstanding and misinformation about opioids in the 
sense that morphine therapy is inevitably associated with impending death or that pain is 
necessary and needs to be endured. As a result, it would be essential to raise public aware-
ness and change their attitudes towards the use of opioids for pain management and pallia-
tive care through continuous education. Moreover, doctor patient communication needs to be 
improved. Patients and their families should be adequately informed about the temporary 
side effects which might be experienced when using opioids such as breathlessness, head-
ache, tiredness, immunity problems, and insomnia. In the same way, patients should be in-
formed about physical tolerance (higher dosage to the same level of pain), dependence as 
well as the effects of rapid discontinuation. Finally, there appears to be lack of trust towards 
the knowledge and expertise of palliative care professionals in Slovakia which is a serious 
issue that needs to be addressed and can only be resolved through education and sustaina-
bility in palliative care services.  
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Textbox 16 Selection of recommendations specific to Slovakia: policy 
§ Increase the number of palliative care beds around the country; 
§ Support outpatient clinics; 
§ Reimburse home-based palliative care services; 
§ Reimburse prescriptions written by palliative care and hospice physicians; 
§ Introduce ‘opioid treatment’ as a subject in the Faculty of Medicine; 
§ Undertake further research on non-cancer patients to examine the use of opioids in clinical 
practice; 
§ Raise the status of palliative care from sub-specialty to specialty; 
§ Set-up undergraduate and postgraduate palliative care training in medical schools; 
§ Provide opportunities for continuous education/ training for healthcare professionals involved 
in pain management, palliative care, and treatment of opioid dependence; 
§ Monitor the process of pain treatment to ensure quality; 
§ Educate the public about appropriate opioid use. 
 
5.4. Voices from Slovak ATOME participants 
In the summer of 2013 and of 2014, national key contacts and representatives of the national 
ATOME country teams were asked what had changed regarding access to opioid medicines 
in their country since the beginning of the project. This is an exemplary answer by one repre-
sentative of the Slovakia country team. 
Textbox 17 Voice from a Slovak ATOME participant 
“There was an increase of co-payment for the patients receiving some strong opioids (oxycodone 
in slow-release tablets, rapid release fentanyl in sublingual tablets)” (Kristina Križanová, Depart-
ment of Palliative Care, National Oncologic Institute, 13.10.2014). 
  




Potential barriers to accessing opioids in Slovakia have been identified in the areas of legis-
lation and policy. The ATOME project recommends that the Slovak legislation should be re-
vised to provide a legal framework that focuses on optimizing healthcare outcomes while 
preventing diversion and misuse. The project also recommends that prescribing and dispens-
ing should be facilitated (limited prescription validity and the maximum amount of controlled 
medicines to be prescribed should be removed as well as the administrative requirements 
regarding the receipt of special prescription forms). The restrictions on the authorization to 
provide methadone maintenance treatment should be reconsidered and access to controlled 
medicines should be ensured for specific patient groups (patients in prison and patients in 
remote areas). Clear language and non-stigmatizing terms in the Slovak legislation should be 
guaranteed. Considering the identified policy barriers in Slovakia the ATOME project advises 
to improve the communication and collaboration between authorities, stakeholders and 
healthcare professionals in order to enhance financial support for palliative care. Basic pallia-
tive care networks should be established to provide contracts with insurance companies and 
to ensure the reimbursement for palliative care services. Access to opioid treatment should 
be improved by reimbursing mobility costs and by extending the authorisation to prescribe 
strong opioids that are reimbursed. Palliative medicine should be recognized as a medical 
speciality. Basic education and training opportunities in palliative care and the use of opioids 
analgesics as well as the treatment of opioid dependence should be included in under- and 
postgraduate curricula for healthcare professionals. Continuous training courses and further 
research should be developed in order to guarantee sufficient knowledge about the use of 
opioids in medical treatment. Furthermore, misunderstandings and misinformation about opi-
oids within the general public should be challenged as well as the lack of trust towards the 
expertise of palliative care professionals – e.g. by enhancing the communication and the in-
formation exchange between physicians and patients. 
Throughout the ATOME project, encouraging developments have been observed in terms of 
improved access to opioids in Slovakia. Some of the recommendations made in this report 
may have already been implemented, but others remain to be as barriers to access to opi-
oids and a balance of preventing misuse and ensuring availability still needs to be achieved. 
The continuing efforts of the country team to implement the specific goals elaborated in the 
early stages of the ATOME project are expected to have facilitated improvements at different 
strategic levels. 
 
ATOME REPORT AND RECOMMENDATIONS - COUNTRY REPORT SLOVAKIA 
 
75 



















Start of the pro-
ject 





bers and national 
counterparts 
   
















Quick scan of legis-
lation started 






ments on behalf 












vá sent additional 
information on 








































gic action plan 
on improving 
access to opi-
oids in Slovakia 
Jan 
2012 
    
Report on the 
results of the 

























































































July -  
Nov 
2012 
In-depth analysis of 
national legislation 
   
Draft overview 
of legal barriers 
to opioid availa-









































in Utrecht on 










































































behalf of the 
ATOME Slovakia 
country team 
Leading role of 
Slovakia country 
team and experts 





Draft report on legal 
barriers in Slovakia 
sent to the Slovak 
country team 
   
Draft report on 





Final report on legal 
barriers in Slovakia 






the preparation of 
the National 
follow-up confer-




Final report on 






mented in Bratislava, 
Slovakia 















































ATOME REPORT AND RECOMMENDATIONS - COUNTRY REPORT HUNGARY 
79 
Access to Opioid Medication in Europe (ATOME) 
Report and recommendations to the Ministry of Human 
Capacities 
6. Country Report - Hungary 
 
6.1. Introduction 
Hungary is one of the countries with statistical evidence of inadequate morphine consump-
tion per capita. In 2006, the adequacy of opioid analgesic consumption was 28% - based on 
a per capita consumption of 69.14 morphine equivalents (mEq) while 250 mEq would have 
been adequate for treatment of all pain conditions28. Hungary was selected as one of the 
countries to participate in the ATOME project for this reason. Four years later, in 2010, the 
adequacy of opioid analgesic consumption had slightly decreased (both in absolute and in 
relative terms) – it was 23%29 (based on a per capita consumption of opioid analgesics of 
76.31 morphine equivalents (mEq) while 325.96 mEq in mg per capita would have been ad-
equate). This report presents a summary of the results of the situational analysis that has 
been undertaken with regard to opioid availability and accessibility in Hungary. The results of 
the situational analysis are divided in two parts: the first part addresses legal and regulatory 
issues and the second part focuses on issues relating to policy. Both parts present the main 
barriers and recommendations for improving access to opioid medication in Hungary. 
6.2. Identified legal and regulatory barriers 
The results of the ATOME legislation review have been divided into nine different categories 
of potential legal and regulatory barriers: i.e. barriers related to prescribing; dispensing; us-
age; trade and distribution; manufacturing; affordability; penalties; language; and other. In 
Hungary, potential legal and regulatory barriers have been identified in eight of these nine 
areas: all areas except affordability (see Annex 2). A selection of these potential barriers is 
highlighted below according to category, followed by recommendations on how to remove 
these barriers. For a more detailed description of the methods and results, see Annex 2. 
PRESCRIBING: The prescribing of opioid medicines in Hungary is subject to many adminis-
trative and non-administrative requirements. For example, the competence to prescribe con-
trolled medicines for a period that exceeds 30 days is restricted to the family practitioner. In 
addition, the total quantity of controlled substances to be prescribed is limited to complete 
package units or dosage units that equal the number of package units. Only specialist physi-
cians are allowed to prescribe those controlled substances whose prescription is subject to 
                                               
28 Seya MJ, Gelders SFAM, Achara UA, Milani B, Scholten WK. A First Comparison between the Consumption of 
and the Need for Opioid Analgesics at Country, Regional and Global Level. Journal of Pain and Palliative Care 
Pharmacotherapy, 2011; 25: 6-18. Accessible at: 
http://apps.who.int/medicinedocs/documents/s17976en/s17976en.pdf 
29 Duthey, B., Scholten, W. Adequacy of Opioid Analgesic Consumption at Country, Global, and Regional Levels 
in 2010, Its Relationship With Development Level, and Changes Compared With 2006. Journal of Pain & Symp-
tom Management 47(2); 2014: 283-97 doi:10.1016/j.jpainsymman.2013.03.015; 
http://www.sciencedirect.com/science/article/pii/S0885392413002728 
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the possession of a specialist board examination. These restrictions can be a potential barri-
er to access, in particular if the family practitioner or specialist physicians are not readily 
available to prescribe these medicines for patients in medical need. Administrative require-
ments that apply to the prescribing of opioid medicines may deter health care professionals 
from prescribing these medicines. For example, the family practitioner is required to fill in a 
notification form and is required to notify the pharmacy chosen by the patient. A new notifica-
tion has to be filled in if the patient requires a larger quantity, a different controlled substance 
or requires treatment for a period exceeding three months.  
DISPENSING: Additional requirements for the dispensing of controlled medicines may in-
crease the administrative burden and may cause pharmacists to be reluctant to dispense 
controlled medicines. According to the Hungarian legislation, controlled medicines are not 
allowed to be dispensed if the prescription was issued more than five working days ago. In 
addition, only a designated pharmacy, appointed in consultation with the patient, is author-
ised to dispense continuous or repeated prescriptions for controlled substances. These legal 
restrictions can be a potential barrier to access, in particular if patients require medical treat-
ment with controlled medicines for a long period and are not able to visit the physician and 
pharmacy frequently (e.g. when living in a remote area and having to travel far to visit the 
physician and pharmacy or when patients rely on the help of family members and friends 
living in a different area due to worsening of the illness). Pharmacies are allowed to dispense 
controlled substances provided that an activity license has been issued by the National Chief 
Medical Officer Authority or the sub-region public health institute of the metropolitan or coun-
ty government office. If unused controlled medicines are returned to the pharmacy, the 
pharmacist is obliged to provide a written record of the return of the controlled substance 
using a five-copy printed document. Many other administrative dispensing requirements can 
be found in the Hungarian legislation, all increasing the administrative burden and potentially 
causing pharmacists to be reluctant to dispense controlled medicines.  
USAGE: Patients requiring continuous or repeated treatment with controlled medicines are 
obliged to visit the same designated pharmacy every time a prescription is issued (see also: 
PRESCRIBING and DISPENSING). Patients with dependence syndrome should be able to 
receive treatment for dependence within a reasonable amount of time. According to the Hun-
garian legislation, the dependence treatment can commence within six months of the issu-
ance of the opinion without early status assessment. This can be a potential barrier to access 
if this implies that patients might have to wait six months or more (depending on the time 
needed for the ‘issuance of the opinion’) to be able to receive treatment. In case of an issu-
ance during a criminal procedure, drug dependence needs to be established by a forensic 
medical expert additionally. This can also be a potential barrier to accessing treatment if the 
total number of forensic medical experts is too low to establish drug dependence within a 
reasonable time. 
TRADE AND DISTRIBUTION: Requirements regarding the trade and distribution (and also 
the manufacturing) of controlled medicines may increase the administrative burden and may 
delay or impede the availability of medicinal products on the market. According to Hungarian 
legislation, the application for an activity license should be accompanied by many docu-
ments. For example, the applicant has to submit an overview of the mechanical and/or elec-
tronic security devices, as well as a description of the system for guarding, records, and 
movement within the site, together with an expert opinion certifying the operability of the se-
curity system. An application for a modification of the license is required even when there 
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has been a change in for example the security or security technology installations required 
for law-enforcement purposes. In addition, the license holder is obliged to reclaim unused 
stocks from its own customers every year, and a police representative has to be present to 
witness the destruction of these controlled substances.  
Textbox 18 Selection of recommendations specific to Hungary: legal and regulatory 
§ Remove the restriction that only the family practitioner is authorised to prescribe controlled 
medicines for a period longer than 15 days. Remove the limited prescription validity of five 
working days and the restrictions that apply to the authorisation to prescribe controlled sub-
stances whose prescription is subject to the possession of a specialist board examination; 
§ Decrease the administrative burden for prescribing and dispensing opioid medicines; 
§ Remove the obligation for patients requiring continuous or repeated treatment with controlled 
medicines to visit one designated pharmacy; 
§ Ensure that patients are able to receive treatment with controlled medicines within a reasona-
ble time, also in the situation that patients are arrested or imprisoned and need controlled 
medicines for the treatment of dependence; 
§ Remove the restriction that only forensic medical experts are allowed to establish depend-
ence, during a criminal procedure, especially if the number of forensic medical experts availa-
ble to establish dependence is too low, causing a delay in onset of treatment; 
§ Decrease the administrative burden for legal entities involved in the trade and distribution 
(and also manufacturing) of opioid medicines.  
6.3. Identified policy barriers 
For Hungary, the main challenges concerning access to opioids were identified in finan-
cial/economic aspects, issues relating to formularies, education and training and social atti-
tudes. 
FINANCIAL/ ECONOMIC ASPECTS: A key policy barrier to opioid access in Hungary relates 
to funding coming from the Health and Social Insurance Fund and the way this funding is 
allocated to support pain management, harm reduction and palliative care. The standard of 
palliative care in the country appears to be ´variable´ with paediatric palliative care not being 
financed and home-based care being only financed to provide one visit per day. Institutions 
should be able to set up palliative care units which cannot be achieved unless funding alloca-
tion is reconsidered. For instance, if 1% of the costs of oncology care would be invested in 
palliative care, this would considerably improve the patients’ quality of life. Research funding 
has also decreased considerably. As a result, forms of financed care should be expanded 
and the Hungarian finance system and the way funds are allocated should be re-thought. 
FORMULARIES: Registration for treatment costs a lot. The cost for advanced formulations is 
also too high. In addition, not all pain medication is fully reimbursed. This discourages pa-
tients from getting the treatment necessary for pain relief. All forms of OAT medication for the 
required dose on an individual basis as well as new forms of palliative care services should 
be reimbursed. Reimbursement is also not sufficient for practitioners providing palliative care. 
Financial incentives should be offered to physicians for good practice and responsible pre-
scribing and administering of opioid medication.  
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EDUCATION AND TRAINING: Palliative care is not recognised as a medical specialty in 
Hungary. Chronic pain management is not included in the programmes implemented by the 
Ministry of Human Resources and there is a lack of recognition, knowledge and training in 
this area. There is no palliative care specialist education for doctors. Many GP’s lack experi-
ence in prescribing due to limited education (they usually refer this responsibility to oncolo-
gists). As a result, specialists should advise GPs on opioid regimens and how to apply the 
pharmacotherapy of pain (practical skills). Education programmes for undergraduate and 
postgraduate education levels must be developed, as well as subspecialty training for pallia-
tive care specialists. Palliative medicine needs to be established as a subspecialty. Mandato-
ry pain management training needs to be provided for doctors during their specialisation and 
Continuing Medical Education (CME) organised (physicians should be required to pass a 
regular exam). Pharmacists should also be taught in pain relief, and both pharmacists and 
physicians should be trained in communication with patients since certain communication 
has been observed to scare patients away from opioids. In addition, physicians need to be 
taught to recognise drug dependence. OAT education initiatives must be increased and more 
practical skills should be provided to this direction. Special training programmes relating to 
OAT within the prison system need to be developed and implemented. Finally, protocols and 
directives need to be issued and included in education.  
SOCIAL ATTITUDES: Health care professionals generally suffer from fear of opioids. Physicians 
discourage patients from using opioids for pain relief due to fear of dependence. Similar fears 
persist between patients and their families. This is mainly because of the lack of awareness 
of opioid use for pain management and palliative care within the society. For example, a pa-
tient once injected with morphine felt very relieved and said to her physician: ‘‘You must have 
given me a magic substance, a miracle has happened!‘‘ But when she told him that she had 
been given morphine, she turned all pale and said „Oh no - now I will become addicted!”. 
Moreover, if a patient finally accepts that strong opioids should be used to treat his or her 
pain effectively, the people in their environment may disapprove (family, friends, etc.). There 
is also a legal uncertainty regarding needle exchange programmes and providing sterile sy-
ringes is still considered to be a crime. Drug users receiving OAT are often marginalised and 
treated as ‘‘criminals‘‘. Taboos in relation to opioids still prevail amongst physicians, patients, 
families as well as the general public. A change in perceptions must be achieved involving 
campaigns, advertisement and patient organisations to raise awareness and inform the 
population about the benefits and the risks of opioid use.  
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Textbox 19 Selection of recommendations specific to Hungary: policy 
§ Increase financing for harm reduction programmes and palliative care physician reimburse-
ment; 
§ Reimburse new forms of palliative care services;  
§ Reimburse all forms of OAT medication for the required dose on an individual basis;  
§ Broaden the range of OAT medication; 
§ Offer financial incentives to physicians for good practice and responsible prescribing and ad-
ministering of opioids; 
§ Establish more palliative and outpatient care units; 
§ Establish palliative care as a medical specialty; 
§ Provide mandatory pain management training for doctors during their specialisation; 
§ Train pharmacists and physicians in communication with patients; 
§ Educate physicians to recognise drug dependence; 
§ Increase OAT education initiatives; 
§ Implement special training programmes relating to OAT with the prison system; 
§ Issue protocols and directives and include them in education; 
§ Raise awareness of the general population with respect to opioid use; 
§ Challenge the stereotypes surrounding opioid use. 
  
ATOME REPORT AND RECOMMENDATIONS - COUNTRY REPORT HUNGARY 
 
84 
6.4. Voices from Hungary ATOME participants 
In the summer of 2013 and of 2014, national key contacts and representatives of the national 
ATOME country teams were asked what had changed regarding access to opioid medicines 
in their country since the beginning of the project. These are exemplary answers by two rep-
resentatives of the Hungary country team. 
Textbox 20 Voices from Hungary ATOME participants 
“The basic decree which defines the rules of prescribing and retail dispensing of controlled sub-
stances has been changed twice during the last two years in the direction of facilitation and simpli-
fication. Two examples: A family practitioner may prescribe a controlled substance in the amount 
which shall not exceed a 90-day supply. Before the amendment of the decree the amount was on-
ly 30 days supply. Furthermore, prescriptions for controlled substances do not have to be written 
in duplicate any longer.  
As a result of the ATOME legislation review country report further simplifications are under prepa-
ration these days. Hopefully they will come into force on the 1st of July. (Returning of unused con-
trolled substances to the pharmacy, changing the terminology of narcotic drugs to controlled sub-
stance etc.)” (Dr Éva Gecső Luxné, 10.06.2013). 
“A new ministerial decree came into force on 14th of September in 2012, and the new provision 
requires that all doctors have the basic knowledge of pain killing and palliative care before obtain-
ing a specialist qualification” (Dr Éva Gecső Luxné, 07.07.2014). 
“As of 2014, physicians in Hungary will be able to take a one-year course to qualify for a license in 
palliative medicine. The licensure program supersedes the previous 40-hour training requirement 
for physicians wishing to qualify for a hospice-palliative position and will be offered through the 
four participating Hungarian medical schools in Pecs, Debrecen, Szeged, and Budapest. The pro-
gram will produce better trained physicians, and result in more desperately needed palliative care 
programmes across the country. The curriculum has been designed, and further work remains to 
be done to finalize the logistics and coordination, so the programme should be up and running by 
late 2014” (Dr Ágnes Csikós, 17.12.2013). 
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6.5. Conclusion 
Potential barriers to accessing opioids in Hungary have been identified in the areas of legis-
lation and policy. The ATOME project recommends that the Hungarian legislation should be 
revised to provide a legal framework that focuses on optimizing healthcare outcomes while 
preventing diversion and misuse. The project also recommends that prescribing and dispens-
ing should be facilitated (limited prescription validity and the restrictions on the authorisation 
to prescribe and to dispense controlled medicines should be removed), in order to ensure 
sufficient treatment for patients with dependence syndrome access to treatment should be 
guaranteed within a reasonable time as well as sufficient capacities to establish drug de-
pendence and the administrative burden for legal entities involved in trade, distribution, and 
manufacturing of opioid medicines should be decreased. Considering the identified policy 
barriers in Hungary the ATOME project advises to reimburse new forms of palliative care 
services and harm reduction programmes, to expand the reimbursement for all pain medica-
tions and all forms of opioid agonist therapy (OAT) and to broaden the range of OAT medica-
tion; ensure an adequate level of professional knowledge and competence by improving ed-
ucation and training in the field of palliative care and harm reduction. Furthermore, the 
awareness and the acceptance of the effectiveness and risks of opioid use should be raised 
within the general society – i.e. within healthcare professionals as well as within patients and 
their families – by involving campaigns, advertisement and patient organisations. 
Throughout the ATOME project, encouraging developments have been observed in terms of 
improved access to opioids in Hungary. Some of the recommendations made in this report 
may have already been implemented, but others remain to be a barrier to access to opioids 
and a balance of preventing misuse and ensuring availability still needs to be achieved. 
The continuing efforts of the country team to implement the specific goals elaborated in the 
early stages of the ATOME project are expected to have facilitated improvements at different 
strategic levels. 
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Access to Opioid Medication in Europe (ATOME) 
Report and recommendations to the Ministry of Health 
7. Country Report - Slovenia 
7.1. Introduction 
Slovenia is one of the countries with statistical evidence of inadequate morphine consump-
tion per capita. In 2006, the adequacy of opioid analgesic consumption was only 51% (based 
on a per capita consumption of 104.09 morphine equivalents (mEq) while 205.78 mEq would 
have been adequate for treatment of all pain conditions30).Slovenia was selected as one of 
the countries to participate in the ATOME project due to this reason. Four years later, in 
2010, the adequacy of opioid analgesic consumption had even decreased (both in absolute 
and in relative terms) – it was only 41%31 (based on a per capita consumption of opioid an-
algesics of 112.63 morphine equivalents (mEq) while 271.88 mEq per capita would have 
been adequate). This report presents a summary of the results of the situational analysis that 
has been undertaken with regard to opioid availability and accessibility in Slovenia. The re-
sults of the situational analysis are divided in two parts: the first part addresses legal and 
regulatory issues and the second part focuses on issues relating to policy. Both parts present 
the main barriers and recommendations for improving access to opioid medication in Slove-
nia.  
7.2. Identified legal and regulatory barriers 
The results of the ATOME legislation review are presented into nine different categories of 
potential legal and regulatory barriers, i.e. barriers related to prescribing; dispensing; usage; 
trade and distribution; manufacturing; affordability; penalties; language; and other. In Slove-
nia, potential legal and regulatory barriers have been identified in six of these nine catego-
ries: all except affordability (see Annex 2). A selection of these potential barriers is highlight-
ed below according to category, and followed by recommendations to remove these barriers. 
For a more detailed description of the methods and results, see Annex 2. 
PRESCRIBING: The prescribing of opioids in Slovenia is subject to administrative and non-
administrative requirements. For example, physicians are obliged to use special forms when 
prescribing opioids and these forms have to be issued in duplicate. Examples of non-
administrative requirements are the limitations that apply to the treatment period (which is 
limited in some cases), the maximum amount of medicines per prescription (based on the 
approved dosing regimen in the SPC) and the duration of the prescription validity. Although 
some requirements may not be recognised as ‘barriers to access’, they may limit access to 
opioids in practice; when multiple barriers are identified in the same category (for example 
                                               
30Seya MJ, Gelders SFAM, Achara UA, Milani B, Scholten WK. A First Comparison between the Consumption of 
and the Need for Opioid Analgesics at Country, Regional and Global Level. Journal of Pain and Palliative Care 
Pharmacotherapy, 2011; 25: 6-18. Accessible at: 
http://apps.who.int/medicinedocs/documents/s17976en/s17976en.pdf 
31 Duthey, B., Scholten, W. Adequacy of Opioid Analgesic Consumption at Country, Global, and Regional Levels 
in 2010, Its Relationship With Development Level, and Changes Compared With 2006. Journal of Pain & Symp-
tom Management 2013; http://www.sciencedirect.com/science/article/pii/S0885392413002728 
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prescribing), the problem is substantially compounded. For example, the limited prescription 
validity of five days in combination with both a maximum amount per prescription and a max-
imum treatment period of 30 days may result in limited access to opioids for medical purpos-
es.  
DISPENSING: In Slovenia, the authorisation to dispense controlled medicines is restricted to 
pharmacists, whereas other medicinal products not containing controlled substances can 
also be dispensed by pharmacy technicians. For this reason, opioids cannot be dispensed if 
the pharmacist is (temporarily) unavailable; this can delay the onset of therapy. When dis-
pensing opioids, pharmacists are required to keep special officially sealed books to record 
the statistics of the dispensing. These books must be kept and signed by the person that 
dispensed the controlled medicine, which increases the administrative burden and may deter 
pharmacists from dispensing such medicines.  
USAGE: Opioid medicines can only be dispensed to patients who are 18 years of age or 
older and are able to produce a valid identity card; this may delay or impede access for pa-
tients in medical need of opioids (see also par. 6.6.4, Annex 2). 
TRADE AND DISTRIBUTION: Incomplete applications for a license to import or export con-
trolled medicines must be supplemented within eight days. This restrictive timescale can de-
lay the availability of opioids if a completely new application is required. 
PENALTIES: The Slovenian legislation contains severe, disproportional sanctions for legal 
entities and individual persons for the violation of administrative requirements, such as the 
requirements related to storage of controlled medicines and substances. These severe sanc-
tions may cause fear of unintended violations and may deter legal entities and individual per-
sons from producing, trading or storing opioids.  
LANGUAGE: In the Slovenian legislation, the distinction between medical use and misuse or 
illicit use is not always clear. In addition, the definition used for controlled substances is may 
contribute to the stigmatization of opioids. This also applies to the use of stigmatising terms 
such as ‘addicts’ and ‘addiction’ in the Slovenian legislation. 
Textbox 21 Selection of recommendations specific to Slovenia: legal and regulatory 
§ Remove the limited prescription validity of five days;  
§ Allow for appropriately trained pharmacy technicians to dispense opioid medicines;  
§ Decrease the administrative burden for prescribing, dispensing and receiving opioid medi-
cines; 
§ Ensure that applying for a license to import or export opioid medicines is not unnecessarily 
complicated;  
§ Ensure that sanctions for unintended violation of administrative rules are not disproportionate 
in relation to the risk of misuse and diversion;  
§ Provide clear language in legislation, use correct definitions and avoid language that stigma-
tises the medical use of opioids or refers to patients with dependence in a disrespectful way.  
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7.3. Identified policy barriers 
For Slovenia, the main challenges concerning access to opioids were identified in finan-
cial/economic aspects, issues relating to formularies, education and training, social attitudes. 
FINANCIAL/ ECONOMIC ASPECTS: One of the major barriers to opioid access in Slovenia 
is lack of funding allocated to harm reduction and palliative care initiatives. There are two 
main forms of dependency treatment currently available in the country - specialized treat-
ment in hospitals (in accordance with Slovenian healthcare provision) and outpatient treat-
ment provided from mobile units by an association of non-governmental organizations 
(NGOs) which are co-financed by various State Ministries only under certain circumstances., 
The Ministry of Health is the competent body to finance social prevention programmes. The 
right to harm reduction treatment is afforded to any dependent person and there is 100% 
coverage of funding by the National Insurance Company. Moreover, funding for palliative 
care is provided through general agreements for each contractual year; a team structure was 
defined in 2010, but currently funding for palliative care is not included in the agreement be-
tween the Ministry of Health and the National Insurance Company. 
FORMULARIES: The prescription procedure of opioids in Slovenia is too liberal; there are no 
guidelines for indications and no control regarding the increase of dose. The average time 
frame of seven minutes that are granted for home visits is yet another problem. Therefore, 
this timeframe should be extended. In addition, the consultation time should be documented 
in the patient charts (codes for documenting can be found on the website of insurance com-
panies). Relevant associations should be addressed to put this into practice. Prescribing 
should also follow guideline recommendations. However, given that existing guidelines in 
Slovenia appear to be not sufficient the guidelines from the US Pain Society relating to the 
use of opioids in chronic non-cancer pain and the WHO Guidelines for the Pharmacological 
Treatment of Persisting Pain in Children with Medical Illnesses could be used as a template 
or for guidance. Still, it is difficult to enforce the use of treatment guidelines in Slovenia since 
certain substances are not being imported. Moreover, a standard legal definition needs to be 
established for measuring pain in all medical settings where pain can occur. Although pain 
medication is widely available, physicians must acknowledge that pain is an acute symptom 
that requires urgent treatment. Many emergency medicines do not have suitable instructions 
for use; therefore those should be drafted and distributed by pharmacies. Not all emergency 
medications are free of charge for patients; therefore, those should be added to the list of 
medicines that are free of charge. Finally, not all pharmacists have sufficient equipment/ staff 
to provide PCAs (Patient-Controlled Analgesia) elastomeric pumps. Although not all pharma-
cies need such provisions, there should be a clear list of pharmacists where these are avail-
able to make sure that the patient does not need to travel to another pharmacy; instead, the 
equipment should be delivered to the pharmacy closest to the patient’s home via an estab-
lished network. 
EDUCATION AND TRAINING: There is a lack of education/competencies amongst 
healthcare professionals in palliative care and pain treatment. Although there is some educa-
tion and training in pain management, it is described as only a few hours duration and limited 
to certain specialties (for example, anaesthesiology, and emergency physicians). Better edu-
cation for healthcare professionals is therefore required in Slovenia. There is a need to in-
crease the qualifications required of post-graduate and practicing healthcare professionals to 
work with opioid medications (based on EAPC recommendations) and change the Laws of 
Medical Practice to enable only healthcare professionals with this specific education to pre-
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scribe opioids In addition, palliative care should be included in the undergraduate education 
of healthcare professionals. Although this action plan was already prepared, the changes in 
the government (the Minister of Health changed at least 3 times during the ATOME project) 
did not allow for this plan to be realised. There is no specialized training in palliative care for 
healthcare professionals in Slovenia32. The requirement for interns to spend two months 
studying palliative care has already been included. A curriculum for postgraduate study pro-
grammes (including pain management and palliative care) should be developed. A network is 
also needed to educate and support GPs given that guidelines on paper are not sufficient. 
This issue must be discussed with physicians’ associations and medical faculties. A more 
structured approach towards education needs to be developed that will include multi-
disciplinarity. Specialists for drug dependence and pain management do not know each oth-
er’s’ fields of competence and as a result they should cooperate more closely. Finally, train-
ing/education should be established for measuring pain in all medical settings where pain 
can occur. This initiative should involve physician societies, professional associations and 
other healthcare professionals. 
SOCIAL ATTITUDES: There is a lack of awareness amongst the general population (pa-
tients, relatives) about the accessibility of pain management/opioid medication in Slovenia. 
Not enough information is provided to the public. In addition, the knowledge health care pro-
fessionals receive on palliative care is also insufficient considering that this topic is not ade-
quately addressed during medical education. A case study of successful use of opioid medi-
cation for pain management demonstrated a fear of using strong opioids on the part of physi-
cians and patients. Physicians are reluctant to prescribe opioids for pain relief due to fear of 
dependence/tolerance or unexpected side effects. Moreover, patients often live in fear that 
their dosage will be reduced and they might suffer relapse. Gaps in harm reduction strategy 
include lack of treatment of dependence for prescribed medications and issues of stigma and 
discrimination. Patients receiving opioid agonist therapy are often stigmatised leading to so-
cial and professional isolation. The issue of fear of opioids needs to be addressed and re-
solved. This may be achieved by expanding public knowledge about pain manage-
ment/opioid medication, using different social media (TV, newspapers, etc.) and professional 
knowledge by developing and implementing training initiatives for health care providers in-
volved in pain management and palliative care.  
                                               
32 Since March 2011 there is a 50 hour course on palliative care. 
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Textbox 22 Selection of recommendations specific to Slovenia: policy 
§ Provide additional funding for pain management and harm reduction initiatives and palliative 
care services (for example, mobile teams to provide coverage in rural areas) via the National 
Insurance Company; 
§ Improve marketing authorization procedures; 
§ Develop a list of pharmacies that possess sufficient and appropriate equipment/staff to pro-
vide opioids;  
§ Provide harm reduction in relation to treatment of dependence for prescribed medications; 
§ Ensure that opioid education is included in undergraduate and postgraduate curricula for rele-
vant healthcare professionals (to include all members of the multidisciplinary team); 
§ Raise awareness and sensitisation about pain management among practicing health-care 
professionals (e.g. via Continued Medical Education; a series of publications about the ration-
al use of opioids in highly-accessed national medical journals; a survey on knowledge and at-
titudes regarding opioid medicines); 
§ Develop initiatives to reduce stigma and discrimination associated with harm reduction; 
§ Raise awareness among the general public via media campaigns, patient information (e.g. 
leaflets/brochures about fear of opioids). 
7.4. Voices from Slovenian ATOME participants 
In the summer of 2013, national key contacts and representatives of the national ATOME 
country teams were asked what had changed regarding access to opioid medicines in their 
country since the beginning of the project. These are examples of answers by one repre-
sentative of the Slovenian country team. 
Textbox 23 Voices from Slovenian ATOME participants 
“The most important contribution of the ATOME project was the adoption of the Essential drug list 
and inclusion of most of the drugs from that list to our essential drug list. So, now we have again 
the prolonged release morphine in different oral formulations and many other drugs, and that 
makes our work easier. 
We have developed a more structured approach towards education that will include all profession 
from the multiprofessional team. It is foreseen to cover Slovenia with mobile palliative units who 
will connect intra and extramural territory.  
There has been a much better cooperation with the MoH. Regular reports of palliative care devel-
opment are included in the meetings of National programme for cancer control. 
There has been a special meeting dedicated to the problem of abusing the prescribed drugs at 
the Slovenian Society for Pain Medicine“ (Mateja Lopuh, 06.06.2013). 
  




Potential barriers to accessing opioids in Slovenia have been identified in the areas of legis-
lation and policy. The ATOME project recommends that the Slovenian legislation should be 
revised (in consultation with healthcare professionals) to provide a legal framework that fo-
cuses on optimizing health care outcomes while preventing diversion and misuse. The pro-
ject also recommends that education on palliative care and pain treatment (at both under-
graduate and postgraduate level) be expanded, that funding in these areas be increased (in 
addition to harm reduction) and that awareness-raising initiatives in all these areas be pro-
moted. 
Throughout the ATOME project, encouraging developments have been observed in terms of 
improved access to opioids in Slovenia. Some of the recommendations made in this report 
may have already been implemented (or are in the process of implementation). For example, 
the WHO Model List of Essential Medicines has been adopted and most of the medicines 
from that list were included in the national Slovenian essential medicines list. There is im-
proved cooperation and collaboration with the Ministry of Health, regular reports of palliative 
care development are included in National Programme for Cancer Control meetings, and 
there has been a special meeting at the Slovenian Society for Pain Medicine relating to the 
misuse of prescribed medicines. 
The continuing efforts of the country team to implement the specific goals elaborated in the 
early stages of the ATOME project can be assumed to have facilitated improvements at dif-
ferent strategic levels; this steady progress has enabled them to continue improving access 
to opioid medicines in Slovenia in alignment with specific recommendations provided in this 
report. 
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Access to Opioid Medication in Europe (ATOME) 
Report and recommendations to the Ministry of Health 
8. Country Report - Serbia 
 
8.1. Introduction 
Serbia is one of the countries with statistical evidence of inadequate morphine consumption 
per capita. In 2006, the adequacy of opioid analgesic consumption was only 8% - based on a 
per capita consumption of 12.81 morphine equivalents (mEq) while 166mEq would have 
been adequate for treatment of all pain conditions (Data for Serbia and Montenegro)33. Ser-
bia was selected as one of the countries to participate in the ATOME project due to its low 
per capita morphine consumption. Four years later, in 2010, the adequacy of opioid analge-
sic consumption had slightly increased (both in absolute and in relative terms) – it was 14%34 
(based on a per capita consumption of opioid analgesics of 40.06morphine equivalents 
(mEq) while 285.61mEq in mg per capita would have been adequate). This report presents a 
summary of the results of the situational analysis that has been undertaken with regard to 
opioid availability and accessibility in Serbia. The results of the situational analysis are divid-
ed in two parts: the first part addresses legal and regulatory issues and the second part fo-
cuses on issues relating to policy. Both parts present the main barriers and recommenda-
tions for improving access to opioid medication in Serbia. 
8.2. Identified legal and regulatory barriers 
The results of the ATOME legislation review have been divided into nine different categories 
of potential legal and regulatory barriers: i.e. barriers related to prescribing; dispensing; us-
age; trade and distribution; manufacturing; affordability; penalties; language; and other. In 
Serbia, potential legal and regulatory barriers have been identified in seven of these nine 
areas: all areas except affordability and other (see Annex 2). A selection of these potential 
barriers is highlighted below according to category, followed by recommendations to remove 
these barriers. For a more detailed description of the methods and results, see Annex 2. 
PRESCRIBING: The prescribing of opioid medicines in Serbia is subject to many administra-
tive and non-administrative requirements. For example, according to the Serbian legislation 
the authorisation to prescribe controlled medicines for the treatment of patients with depend-
ence is restricted to medical practitioners working in healthcare institutions, private practices 
and other designated legal entities performing healthcare activities. This restriction can be a 
potential barrier to access, in particular if the total number of healthcare professionals availa-
                                               
33 Seya MJ, Gelders SFAM, Achara UA, Milani B, Scholten WK. A First Comparison between the Consumption of 
and the Need for Opioid Analgesics at Country, Regional and Global Level. Journal of Pain and Palliative Care 
Pharmacotherapy, 2011; 25: 6-18. Accessible at: 
http://apps.who.int/medicinedocs/documents/s17976en/s17976en.pdf 
34Duthey, B., Scholten, W. Adequacy of Opioid Analgesic Consumption at Country, Global, and Regional Levels 
in 2010, Its Relationship With Development Level, and Changes Compared With 2006. Journal of Pain & Symp-
tom Management 47(2); 2014: 283-97 doi:10.1016/j.jpainsymman.2013.03.015; 
http://www.sciencedirect.com/science/article/pii/S0885392413002728 
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ble (and allowed) to prescribe controlled medicines is (too) low or healthcare institutions do 
not meet the needs of patients needing controlled medicines (e.g. palliative patients). 
According to the Serbian legislation, the total amount of controlled medicine to be prescribed 
is limited. For example, a physician may prescribe a maximum amount of 0.2 g morphine or 
0.2 g methadone. For the treatment of malignant diseases, the total amount to be prescribed 
is limited to a treatment duration of 14 days per prescription. For other conditions, medicines 
containing controlled substances can be prescribed for a maximum treatment period of 30 
days per prescription. In addition, the validity of a special medical prescription (used for pre-
scribing controlled substances) is limited to seven days from the date of issue. These re-
strictions are potential barriers to access; patients who require medical treatment with con-
trolled medicines for a longer period will need to visit the physician and pharmacy frequently. 
TRADE AND DISTRIBUTION: Requirements regarding the trade and distribution of con-
trolled medicines may increase the administrative burden and may delay or impede the 
availability of medicinal products on the market. According to Serbian legislation, legal enti-
ties must have open-ended employment contracts with any employee responsible for con-
trolled substances and with a deputy officer in charge to be able to submit an application for 
a production or trading license. This requirement may have financial consequences for the 
legal entity and may also increase the administrative burden, which can cause legal entities 
to be reluctant to produce or trade controlled substances. In addition, controlled substances 
may only be transported in metal containers with security locks, in specially constructed lug-
gage compartments equipped with a locking mechanism, or in an enclosed compartment of a 
vehicle that must be adapted in such a way that controlled substances cannot be removed. 
In addition, for the storage of controlled substances legal entities are obliged to ensure the 
permanent presence of a security service and appropriate technical installations. The cost of 
these safety measures may be disproportionate to the actual risk of diversion and may there-
fore deter legal entities from trading in controlled medicines. 
PENALTIES: Provisions containing intimidating language or severe sanctions for unintended 
violations may deter legal entities from manufacturing or distributing controlled medicines. 
According to the Serbian legislation, severe sanctions apply for violation of provisions con-
cerning controlled medicines. In particular provisions containing very high penalties for pri-
vate persons and provisions with high minimum sanctions and high maximum sanctions (e.g. 
3-12 years imprisonment for the unlawfully purchasing, keeping or transporting for sale of 
narcotics) can be considered intimidating. 
LANGUAGE: In the Serbian legislation, the distinction between medical use and misuse or 
illicit use is not always clear. The misuse of controlled medicines is often referred to as the 
use of controlled medicines. The phrase ‘reduction of demand for psychoactive controlled 
substances’ is often used to indicate that there should be a reduction of misuse. This lan-
guage may cause fear and confusion and may deter healthcare professionals from prescrib-
ing or dispensing opioid medicines or may deter patients from using controlled medicines for 
legitimate purposes, in particular if severe sanctions are involved for unintended violations. In 
addition, the terms ‘addict(s)’, ‘addiction’ and ‘persons addicted’ are considered to be stigma-
tising, but are used in the reviewed Serbian legislation. This also applies to referring to con-
trolled medicines as dangerous or harmful drugs. 
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Textbox 24 Selection of recommendations specific to Serbia: legal and regulatory 
§ Remove the prescription validity of 7 days that applies to prescriptions for medicines contain-
ing controlled substances; 
§ Remove restrictions that apply to the amount to be prescribed, in particular if these re-
strictions do not apply to other non-controlled medicinal products; 
§ Decrease the administrative burden for prescribing and dispensing opioid medicines; 
§ Remove the overly strict requirements regarding the storage of controlled medicines in prem-
ises; 
§ Ensure that the costs of security measures for the storage of controlled medicines are not 
disproportional compared to the risk of misuse and diversion; 
§ Revise provisions containing punitive sanctions, in particular provisions containing severe 
penalties for natural persons and provisions with high minimum sanctions; 
§ Ensure that punitive provisions contain exceptions for unintended violations; unintended er-
rors that do not result in diversion of controlled medicines or serious health consequences 
should not be subject to criminal penalties; 
§ Provide clear language in legislation and avoid language that stigmatises the medical use of 
opioids or refers to patients with dependence in a disrespectful way. 
8.3. Identified policy barriers 
For Serbia, the main challenges concerning access to opioids were identified in finan-
cial/economic aspects, issues relating to formularies, education and training and social atti-
tudes. 
FINANCIAL/ ECONOMIC ASPECTS: In 2004, the Serbian Government implemented the 
National Health Accounts (NHA) in an attempt to produce evidence to help policy makers 
and health managers better understand the way the health system operates and inform ac-
tion to improve performance. As a result, the increased transparency of financial flows in the 
health sector could enable a more reliable distribution of funds. In 2007 twenty-six centres for 
harm reduction offering opioid agonist therapy (OAT) were established in Serbia with the 
financial support offered by the Global Fund. However, there is still no underlying systematic 
approach and the funding provided by the Global Fund will run out 2014, leaving the centres 
with an unclear future. There are also evident difficulties in the funding of opioids by the Na-
tional Health Insurance Fund (NHIF) since prescription requires authorization from the pre-
scribing institution. 
FORMULARIES: There is an urgent need to establish palliative medicine as a medical spe-
cialty in Serbia35. Although palliative care is being increasingly recognized as a medical dis-
cipline, a disease-oriented (cure) vs. patient oriented holistic approach (care) dichotomy still 
exists in the country. Several hospitals have started pain clinics but holistic palliative care 
has yet to be introduced in these settings. Another important policy barrier relates to the 
‘overly restrictive regulations for the prescribing, dispensing and reimbursement of opioids’ in 
                                               
35 This need has already been fulfilled. Since 2009 palliative care is part of the curriculum for some specializations 
and sub specializations such as oncology, radiology, vascular surgery and general practitioners. According to the 
Serbian rulebook on specialization and sub specialization of healthcare professionals and associates, palliative 
medicine is a sub specialization accompanied by pain treatment since October 2013.  
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Serbia. Some palliative care medicines are available free of charge through the public 
healthcare service but some medicines used in palliative care are not covered when used 
specifically for symptom management rather than disease-specific applications. In addition, 
general practitioners (GPs) are not allowed to prescribe opioids independently but must have 
an official recommendation from a hospital doctor who usually does not see palliative care 
patients. This policy often results in a situation where doctors must recommend opioids with-
out seeing the patient. A number of reforms have been introduced to address such issues in 
the healthcare system; however, these reforms have failed to implement a basic level of 
healthcare provision for all members of the Serbian population and, as a result, there are 
varying levels of standards in the healthcare services provided throughout the country. 
EDUCATION AND TRAINING: Although some medical training and education relating to pain 
management was included in the manual of palliative care issued in 2013, there are currently 
no modules relating to ‘pain medicine’ in the medical undergraduate curriculum. There have 
been some courses and presentations on palliative care topics (mostly on symptom control) 
and several nursing schools have introduced modules on palliative care. There is some train-
ing and education available. However, since palliative care is not a medical specialty, there 
are only a few palliative care specialists in Serbia who had opportunities to access interna-
tional specialist training36. Although approximately 1500 healthcare professionals have re-
ceived some palliative care training, education initiatives in this area are considered to be 
insufficient. Palliative care education and training needs to be included in the programmes of 
Continuing Medical Education as well as the curricula of medical schools and nursing colleg-
es. It is imperative that healthcare professionals receive further education and training in ar-
eas such as pain management, pain medicine and palliative care and as a result such initia-
tives need to be encouraged and supported.  
SOCIAL ATTITUDES: Besides any legal and regulatory barriers, the low morphine consump-
tion in Serbia is related to a range of attitudinal barriers including barriers in knowledge about 
the use of opioids for pain management and palliative care i.e. ‘much misinformation and 
misunderstanding’ (e.g. outdated terminology in relation to opioids, use of stigmatizing/ un-
clear language) resulting in strong fear of opioid use. In a 2013 survey on fear of opioids, 
88% of physicians were found to be reluctant to prescribe opioids and only 7% of patients did 
not object when morphine was suggested for pain relief. Physicians’ reluctance was mostly 
linked to fear of respiratory depression while patients’ fears related to concerns about toler-
ance, dependence and adverse effects as well as the association of morphine with imminent 
death (the prescription of morphine being considered as a death sentence). In addition, some 
patients did not want to appear as a weakling and stated that they would not need morphine 
but rather bear the pain, holding on to a cultural belief that it is better not to say that opioids 
are helpful. Beyond physicians and patients, policy makers need to be convinced that pre-
scribing opioids does not automatically result in opioid dependence or hastened death. Bro-
chures about fear of opioids addressing the concerns / misunderstandings about misuse, 
dependence, tolerance and withdrawal need to be produced and distributed throughout the 
country37. 
                                               
36 This has been changed in 2009 and 2013 (see 36). 
37 This request change has already been achieved. Serbian palliative care guidelines have been disseminated 
(Milicevic, 2004). A book on pharmacotherapy of cancer pain has been published (Bosnjak, 2007). Educational 
brochures on fear of opioids for healthcare professionals and patients/ families have been produced (Bosnjak, 
2009). Lectures about cancer pain management, the principle of balance and fear from opioids have been held. 
Educational posters on fear of opioids (for healthcare professionals and patients) and patients’ rights to pain relief 
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Textbox 25 Selection of recommendations specific to Serbia: policy 
§ Provide a clear statement that opioid use is legal (with or without mandatory authority); 
§ Ensure reimbursement of opioids from the MOH/NHIF; 
§ Increase the number and type of available opioids (particularly for breakthrough pain)38; 
§ Develop a provision that allows for ‘off-label’ use of opioids under strict circumstances; 
§ Enhance prescription of opioids for non-cancer pain; 
§ Enable physicians to prescribe more than one opioid at on one prescription form; 
§ Enable pharmacies to dispense opioids at the local level; 
§ Include pharmacists in the National Strategy of Palliative Care and provide them with special 
training courses; 
§ Establish palliative medicine as a medical specialty; 
§ Include palliative care education and training in the programmes of Continuing Medical Edu-
cation as well as the curricula of medical schools and nursing colleges; 
§ Promote education/training initiatives in areas such as pain management, pain medicine and 
palliative care; 
§ Collect and share information about OAT between different groups interested in receiving 
treatment (i.e. HIV/AIDS groups); 
§ Raise awareness of opioids amongst healthcare professionals and the general public; 




                                                                                                                                                   
have been presented. A palliative care network with professional associations, NGOs and the WHO country office 
has been established in Serbia. 
38 Since 26th of December 2006 immediate release (IR) and slow release (SR) morphine can be imported to Ser-
bia. The pharmacy of the Institute for Oncology and Radiology of Serbia started to produce oral morphine solution 
in May 2007. In June 2008 the central pharmacy in Belgrade imported oral morphine and IR morphine has been 
registered in Serbia for the first time. SR hydromorphone has been registered in October 2007. Since 2012 meth-
adone can be reimbursed for cancer pain treatment. In 2014 lactulosis has been accepted by the Health Insur-
ance Fund for prevention and treatment of opioid induced constipation. 
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8.4. Voices from Serbia ATOME participants 
In the summer of 2013, national key contacts and representatives of the national ATOME 
country teams were asked what had changed regarding access to opioid medicines in their 
country since the beginning of the project. These are examples of answers by two represent-
atives of the Serbian country team. 
Textbox 26 Voices from Serbia ATOME participants 
“The ATOME project certainly has raised the Government’s level of awareness about the need to 
make opioids available and accessible. The WHO guidelines translated to Serbian are a valuable 
educational tool and the ATOME analysis of the presence of legislative barriers provides an excel-
lent platform to start changing regulations and practice” (Dr Snezana Bosnjak, 16.06.2013). 
“Our project ‘Development of Palliative Care Services in Serbia’ paid a lot of attention to legisla-
tion. It is my pleasure to inform you that at the end of December 2013 the Government adopted a 
new law on healthcare that officially enables NGOs to provide palliative care and to prescribe all 
medications in the same way as public or private institutions (RE article 64:6.2.1.). This law must 
be approved by the Parliament, too” (Dr Natasa Milicevic, 18.02.2014). 
  




Potential barriers to accessing opioids in Serbia have been identified in the areas of legisla-
tion and policy. The ATOME project recommends that the Serbian legislation should be re-
vised to provide a legal framework that focuses on optimizing healthcare outcomes while 
preventing diversion and misuse. The project also recommends that prescribing should be 
facilitated (maximum amount of controlled medicines to be prescribed and the limited pre-
scription validity should be removed; the restrictions on the authorisation to prescribe con-
trolled medicines for the treatment of patients with dependence should be reconsidered). The 
administrative burden for legal entities involved in trade and distribution of opioid medicines 
should be decreased. It should be ensured that punitive provisions contain exceptions for 
unintended violations. Clear language and non-stigmatizing terms in the Serbian legislation 
should be guaranteed. Considering the identified policy barriers in Serbia the ATOME project 
advises to develop a systematic analysis of financial flows in the health sector, and to ensure 
financial support for harm reduction initiatives. The number and type of available opioids 
should be increased (e.g. for breakthrough pain) and the reimbursement of opioids should be 
improved. Palliative medicine should be established as a medical speciality in Serbia; educa-
tion and training in palliative care and pain management should be included in the pro-
grammes of Continuing Medical Education as well as the curricula of medical schools and 
nursing colleges. Furthermore, the awareness concerning opioid treatment amongst 
healthcare professionals and the general population should be raised – e.g. by producing 
and distributing brochures on fear of opioids addressing the misunderstandings about mis-
use, dependence, and tolerance throughout the country. 
Throughout the ATOME project, encouraging developments have been observed in terms of 
improved access to opioids in Serbia. Some of the recommendations made in this report may 
have already been implemented, but others remain to be a barrier to access to opioids and a 
balance of preventing misuse and ensuring availability still needs to be achieved. 
The continuing efforts of the country team to implement the specific goals elaborated in the 
early stages of the ATOME project are expected to have facilitated improvements at different 
strategic levels. 
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Access to Opioid Medication in Europe (ATOME) 
Report and recommendations to the Ministry of Health 
9. Country Report - Bulgaria 
 
9.1. Introduction 
Bulgaria is one of the countries with statistical evidence of inadequate morphine consumption 
per capita. In 2006, the adequacy of opioid analgesic consumption was 8% - based on a per 
capita consumption of 12.20 morphine equivalents (mEq) while 156 mg would have been 
adequate for treatment of all pain conditions39. Bulgaria was selected as one of the countries 
to participate in the ATOME project due its low per capita consumption. Four years later, in 
2010, the adequacy of opioid analgesic consumption had decreased even further in relative 
terms – it was only 6%40 (based on a per capita consumption of opioid analgesics of 13.27 
morphine equivalents (mEq) while 236 mEq in mg per capita would have been adequate). 
This report presents a summary of the results of the situational analysis that has been under-
taken with regard to opioid availability and accessibility in Bulgaria. The results of the situa-
tional analysis are divided in two parts: the first part addresses legal and regulatory issues 
and the second part focuses on issues relating to policy. Both parts present the main barriers 
and recommendations for improving access to opioid medication in Bulgaria.  
9.2. Identified legal and regulatory barriers 
The results of the ATOME legislation review have been divided into nine different categories 
of potential legal and regulatory barriers, i.e. barriers related to prescribing; dispensing; us-
age; trade and distribution; manufacturing; affordability; penalties; language; and other. In 
Bulgaria, potential legal and regulatory barriers have been identified in all nine categories 
(see Annex 2). A selection of these potential barriers is highlighted below according to cate-
gory, followed by recommendations to remove these barriers. For a more detailed description 
of the methods and results, see Annex 2.  
PRESCRIBING: The prescribing of opioids in Bulgaria is subject to many overly strict admin-
istrative and non-administrative requirements. For example, according to the Bulgarian legis-
lation the authorisation to provide treatment for dependence (including the prescribing of me-
dicinal products containing controlled medicines) is subject to a license issued by the Ministry 
of Health. In addition, for cancer patients opioid analgesics can in certain cases only be pre-
scribed by physicians appointed by the director of the medical institution. These restrictions 
interfere with the professional autonomy of adequately trained healthcare professionals. In 
                                               
39 Seya MJ, Gelders SFAM, Achara UA, Milani B, Scholten WK. A First Comparison between the Consumption of 
and the Need for Opioid Analgesics at Country, Regional and Global Level. Journal of Pain and Palliative Care 
Pharmacotherapy, 2011; 25: 6-18. Accessible at: 
http://apps.who.int/medicinedocs/documents/s17976en/s17976en.pdf 
40 Duthey, B., Scholten, W. Adequacy of Opioid Analgesic Consumption at Country, Global, and Regional Levels 
in 2010, Its Relationship With Development Level, and Changes Compared With 2006. Journal of Pain & Symp-
tom Management 47(2); 2014: 283-97 doi:10.1016/j.jpainsymman.2013.03.015; 
http://www.sciencedirect.com/science/article/pii/S0885392413002728  
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addition, the total amount of controlled medicine to be prescribed is limited to the quantity 
necessary for a 30 day treatment course. Moreover, the validity of a special medical prescrip-
tion used for prescribing controlled medicines is limited to 7 days from the day of issuance of 
the prescription. These restrictions are potential barriers to access; patients who require 
medical treatment with controlled medicines for a longer period will need to visit the physician 
and pharmacy frequently.  
Administrative requirements for medical practitioners in the Bulgarian legislation regarding 
the treatment of patients with controlled medicines can be considered disproportional. In Bul-
garia, medicinal products that contain controlled substances must be prescribed using a pre-
scription form for such substances. These special forms in three copies in yellow and green 
colour can be purchased from the regional healthcare centres. The third copy must be stored 
by the physician or dentist for one year. After this year, the prescription forms must be sub-
mitted together with an acceptance certificate to the Regional Healthcare Centre inspectors. 
These (and many other) requirements may increase the administrative burden and may have 
the effect that medical practitioners are unable (in case that no prescription forms are availa-
ble) or reluctant to treat patients with controlled medicines.  
DISPENSING: Additional requirements for the dispensing of controlled medicines may in-
crease the administrative burden and may cause pharmacists to be reluctant or unable to 
dispense controlled medicines. In Bulgaria, the procedures for dispensing controlled medi-
cines are complex and bureaucratic. For example, the pharmacist is obliged to note on the 
first copy of every prescription for controlled medicines the full name and information from 
the ID document of the person bringing the prescription. It is unclear whether the Bulgarian 
legislation allows this task to be delegated to for example pharmacy technicians. In addition, 
many administrative requirements concerning the record keeping should be followed with 
strict reporting timelines. These administrative requirements increase the burden and poten-
tially cause pharmacists to be reluctant to dispense controlled medicines, which may impede 
availability and accessibility. In addition, in Bulgaria only pharmacies that have been awarded 
a license for retail trade and storage of controlled substances are allowed to dispense medic-
inal products containing such substances. Moreover, these licensed pharmacies can only 
dispense medicinal products containing controlled substances if they are located in the re-
gion where the prescription was issued. This can be a potential barrier to accessing con-
trolled medicines, especially when patients are not or no longer able to visit the pharmacy - 
for example due to worsening of the illness – and rely on the help of family members and 
friends living in a different (remote) area.  
USAGE: Similar to the requirements for dispensing (see above), patients requiring treatment 
with controlled medicines are continuously or repeatedly obliged to visit the pharmacy locat-
ed in the territory of the region where the prescription was issued. In addition, the Bulgarian 
legislation limits access to substitution and maintenance programmes for the treatment of 
dependence to persons who are at least 18 years of age and have previously attended at 
least three formally documented treatment programs, but have not ceased to misuse con-
trolled substances. These requirements are potential barriers to access; patients, including 
adolescents and children when indicated, should be able to receive necessary controlled 
medicines based on an authorised medical prescription when needed within a reasonable 
time. 
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LANGUAGE: The absence or the incorrect use of definitions may cause confusion relating to 
terminology used in legislation and can cause fear for the use of opioid medicines in medical 
practice, in particular if stigmatising language is used. In the reviewed Bulgarian legislation, 
controlled substances are referred to as intoxicating substances. In addition, the language 
used in the Bulgarian legislation and the distinction between medical use and misuse or illicit 
use are not always clear. Moreover, the terms ‘addict(s)’, ‘addiction’, ‘persons addicted’ and 
the reference to controlled medicines as ‘dangerous/intoxicating drugs’ are considered to be 
stigmatising, and are frequently used in the reviewed Bulgarian legislation. 
Textbox 27 Selection of recommendations specific to Bulgaria: legal and regulatory 
§ Ensure that competent medical practitioners are authorised to prescribe controlled medicines, 
without further license requirements that only apply to the prescribing of controlled medicines; 
§ Reconsider the prescription validity of 7 days that applies to prescriptions for medicines con-
taining controlled substances; 
§ Remove restrictions that apply to the amount to be prescribed, in particular if these re-
strictions do not apply to other non-controlled medicinal products; 
§ Decrease the administrative burden for prescribing and dispensing controlled medicines; 
§ Remove the requirement for pharmacies to obtain a special license and the geographical re-
striction that applies to the dispensing of controlled medicines issued by physicians of other 
regions; 
§ Ensure that all patients are able to receive treatment for dependence with controlled medi-
cines when needed within a reasonable time; 
§ Provide clear language in legislation and avoid language that stigmatises the medical use of 
opioids or refers to patients with dependence in a disrespectful way. 
 
9.3. Identified policy barriers41 
For Bulgaria, the main challenges concerning access to opioids were identified in govern-
mental support including financial/economic aspects, issues relating to formularies, educa-
tion and training and social attitudes.  
Although the availability of opioids in Bulgaria is described as ‘good’ as both oral morphine 
and fentanyl are currently available in the country, the affordability is very limited as this med-
ication is very expensive and the cost is not always covered by government funding. An 
enormous sum of money is being blocked; as a result opioid treatment cannot be adequately 
reimbursed. Enlarging the list of opioids financed or reimbursed by the National Health Care 
Cash could be one possible way to overcome this barrier. It is deemed necessary, that the 
                                               
41 This information was retrieved from a report on the ATOME six-country workshop (29th September – 1st October 
2011), as well as the action plan and the strategy planning work sheet submitted by the national counterparts. To 
follow-up on these outcomes, the ATOME work plan intended implementation of a national ATOME conference, 
as well as continuing exchange with the national country team. This would have allowed for providing more accu-
rate information, identifying any changes or improvements in relation to policy barriers from 2011 to date, and 
ensuring that the recommendations made in this final report are accurate and up-to-date. However, after the initial 
workshops, no further contact has been possible with the national counterparts and for this reason, the final 
ATOME national conference could not be organized in Bulgaria.  
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European Commission formulates concrete suggestions to put pressure upon the govern-
ment and professional organizations, trade unions and patient organizations to achieve this. 
Palliative care appears to be widely discussed in Bulgaria due to the huge impact it appears 
to have on society. However, the Ministry of Finance shows little interest in providing finan-
cial support for palliative care in the country. In addition, no good network of palliative care 
facilities is established and this poses a ‘very serious problem’ for the country. Although 
healthcare in Bulgaria is organised in ‘clinical pathways’, palliative care is not included in 
these pathways. There are some training and education initiatives in palliative medicine with-
in other medical specialties; for example, in neurology and anaesthesiology. 
Rehabilitation programmes for opioid dependence are not well developed; geographical cov-
erage of treatment is described as ‘not good’ and there is a lack of financing for harm reduc-
tion initiatives. There are rehabilitation programmes currently operating in the country (204 
treatment slots, half of them free of charge). Treatment places are also available for 3,100 
patients but only 1/3 of these are free of charge. In addition to treatment in specialized cen-
tres, patients are also treated for dependence in psychiatry.  
In Bulgaria it is rather uncommon for a doctor to refer either a patient or a family member to 
someone who can provide psychological support. This poses serious challenges to treatment 
of pain with opioids in Bulgaria considering that major psycho-somatic problems (fear of pain, 
dependence and death) have been identified being directly associated with patients being 
unaware of their diagnosis and prognosis. 
Textbox 28 Selection of recommendations specific to Bulgaria: policy 
§ Enlarge the list of opioids financed or reimbursed by the National Health Care Cash; 
§ Increase the funding allocated to palliative care and harm reduction initiatives; 
§ Include palliative care in the ‘pathways’ based on which healthcare is organised; 
§ Provide incentives to increase interest in palliative care; 
§ Establish a network of palliative care facilities; 
§ Ensure more free-of-charge treatment places on rehabilitation programmes; 
§ Promote education and training in opioid treatment; 
§ Encourage and support patients and families to seek for psychological help to address major 
psycho-somatic problems identified in relation to opioid treatment and end of life care. 
  




Potential barriers to accessing opioids in Bulgaria have been identified in the areas of legisla-
tion and policy. The ATOME project recommends that the Bulgarian legislation should be 
revised to provide a legal framework that focuses on optimizing healthcare outcomes while 
preventing diversion and misuse. The project also recommends that prescribing and dispens-
ing should be facilitated (license requirements for practitioners, limited prescription validity 
and the maximum amount of controlled medicines to be prescribed should be removed as 
well as the administrative requirements regarding the receipt of special prescription forms 
and the limitation of regional dispensing). The restrictions on the authorization to provide 
methadone maintenance treatment should be reconsidered and access to controlled medi-
cines should be ensured for all patients who require it in a reasonable timeframe (also pa-
tients under 18 years). Clear language and non-stigmatizing terms in the Bulgarian legisla-
tion should be guaranteed. Considering the identified policy barriers in Bulgaria the ATOME 
project advises to enlarge the list of medicines that are reimbursed and to enhance financial 
support and integrate palliative care provision into existing clinical pathways. Palliative care 
networks should be established to negotiate contracts with insurance companies, to provide 
incentives for palliative care provision and to increase healthcare professionals’ engagement 
in palliative care. More free-of-charge treatment should be provided in rehabilitation pro-
grammes for patients with opioid dependence syndrome. Basic education and training oppor-
tunities in the use of opioid analgesics should be included in the curricula for healthcare pro-
fessionals. Furthermore, psychological support for patients receiving opioid treatment and 
their families should be established in the Bulgarian healthcare system. 
Some of the recommendations made in this report may have already been implemented, but 
others remain to be barriers to access to opioids and a balance of preventing misuse and 
ensuring availability still needs to be achieved. 
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Access to Opioid Medication in Europe (ATOME) 
Report and recommendations to the Ministry of Health 
10. Country Report - Turkey 
 
10.1. Introduction 
Turkey is one of the countries with statistical evidence of inadequate morphine consumption 
per capita. In 2006, the adequacy of opioid analgesic consumption was only 6% - based on a 
per capita consumption of 6.76 morphine equivalents (mEq) while 118 mg would have been 
adequate42. Turkey was selected as one of the countries to participate in the ATOME project 
due to this factor. Four years later, in 2010, the adequacy of opioid analgesic consumption 
had slightly increased (both in absolute and in relative terms) – but was still only 7%43 (based 
on a per capita consumption of opioid analgesics of 14.31 morphine equivalents (mEq) while 
196.50 mEq in mg per capita would have been adequate). This report presents a summary of 
the results of the situational analysis that has been undertaken with regard to opioid availabil-
ity and accessibility in Turkey. The results of the situational analysis are divided in two parts: 
the first part addresses legal and regulatory issues and the second part focuses on issues 
relating to policy. Both parts present the main barriers and recommendations for improving 
access to opioid medication in Turkey. 
10.2. Identified legal and regulatory barriers 
The results of the ATOME legislation review are presented into nine different categories of 
potential legal and regulatory barriers, i.e. barriers related to prescribing; dispensing; usage; 
trade and distribution; manufacturing; affordability; penalties; language; and other. In Turkey, 
potential legal and regulatory barriers have been identified in eight of these nine categories: 
all except affordability (see Annex 2). A selection of these potential barriers is highlighted 
below according to category, and followed by recommendations to remove these barriers. 
For a more detailed description of the methods and results, see Annex 2. 
PRESCRIBING: The prescribing of opioids in Turkey is subject to many administrative and 
non-administrative requirements. For example, physicians are obliged to use special forms 
with serial numbers when prescribing opioids. The special forms have to be issued in tripli-
cate and are not available free of charge for physicians; they have to be purchased. Exam-
ples of non-administrative requirements are the limitations that apply to the maximum 
amount of controlled medicine per prescription (predefined maximum dosages). Although 
some requirements may not be recognised immediately as ‘barriers to access’, they may limit 
                                               
42 Seya MJ, Gelders SFAM, Achara UA, Milani B, Scholten WK. A First Comparison between the Consumption of 
and the Need for Opioid Analgesics at Country, Regional and Global Level. Journal of Pain and Palliative Care 
Pharmacotherapy, 2011; 25: 6-18. Accessible at: 
http://apps.who.int/medicinedocs/documents/s17976en/s17976en.pdf 
43 Duthey, B., Scholten, W. Adequacy of Opioid Analgesic Consumption at Country, Global, and Regional Levels 
in 2010, Its Relationship With Development Level, and Changes Compared With 2006. Journal of Pain & Symp-
tom Management 47(2); 2014: 283-97 doi:10.1016/j.jpainsymman.2013.03.015; 
http://www.sciencedirect.com/science/article/pii/S0885392413002728 
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access to opioids in practice; multiple barriers identified in the same category (e.g. prescrib-
ing) can substantially exacerbate the problem. The complex prescribing procedures in com-
bination with the predefined maximum dosages and the fact that prescription forms have to 
be purchased may for instance result in limited access to opioids for medical purposes.  
DISPENSING: In Turkey, a special license is required for pharmacies where controlled medi-
cines are dispensed. When dispensing opioids, pharmacists are required to complete an in-
dicated part of all copies of the prescription form, which increases the administrative burden 
and may deter pharmacists from dispensing such medicines. If an incorrect prescription form 
is used (for example the use of a green prescription form instead of a red form to dispense 
‘narcotic drugs’), the pharmacist is not allowed to dispense the controlled medicine under any 
circumstances, which can impede access to necessary medicines in the situation of an 
emergency. 
TRADE AND DISTRIBUTION: In Turkey, the authorisation to apply for an export license is 
limited to pharmacists and laboratory owners. Incomplete applications for a license to import 
or export controlled medicines must be supplemented within eight days. This restrictive time-
scale can delay the availability of opioids if a completely new application is required. 
LANGUAGE: The language used in the Turkish legislation is not always clear and may cause 
confusion, in particular if legitimate use is confused with misuse or illicit use. In addition, the 
definition used for ‘substance misuse’ and ’intoxication’ may contribute to the stigmatisation 
of opioids used in medical practice. This also applies to the use of stigmatising terms such as 
‘addicts’ and ‘addiction’ and to referring to controlled substances as ‘toxic substances’. 
OTHER: Educational programs for healthcare professionals on controlled substance misuse 
appear not to be easily accessible; an application is required which will be evaluated by the 
Ministry and approved if the request is found to be appropriate. In addition, only designated 
institutions are allowed to provide these educational services. Public institutions and organi-
sations and private legal entities or natural persons are not allowed to provide educational 
services, unless permission has been granted by the Ministry. 
Physicians are required to indicate personal information regarding the employment of the 
patient on the prescription. Although this information may be required for the reimbursement 
of these medicines, it potentially violates the privacy of patients and may cause them to be 
reluctant to initiate or continue treatment with controlled medicines. 
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Textbox 29 Selection of recommendations specific to Turkey: legal and regulatory 
§ Remove the limitations that apply to the maximum amount of controlled medicine allowed per 
prescription;  
§ Allow the dispensing of opioid medicines in all pharmacies without additional license require-
ments;  
§ Decrease the administrative burden for prescribing, dispensing and receiving opioid medi-
cines; 
§ Ensure that applying for a license to import or export opioid medicines is not unnecessarily 
complicated;  
§ Provide clear language in legislation, use correct definitions and avoid language that stigma-
tises the medical use of opioids or refers to patients with dependence in a disrespectful way; 
§ Ensure that all healthcare professionals can easily access educational programmes on con-
trolled substances misuse. 
10.3. Identified policy barriers 
For Turkey, the main challenges concerning access to opioids were identified in finan-
cial/economic aspects, issues relating to formularies, education and training and social atti-
tudes. 
FINANCIAL/ECONOMIC ASPECTS: Although treatment centres (currently 28 in Turkey) are 
funded by the government and treatment is provided free of charge, more money needs to 
be invested on supporting further education and training of physicians, pharmacists, nurses 
and lawyers, the lack of which is seen to pose barriers to the use of opioids in the country. 
FORMULARIES: The lack of access to treatment comprises a major issue in Turkey at the 
moment. Service provision is administered by the Ministry of Health and some treatment 
hospitals but, outside these settings, treatment cannot be provided. The Department of Can-
cer runs a National Cancer Control Program (2009-2015) including breast, colorectal and 
cervical cancer scanning but pain management is not included. In addition, chronic pain is 
not recognised as a condition. The lack of regulations for the pharmacists’ provision of phar-
maceutical care issues and the lack of an appropriate location for a provision of health ser-
vice to patients exacerbate the problem. There are overly bureaucratic procedures (high lev-
els of paper work and excessive admission criteria) and stringent controls, especially in rela-
tion to drug prescription and distribution. There are also severe punitive provisions for errors 
or problems in the prescription and dispensing of opioids. The prescription period is too re-
strictive while the use of strong opioids is restricted only to certain conditions such as cancer 
pain or terminal cancer pain. Therefore it is requested to extend the prescription period from 
one week to one month. All these restrictions pose barriers to the availability and accessibil-
ity of opioids while at the same time do not contribute to the prevention of misuse or diver-
sion. 
EDUCATION AND TRAINING: There is some education and training in opioids in Turkey but 
training in pain management and palliative care is ‘virtually non-existent’. An education en-
hancing the knowledge about opioid medicines and reducing fear of using opioids is neces-
sary for physicians, pharmacists, nurses and lawyers. This needs to be addressed and over-
come by good training and awareness rising. Issues of misuse or diversion are also not in-
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cluded in the existing education and training programmes. In addition, the correct diagnosis 
of pain needs to be taught and to this end lectures at medical faculties shall be initiated.  
SOCIAL ATTITUDES: A key ethical issue relating to palliative and end-of-life care in Turkey 
is the fear about the use of opioids (‘fear of opioids’). This may result in low usage and poten-
tially increased suffering at the end of life. Morphine is associated with impeding death which 
deters people from wanting to use opioids. Moreover, opioids are frequently associated with 
drug dependence and misuse. As a result, some people are reluctant to apply for treatment 
because they feel stigmatised.  
Textbox 30 Selection of recommendations specific to Turkey: policy 
§ Introduce oral morphine and other immediate-release opioids to the market; 
§ Reduce bureaucracy in prescribing practices; 
§ Increase awareness of pain relief and reduce fear of opioids embedded in an understanding 
of religious and cultural differences; 
§ Education on appropriate pain assessment and evidence based approaches of pain relief 
needs to be provided, for example through lectures at Universities; 
§ Increase awareness about opioid medicines (and that pain can be alleviated) amongst the 
general public through media initiatives; 
§ Provide more palliative care services and additional education and training. 
10.4. Voices from Turkey ATOME participants 
In the summer of 2013, national key contacts and representatives of the national ATOME 
country teams were asked what had changed regarding access to opioid medicines in their 
country since the beginning of the project. These are exemplary answers by one representa-
tive of the Turkey country team. 
Textbox 31 Voices from Turkey ATOME participants 
“ATOME’s aim is to create awareness about opioids in governments. Currently legislation and 
laws are still improving. They have started to use correct language, prescriptions and new termi-
nology. 
As of 01.07.2012, Turkey has started to implement an e-prescription system. However, the red, 
green, purple and orange e-prescriptions/prescriptions – will continue to have to be created on 
paper as well because of controls on the storage of copies in the pharmacies. Then they should 
be sent to the Provincial Health Directorates. In reality, electronic prescriptions extended the bu-
reaucratic process of prescribing” (Dr Serpil Özsezgin, 13.06.2013). 
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10.5. Conclusion 
Potential barriers to accessing opioids in Turkey have been identified in the areas of legisla-
tion and policy. The ATOME project recommends that the Turkish legislation should be re-
vised to provide a legal framework that focuses on optimizing healthcare outcomes while 
preventing diversion and misuse. The project also recommends that prescribing and dispens-
ing should be facilitated (maximum dosages should be removed and special licenses for 
pharmacies should be approachable), clear language in legislation should be guaranteed 
and education on opioid medicines should be available for all healthcare professionals in 
order to ensure appropriate use of controlled substances – including opioids - and to coun-
teract fear of opioids. Considering the identified policy barriers in Turkey the ATOME project 
advises to introduce additional opioids (especially immediate-release opioids) in the country, 
reduce bureaucracy in the prescription procedure and increase the awareness of the im-
portance of pain therapy in society. 
Throughout the ATOME project, encouraging developments have been observed in terms of 
improved access to opioids in Turkey. Some of the recommendations made in this report 
may have already been implemented but others remain to be a barrier to access to opioids 
and a balance of preventing misuse and ensuring availability still needs to be achieved. 
The continuing efforts of the country team to implement the specific goals elaborated in the 
early stages of the ATOME project can be assumed to have facilitated improvements at dif-
ferent strategic levels. 
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Access to Opioid Medication in Europe (ATOME) 
Report and recommendations to the Ministry of Health 
11. Country Report - Greece 
11.1. Introduction 
Greece is one of the countries with statistical evidence of inadequate morphine consumption 
per capita. In 2006, the adequacy of opioid analgesic consumption was 54% - based on a 
per capita consumption of 92.49 morphine equivalents (mEq) while 171 mg would have been 
adequate for treatment of all pain conditions44. Greece was selected as one of the countries 
to participate in the ATOME project due to this factor. Four years later, in 2010, the adequacy 
of opioid analgesic consumption had slightly decreased (both in absolute and in relative 
terms) – it was 46%45 (based on a per capita consumption of opioid analgesics of 98.32 mor-
phine equivalents (mEq) while 214.42 mEq in mg per capita would have been adequate). 
This report presents a summary of the results of the situational analysis that has been under-
taken with regard to opioid availability and accessibility in Greece. The results of the situa-
tional analysis are divided in two parts: the first part addresses legal and regulatory issues 
and the second part focuses on issues relating to policy. Both parts present the main barriers 
and recommendations for improving access to opioid medication in Greece. 
11.2. Identified legal and regulatory barriers 
The results of the ATOME legislation review have been divided into nine different categories 
of potential legal and regulatory barriers, i.e. barriers related to prescribing; dispensing; us-
age; trade and distribution; manufacturing; affordability; penalties; language; and other. In 
Greece, potential legal and regulatory barriers have been identified in eight of these nine 
categories: all except trade and distribution (see Annex 2). A selection of these potential bar-
riers is highlighted below according to category, followed by recommendations to remove 
these barriers. For a more detailed description of the methods and results, see Annex 2.  
PRESCRIBING: The prescribing of opioid medicines in Greece is subject to administrative 
and non-administrative requirements. For example, special forms, available to doctors by 
their local medical associations upon request, must be used in duplicate to prescribe opioids. 
The special forms must contain a double red line on the top right side, a serial number and 
the text ‘special narcotic drug prescription’ and full details of the patient, including the pa-
tient’s symptoms and disease. When prescribing opioids, it is prohibited to prescribe an 
amount that exceeds the daily dose allowed by the Greek pharmacopoeia, while each pre-
scription form should be issued for only a five-day treatment. This results in the need for re-
peated prescriptions on a weekly basis. Exceptions are made only in specified cases provid-
                                               
44 Seya MJ, Gelders SFAM, Achara UA, Milani B, Scholten WK. A First Comparison between the Consumption of 
and the Need for Opioid Analgesics at Country, Regional and Global Level. Journal of Pain and Palliative Care 
Pharmacotherapy, 2011; 25: 6-18. Accessible at: 
http://apps.who.int/medicinedocs/documents/s17976en/s17976en.pdf 
45 Duthey, B., Scholten, W. Adequacy of Opioid Analgesic Consumption at Country, Global, and Regional Levels 
in 2010, Its Relationship With Development Level, and Changes Compared With 2006. Journal of Pain & Symp-
tom Management 47(2); 2014: 283-97 doi:10.1016/j.jpainsymman.2013.03.015; 
http://www.sciencedirect.com/science/article/pii/S0885392413002728 
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ed that special permission has been granted. In addition, restrictions apply to the total 
amount of controlled medicine to be dispensed on a single prescription. In the case of cancer 
patients, the physician is allowed to prescribe an amount that exceeds the maximum daily 
dose for a five-day treatment, provided that a permit has been granted by the health depart-
ment of the local prefectural administration. This permit is only valid for one month. This legal 
restriction on the daily dosage - especially in combination with a limited treatment period and 
additional administrative requirements - of controlled medicines can be a potential barrier to 
access. This is in particular the case if the maximum daily dosage allowed is lower than the 
dosage advised by evidence based medical treatment guidelines. Individual patient needs 
may require higher dosages than allowed by Greek legislation, which may result in inade-
quate treatment with controlled medicines of individual patients. 
DISPENSING: Additional requirements for the dispensing of controlled medicines may in-
crease the administrative burden and may cause pharmacists to be reluctant to dispense 
controlled medicines. According to the Greek legislation, pharmacists are required to use 
special books for recording the statistics concerning the dispensing of opioid medicines. In 
addition special prescriptions must be signed by the pharmacist and patient and these forms 
must be appropriately stamped by the authorities. 
USAGE: In Greece, opioid substitution therapy for patients who are held in detention by the 
police or prosecution authorities is only provided in the places where the rehabilitation pro-
gram is running. This geographical restriction to the availability of controlled substances can 
impede access, depending on the geographical spread of the places where the rehabilitation 
programs are running. The Greek legislation limits the treatment period of patients that have 
been arrested and need controlled medicines for the treatment of dependence syndrome to 
twelve days. 
PENALTIES: The Greek legislation contains severe punitive sanctions for violation of provi-
sions concerning the prescribing and dispensing of controlled medicines. These severe sanc-
tions, even for unintended violations, may deter healthcare workers from legitimate prescrib-
ing and dispensing of controlled substances and may deter patients from using controlled 
medicines when medically needed. For example, it is forbidden for pharmacists to provide 
narcotic drugs for daily use in amounts greater than the daily dose allowed by the Greek 
pharmacopoeia even when a greater dose is prescribed by a physician, unless a special 
permission has been granted. According to the Greek legislation, pharmacists who provide 
narcotic drugs in violation of this article shall be punished and two-time offenders shall be 
prosecuted and punished with a prison term of up to two years. In addition, pharmacists who 
do not submit the annual statements before the deadline stipulated shall be penalized in ac-
cordance with the provisions of the act on pharmacy inspections in force at that time. Moreo-
ver, a penalty shall be imposed in accordance with the same provisions, to any pharmacist or 
pharmacy manager who does not consistently maintain the special book for recording the 
statistics concerning the dispensing of opioid medicines or does not store medical prescrip-
tions used to dispense narcotics. Punitive provisions should contain exceptions for unintend-
ed violations; unintended errors that do not result in diversion of controlled medicines or seri-
ous health consequences should not be subject to criminal penalties. 
LANGUAGE: In the Greek legislation, the distinction between medical use and misuse or 
illicit use is not always clear. In addition, the definition used for ‘narcotic drugs’ can cause 
fear for the use of opioid medicines in medical practice and may contribute to the stigmatiza-
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tion of patients in need of opioids. This also applies to the use of stigmatising terms such as 
‘addicts’ and ‘addiction’ in the Greek legislation. 
Textbox 32 Selection of recommendations specific to Greece: legal and regulatory 
§ Remove the limitations that apply to the amount of controlled medicine to be prescribed (the 
maximum daily dose and the limited duration of treatment per prescription form) and remove 
the requirement for a permit or special license to prescribe a higher daily dose than provided 
by the Greek pharmacopoeia; 
§ Decrease the administrative burden for prescribing, dispensing and receiving opioid medi-
cines; 
§ Ensure that patients are able to continue their treatment with controlled medicines when they 
are hospitalized in health facilities or when they are arrested or imprisoned, regardless of 
whether they need pain treatment, treatment for dependence syndrome or for other diseases; 
§ Ensure that sanctions for unintended violation of administrative rules are not disproportionate 
in relation to the risk of misuse and diversion;  
§ Provide clear language in legislation, use correct definitions and avoid language that stigma-
tises the medical use of opioids or refers to patients with dependence in a disrespectful way.  
11.3. Identified policy barriers 
For Greece, the main challenges concerning access to opioids were identified in governmen-
tal support, issues relating to formularies, education and training and social attitudes.  
GOVERNMENTAL SUPPORT: There is little support from the government to develop harm 
reduction initiatives, promote opioid use for the treatment of pain and expand palliative care 
in Greece. This is reinforced by a lack of interest on behalf of politicians in these topics con-
sidering that, for the last 30 years, they have kept prioritising other health subjects on their 
political agenda. The financial crisis has currently placed plans at a standstill; still the Greek 
government has made a commitment to provide funding for the development of twenty eight 
new centres to provide opioid substitution therapy to patients with drug dependence prob-
lems.  
FORMULARIES: Prescribed medicines provided for those with the diagnosis of cancer are 
free of charge but patients suffering from chronic pain have to pay a low percentage of the 
medicines’ cost. However, there is a high number of people without access to the healthcare 
system (e.g. the unemployed) which means that no matter how low the cost of a prescription 
they may not able to afford it. Consumption of opioids is very low and the cost for withdraw-
ing and destroying the medicines that are not used is extremely high. Patients often have 
limited access to opioids due to bureaucratic difficulties while most of the hospitals treating 
patients with life threatening diseases are insufficiently staffed.  
EDUCATION AND TRAINING: Knowledge deficits in all those involved comprise the major 
barrier to the use of opioids in Greece. Limited knowledge and reluctance regarding the use 
of opioids exist amongst physicians due to the lack of adequate education and training initia-
tives. This often results in the under-treatment of patients. Currently, education initiatives in 
Greece are at a low level and provided in a fragmented fashion. There is also no standard 
training in opioid analgesia in the basic curriculum of physicians and other healthcare profes-
sionals as well as no comprehensive continuing education and training in this area. Many 
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physicians are afraid to prescribe opioids due to a fear of ‘criminal involvement’, in the event 
that the patient dies. Moreover, in most cases very low doses of strong opioids are being 
used which are much lower than would be necessary to relieve the pain experienced by the 
patient. Training is therefore essential to overcome fear of opioids, understand the medical 
use of opioids and learn how to handle opioid use, dependence and tolerance. Besides opi-
oid management, it is important that palliative care is also included in the basic training of 
physicians and other healthcare professionals. Promising initiatives have been the availability 
of a Greek translation of WHO guidelines regarding pain relief in adults as well as the recent 
translation of WHO guidelines on persisting pain in children46 and the WHO Policy Guidelines 
on Ensuring balance in national policies on controlled substances. 47 
SOCIAL ATTITUDES: Fear of opioids comprises a key ethical issue relating to the use of 
opioids in Greece for patients, families, healthcare professionals and the general public. 
There are many misunderstandings, fears and negative cultural stereotypes associated with 
the use and misuse of opioids (e.g. the stigmatised status of dependence). No family would 
ever like to have a treatment centre in their neighbourhood even if that same family had a 
member with a drug dependence problem. Furthermore, suffering is often regarded as a 
normal state of affairs and, as a result, pain does not get the attention and the respect it de-
serves. Patients think that taking opioids for pain relief means they are going to die soon. 
Many physicians are also sceptical about the prescribing of opioids for pain management 
leading to a significant amount of cases being under-treated. Opioid use and dependence 
are strongly correlated in the public opinion. The need to raise public awareness, reinforce 
civil society dialogue and readdress public attitudes towards opioids remains a critical issue 
in Greece.  
                                               
46 The Greek translation is available at: 
http://apps.who.int/iris/bitstream/10665/44540/29/9789608630772_Guidelines_gre.pdf?ua=1 
47 The Greek translation is available at: 
http://www.who.int/medicines/areas/quality_safety/GLs_Ens_Balance_NOCP_sanend_GRK.pdf 
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Textbox 33 Selection of recommendations specific to Greece: policy 
§ Raise awareness of government officials regarding the importance of pain management; 
§ Educate healthcare and other professionals about the importance of opioid use in pain man-
agement and the ways to overcome fear of opioids; 
§ Establish palliative care as a specialty or at least as a specialisation for doctors and nurses; 
§ Include palliative care and opioid management in basic university curricula for all healthcare 
professionals; 
§ Expand training programs in palliative care and opioid management for healthcare profes-
sionals and medical students; 
§ Establish mandatory courses for continued education of all healthcare professionals involved 
with patients suffering from life threatening diseases; 
§ Establish academic centres to promote research and education in palliative care; 
§ Promote interconnection and collaboration of palliative care centres; 
§ Develop and implement guidelines for opioid maintenance therapy (translate theory into prac-
tice); 
§ Introduce more measures for the prevention of harm reduction; 
§ Educate the public about the usefulness of opioids for the treatment of pain; 
§ Disseminate brochures to overcome the ‘misunderstandings and cultural attitudes’ surround-
ing opioid use. 
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11.4. Voices from Greece ATOME participants 
In the summer of 2013, national key contacts and representatives of the national ATOME 
country teams were asked what had changed regarding access to opioid medicines in their 
country since the beginning of the project. These are exemplary answers by one representa-
tive of the Greek country team. 
Textbox 34 Voices from Greece ATOME participants  
“During the workshop at the national follow-up conference in November 2012, participants agreed 
on the necessary changes that needed to be submitted in the form of a memorandum to the Min-
istry of Justice, in relation to the new ‘Narcotics Law’. A number of appropriate suggestions were 
taken into consideration and included in the law. The New Law was passed on 20 March 2013 
(Law number 4139/ 2013).  
In summary:  
1. Terminology: Previously the law was named ‘Code of Narcotics’. Our suggestion was ‘Law on 
controlled substances’. Even though the term narcotic is still widely used in the law to describe 
controlled substances, the law is now characterized as ‘Law about substances causing addiction’. 
2. Before the law referred only to ‘drug addicts’. Now the law mentions also patients with chronic 
illnesses, in its 1st article, as potential users of these substances. 
3. Most of the issues regarding controlled substances are being decided in the Committee of Nar-
cotics, in the Ministry of Health. Previously, the Committee had 7 members, now it has 13, one of 
them being a doctor specialized in palliative medicine. This Committee is now also responsible for 
the availability of controlled substances throughout the country.  
4. Regarding the dose and duration of treatment, previously the Committee of Narcotics was re-
sponsible to approve the doctor’s application for overcoming the maximum dose. An addition in 
the new law states that pharmacists can execute a doctors’ prescription with a higher than the ap-
proved dose, on emergency cases. 
There were more changes in the new law regarding substitution therapy and diversion initiated by 
the Ministry of Justice (for example de-penalization of cannabis) or the Substitution Therapy Pro-
gram Teams (OKANA, etc.)” (Dr Aliki Tserkezoglou, Director of Palliative Care Team Gallilee, 
12.06.2013). 
  




Potential barriers to accessing opioids in Greece have been identified in the areas of legisla-
tion and policy. The ATOME project recommends that the Greek legislation should be re-
vised to provide a legal framework that focuses on optimizing healthcare outcomes while 
preventing diversion and misuse. The project also recommends that prescribing and dispens-
ing should be facilitated (maximum daily dosage per prescription and the maximum treatment 
period per prescription should be removed as well as the requirement for a permit, approved 
by the authorities, to prescribe a higher daily dose), the treatment continuation of specific 
patient groups (hospitalized, arrested or imprisoned) should be ensured, sanctions for unin-
tended violation of administrative rules should be revised and clear language and correct 
definitions in legislation should be guaranteed to avoid stigmatisation. Considering the identi-
fied policy barriers in Greece, the ATOME project recommends that there is an increase in 
the awareness of governmental officials regarding the importance of pain management, to 
extend governmental support to develop harm reduction initiatives and to ensure better ac-
cess to treatment for patients suffering from chronic pain and for unemployed people. Fur-
thermore, education and training for healthcare professionals concerning medical use of opi-
oids are necessary to avoid under-treatment and the reinforcement of the civil society dia-
logue should be ensured to handle the critical public attitudes towards opioids. 
Throughout the ATOME project, encouraging developments have been observed in terms of 
improved access to opioids in Greece. Some of the recommendations made in this report 
may have already been implemented, but others remain to be a barrier to access to opioids 
and a balance of preventing misuse and ensuring availability still needs to be achieved. 
The continuing efforts of the country team to implement the specific goals elaborated in the 
early stages of the ATOME project are expected to have facilitated improvements at different 
strategic levels. 
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Access to Opioid Medication in Europe (ATOME) 
Report and recommendations to the Ministry of Health 
12. Country Report - Cyprus 
 
12.1. Introduction 
Cyprus is one of the countries with statistical evidence of inadequate morphine consumption 
per capita. In 2006, the adequacy of opioid analgesic consumption was only 12% - based on 
a per capita consumption of 13.89 morphine equivalents (mEq) while 116 mg would have 
been adequate48. Cyprus was selected as one of the countries to participate in the ATOME 
project due to its low per capita morphine consumption. Four years later, in 2010, the ade-
quacy of opioid analgesic consumption had even slightly decreased (both in absolute and in 
relative terms) – it was only 10%49 (based on a per capita consumption of opioid analgesics 
of 13.61 morphine equivalents (mEq) while 138.35 mEq in mg per capita would have been 
adequate). This report presents a summary of the results of the situational analysis that has 
been undertaken with regard to opioid availability and accessibility in Cyprus. The results of 
the situational analysis are divided in two parts: the first part addresses legal and regulatory 
issues and the second part focuses on issues relating to policy. Both parts present the main 
barriers and recommendations for improving access to opioid medication in Cyprus.  
12.2. Identified legal and regulatory barriers 
The results of the ATOME legislation review have been divided into nine different categories 
of potential legal and regulatory barriers, i.e. barriers related to prescribing; dispensing; us-
age; trade and distribution; manufacturing; affordability; penalties; language; and other. In 
Cyprus, potential legal and regulatory barriers have been identified in seven of these nine 
categories: all except manufacturing and affordability (see Annex 2). A selection of these 
potential barriers is highlighted below according to category, followed by recommendations to 
remove these barriers. For a more detailed description of the methods and results, see An-
nex 2.  
PRESCRIBING: The prescribing of opioids in Cyprus is subject to administrative and non-
administrative requirements. For example, the total amount of controlled medicine to be pre-
scribed and the validity of medical prescriptions used for prescribing opioid medicines are 
limited to 13 weeks. Although these limitations do not seem to be very strict, they can be a 
potential barrier to access for patients who require long term treatment with opioid medicines. 
In addition, a license is required for medical practitioners to be authorised to prescribe or 
                                               
48 Seya MJ, Gelders SFAM, Achara UA, Milani B, Scholten WK. A First Comparison between the Consumption of 
and the Need for Opioid Analgesics at Country, Regional and Global Level. Journal of Pain and Palliative Care 
Pharmacotherapy, 2011; 25: 6-18. Accessible at: 
http://apps.who.int/medicinedocs/documents/s17976en/s17976en.pdf 
49 Duthey, B., Scholten, W. Adequacy of Opioid Analgesic Consumption at Country, Global, and Regional Levels 
in 2010, Its Relationship With Development Level, and Changes Compared With 2006. Journal of Pain & Symp-
tom Management 47(2); 2014: 283-97 doi:10.1016/j.jpainsymman.2013.03.015; 
http://www.sciencedirect.com/science/article/pii/S0885392413002728 
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administer methadone for the treatment of patients with dependence. This restriction can be 
a potential barrier to access, in particular if the total number of medical practitioners available 
to prescribe controlled medicines for patients with dependence syndrome is too low. Other 
administrative requirements include the obligation for medical practitioners treating persons 
“whom he considers or has reasonable grounds to consider to be addicted to any controlled 
drug” to send detailed patient information to a medical officer designated by the Minister of 
Health within seven days from the first visit of the patient. These requirements may increase 
the administrative burden of medical practitioners and may deter patients from visiting a 
medical practitioner due to privacy reasons.  
USAGE: In Cyprus, it is prohibited to possess or use utensils that have been used or can be 
used in connection with the smoking, taking, or preparation of – amongst other – cannabis. 
An exception has been made for the procurement of syringes and needles, provided that 
they are contained in their original packaging. The prohibition regarding the possession or 
usage of utensils in Cyprus may contribute to the stigmatisation of legitimate use of con-
trolled medicines.  
PENALTIES: The Cypriot legislation contains punitive provisions that can be considered dis-
proportional and may contribute to the stigma of the use of controlled medicines. For exam-
ple, printed photographs of controlled drugs are considered to promote the illegal use of con-
trolled drugs. This implicates that it is an offence to for example show pictures of controlled 
drugs in educational text books. 
LANGUAGE: The Cypriot legislation is written in Old Greek, which makes it difficult to read 
and understand these legal texts. In addition, many definitions are missing in the Cypriot leg-
islation and stigmatising language is used. Unclear and stigmatising language may deter 
healthcare providers from prescribing or dispensing opioid medicines and may deter patients 
from using medically needed controlled medicines, in particular if violation of these unclear 
provisions may lead to (severe) sanctions for healthcare providers or patients.  
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Textbox 35 Selection of recommendations specific to Cyprus: legal and regulatory 
§ Reconsider limitations that apply to the maximum amount of opioid medicine allowed per pre-
scription and the validity of a medical prescription for opioid medicines if they are stricter than 
the limitations that apply to non-controlled medicines;  
§ Decrease the administrative burden and remove the license requirement for prescribing opioid 
medicines used for the treatment of dependence; 
§ Remove provisions regarding the possession of utensils that contribute to the stigmatisation 
of legitimate opioid use while having no or limited impact on the prevention of misuse and di-
version; 
§ Revise punitive provisions that are considered to be disproportional and ensure that language 
used in punitive sanctions does not cause fear for the use of opioid medicines in medical 
practice;  
§ Ensure clear language in legislation by rewriting the Old Greek language in all Cypriot legal 
documents and by providing clear and consistent definitions of terms used in legal docu-
ments; 
§ Avoid language that stigmatises the medical use of opioids or refers to patients with depend-
ence in a disrespectful way. 
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12.3. Identified policy barriers 
For Cyprus, the main challenges concerning access to opioids were identified in finan-
cial/economic aspects, issues relating to formularies, education and training and social atti-
tudes.  
FINANCIAL/ ECONOMIC ASPECTS: There are no governmental organisations currently 
supporting palliative care in Cyprus which means that palliative care provision needs to rely 
mostly on charity funds. The Ministry of Health only provides a ‘very small amount funding’. 
Without governmental funding it is practically not possible to develop effective standards or 
policies, which leads to lack or ineffective quality control over the services provided. Gov-
ernmental support has been requested to enable medical staff to participate in more educa-
tion and training initiatives. An international pharmaceutical company, a branch of which cur-
rently operates in Cyprus, has offered sponsoring the development of a leaflet to inform pa-
tients and healthcare professionals on the use of opioids, including on unjustified fears for 
opioid medicines. However, funding for reliable information material independent from com-
mercial sponsoring would be clearly preferable in order to provide unbiased information to 
patients and professionals. Unfortunately, the economic crisis the country is currently experi-
encing has put everything at a standstill. 
FORMULARIES: Controlled substances are available only in 40 private pharmacies which 
only stock oxycodone for which patients have to pay. The only oral immediate release opioid 
available free in government pharmacies (e.g. for breakthrough pain) is morphine but there is 
no provision for patients with a morphine allergy. In addition, there is no high dose of imme-
diate-release morphine available in Cyprus. There is also a major difficulty in prescribing opi-
oids for non-cancer patients. There is suboptimal communication between the government 
and healthcare professionals. Availability in rural centres is more problematic since there are 
normally only general practitioners (GPs) who are not specialised in treatment with opioids.  
EDUCATION AND TRAINING: Although there is expertise in palliative care available in Cy-
prus, there is ‘very little’ education and training in relation to pain control. This needs to be 
focused on both an undergraduate and postgraduate level and be based on a multi-level 
approach and not viewed as a ‘luxury’ in relation to palliative medicine. Physicians and nurs-
es are often trained overseas due to the lack of courses in the country. Currently healthcare 
professionals wait for the National Cancer Control Strategy to be implemented in order to 
support education and multi-professional teams (including physicians, nurses, social workers 
and psychologists). Training in harm reduction for healthcare providers needs to be devel-
oped.  
SOCIAL ATTITUDES: Fear of opioids (unjustified and exaggerated fear for opioid medicines) 
and ignorance comprise key ethical issues relating to opioid use and palliative care in Cyprus 
for both patients and healthcare professionals. Pain does not get the attention and the re-
spect it deserves. Patients are not trained in order to be able to assess their own pain (both 
physical and spiritual). There are also sceptical attitudes towards pain assessment amongst 
many physicians. Statements such as ‘you have already got your medication so you should 
not have pain’ indicate the problematic nature of such attitudes. In addition, no control seems 
to exist over the advice and information that is provided to patients and families about the 
use of opioids for pain treatment and palliative care. The need to reinforce civil society dia-
logue and readdress public and healthcarers attitude towards opioids remains a critical issue 
in Cyprus.  
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Textbox 36 Selection of recommendations specific to Cyprus: policy 
§ Develop national treatment guidelines for opioid use in pain management;  
§ Develop systems of policy and organisation of pain management (e.g. pain guidelines, use of 
protocols) for both cancer and non-cancer patients;  
§ Integrate an inter-disciplinary approach to pain management; 
§ Encourage pharmaceutical companies to register and place new opioids on the market;  
§ Improve communication between government, healthcare professionals, users of the 
healthcare system and pharmaceutical companies; 
§ Increase the number and scope of out-of-hours outlets (e.g. pharmacies, clinics) to ensure 
availability of emergency supplies of opioids; 
§ Invest on education and training initiatives; 
§ Increase education and training relating to opioid use amongst healthcare professionals; 
§ Reinforce civil society dialogue and readdress public attitude towards opioids; 
§ Generate two separate fear of opioids leaflets one to be distributed to patients and the other 
to health professionals; 
§ Train patients to be able to assess their own pain. 
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12.4. Voices from Cyprus ATOME participants 
In the summer of 2013 ATOME participants were asked what had changed regarding access 
to opioid medicines in their country since the beginning of the project. These are the answers 
of three participants from Cyprus. 
Textbox 37 Voices from Cyprus ATOME participants 
“The country team of the ATOME Project made some recommendations on the Cyprus' legisla-
tion, which were discussed with the involved partners, but no actual changes in legislation have 
been made. The legislation is under study and hopefully the given recommendations will be taken 
under serious consideration for future revision” (Nasia Fotsiou, Cyprus Antidrug Council 
06.06.2013). 
“ATOME suggestions have been presented to the Antinarcotics Council
1
. As soon as the recom-
mendations have been considered by the Legal Services a project of adjusting the legislation and 
issuing guidelines for healthcare professionals will be undertaken. Unfortunately the current eco-
nomic crisis in Cyprus has shifted the focus of the political leaders so the review will not be made 
very soon” (Ioannis Kkolos, Pharmacist Pharmaceutical Services, Ministry of Health, 06. 06.2013). 
“At the first ATOME project meeting we learned that methadone could be prescribed by doctors 
other than psychiatrists. We now prescribe methadone with strict records kept for the Ministry of 
Health. The use of methadone shows very good results in patients whose pain was otherwise not 
well controlled and who suffered from severe side effects.  
Recently some networking of different groups happened. For example, through organising the 
ATOME project nurses working at the MoH and universities have included pain management as a 
core subject and palliative care as an extra (elective) option - in nursing education” (Barbara Pitsil-
lides, 06.06.2013). 
1The Antinarcotics Council is the formal body for the determination of the state´s policy on narcotics and psy-
chotropics. 
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12.5. Conclusion 
Potential barriers to accessing opioids in Cyprus have been identified in the areas of legisla-
tion and policy. The ATOME project recommends that the Cypriot legislation should be re-
vised to provide a legal framework that focuses on optimizing healthcare outcomes while 
preventing diversion and misuse. The project also recommends that prescribing should be 
facilitated (maximum treatment period and validity of a prescription should be reconsidered if 
they are stricter than the limitations that apply to non-controlled medicines and special li-
censes for prescribing opioid medicines for treatment of patients with dependence syndrome 
should be reconsidered). Clear language in legislation should be guaranteed by rewriting 
legal documents using modern Greek language. To avoid stigmatisation, language used in 
punitive sanctions should be revised as well as provisions regarding the possession of spe-
cific utensils. Considering the identified policy barriers in Cyprus the ATOME project advises 
to extend governmental funding to ensure education and training in the country and the de-
velopment of effective quality standards. Furthermore, additional opioids (especially immedi-
ate-release opioids and medication for non-cancer patients), better availability in rural areas, 
introduce patients’ training with regard to pain assessment and increase the awareness of 
the importance of pain therapy in society are important changes which are needed in Cyprus. 
Throughout the ATOME project, encouraging developments have been observed in terms of 
improved access to opioids in Cyprus. Some of the recommendations made in this report 
may have already been implemented, but others remain to be a barrier to access to opioids 
and a balance of preventing misuse and ensuring availability still needs to be achieved. 
The continuing efforts of the country team to implement the specific goals elaborated in the 
early stages of the ATOME project can be assumed to have facilitated improvements at dif-
ferent strategic levels. 
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